{"PMC7297525": [["INTRODUCTIONIn December 2019, an outbreak of a highly contagious pneumonia of unknown etiology was reported in the city of Wuhan, China, with many infected patients presenting severe acute respiratory syndrome (SARS).", [["pneumonia", "DISEASE", 65, 74], ["acute respiratory syndrome", "DISEASE", 183, 209], ["SARS", "DISEASE", 211, 215], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["a highly contagious pneumonia", "PROBLEM", 45, 74], ["severe acute respiratory syndrome", "PROBLEM", 176, 209], ["highly", "OBSERVATION_MODIFIER", 47, 53], ["contagious", "OBSERVATION_MODIFIER", 54, 64], ["pneumonia", "OBSERVATION", 65, 74], ["infected", "OBSERVATION_MODIFIER", 147, 155], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["acute", "OBSERVATION_MODIFIER", 183, 188], ["respiratory syndrome", "OBSERVATION", 189, 209]]], ["The etiological agent, identified from epithelial cells of infected patients\u2019 airways, was a coronavirus (SARS-CoV-2), belonging to subgenus Sarbecovirus and subfamily Orthocoronavirinae, the seventh member of the coronavirus family that is known to infect humans (1).", [["epithelial cells", "ANATOMY", 39, 55], ["airways", "ANATOMY", 78, 85], ["epithelial cells", "CELL", 39, 55], ["patients", "ORGANISM", 68, 76], ["airways", "MULTI-TISSUE_STRUCTURE", 78, 85], ["SARS-CoV-2", "ORGANISM", 106, 116], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 168, 186], ["coronavirus", "ORGANISM", 214, 225], ["humans", "ORGANISM", 257, 263], ["epithelial cells", "CELL_TYPE", 39, 55], ["patients", "SPECIES", 68, 76], ["coronavirus", "SPECIES", 214, 225], ["humans", "SPECIES", 257, 263], ["SARS-CoV-2", "SPECIES", 106, 116], ["humans", "SPECIES", 257, 263], ["epithelial cells of infected patients\u2019 airways", "PROBLEM", 39, 85], ["a coronavirus (SARS-CoV", "PROBLEM", 91, 114], ["epithelial cells", "OBSERVATION", 39, 55], ["infected", "OBSERVATION_MODIFIER", 59, 67], ["airways", "ANATOMY", 78, 85]]], ["The infection was named coronavirus disease (COVID-19).INTRODUCTIONCOVID-19 pneumonia shares etiological and clinical similarities to other contemporary syndromes also caused by coronaviruses, including the Middle East Respiratory Syndrome (MERS), identified in 2012, and SARS, in 2003 (3).", [["infection", "DISEASE", 4, 13], ["coronavirus disease", "DISEASE", 24, 43], ["pneumonia", "DISEASE", 76, 85], ["Middle East Respiratory Syndrome", "DISEASE", 207, 239], ["MERS", "DISEASE", 241, 245], ["SARS", "DISEASE", 272, 276], ["coronavirus", "ORGANISM", 24, 35], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 207, 246], ["The infection", "PROBLEM", 0, 13], ["coronavirus disease", "PROBLEM", 24, 43], ["COVID", "TEST", 45, 50], ["pneumonia", "PROBLEM", 76, 85], ["other contemporary syndromes", "PROBLEM", 134, 162], ["coronaviruses", "PROBLEM", 178, 191], ["the Middle East Respiratory Syndrome", "PROBLEM", 203, 239], ["infection", "OBSERVATION", 4, 13], ["coronavirus disease", "OBSERVATION", 24, 43], ["pneumonia", "OBSERVATION", 76, 85], ["coronaviruses", "OBSERVATION", 178, 191], ["Middle", "ANATOMY_MODIFIER", 207, 213], ["Respiratory Syndrome", "OBSERVATION", 219, 239]]], ["Similar to other viral infectious diseases, COVID-19 is not restricted to the pulmonary parenchyma, with reports of myocarditis, hypercoagulability status, acute renal failure, mesenteric lymphadenitis, and encephalitis (4).INTRODUCTIONThis article aimed to demonstrate the chest imaging findings of COVID-19 on different modalities, to review national and international recommendations on imaging assessment of COVID-19 (5-9), and to discuss the use of a structured chest computed tomography (CT) report for the disease.ROLE OF IMAGING IN COVID-19 PULMONARY INFECTIONChest imaging should be carefully indicated in patients with suspected COVID-19 infection not only to reduce the patients radiation exposure but also to reduce unnecessary exposure of other patients and healthcare workers, and to rationalize the use of personal protective equipment and resources for disinfecting the patient care equipment (9).ROLE OF IMAGING IN COVID-19 PULMONARY INFECTIONThe use of chest imaging in COVID-19 suspected cases does not replace specific diagnostic tests such as the detection of viral RNA by reverse transcription polymerase chain reaction (RT-PCR) and serological detection of antibodies to SARS-CoV-2.", [["pulmonary parenchyma", "ANATOMY", 78, 98], ["renal", "ANATOMY", 162, 167], ["mesenteric", "ANATOMY", 177, 187], ["chest", "ANATOMY", 274, 279], ["chest", "ANATOMY", 971, 976], ["viral infectious diseases", "DISEASE", 17, 42], ["myocarditis", "DISEASE", 116, 127], ["hypercoagulability", "DISEASE", 129, 147], ["acute renal failure", "DISEASE", 156, 175], ["mesenteric lymphadenitis", "DISEASE", 177, 201], ["encephalitis", "DISEASE", 207, 219], ["infection", "DISEASE", 648, 657], ["SARS", "DISEASE", 1194, 1198], ["COVID-19", "CELL", 44, 52], ["pulmonary parenchyma", "MULTI-TISSUE_STRUCTURE", 78, 98], ["renal", "ORGAN", 162, 167], ["mesenteric", "ORGAN", 177, 187], ["patients", "ORGANISM", 615, 623], ["patients", "ORGANISM", 681, 689], ["patients", "ORGANISM", 758, 766], ["patient", "ORGANISM", 886, 893], ["chest", "ORGANISM_SUBDIVISION", 971, 976], ["SARS-CoV-2", "ORGANISM", 1194, 1204], ["COVID-19", "DNA", 44, 52], ["viral RNA", "RNA", 1081, 1090], ["antibodies", "PROTEIN", 1180, 1190], ["patients", "SPECIES", 615, 623], ["patients", "SPECIES", 681, 689], ["patients", "SPECIES", 758, 766], ["patient", "SPECIES", 886, 893], ["SARS-CoV", "SPECIES", 1194, 1202], ["other viral infectious diseases", "PROBLEM", 11, 42], ["COVID", "TEST", 44, 49], ["myocarditis", "PROBLEM", 116, 127], ["hypercoagulability status", "PROBLEM", 129, 154], ["acute renal failure", "PROBLEM", 156, 175], ["mesenteric lymphadenitis", "PROBLEM", 177, 201], ["encephalitis", "PROBLEM", 207, 219], ["the chest imaging", "TEST", 270, 287], ["COVID", "TEST", 300, 305], ["imaging assessment", "TEST", 390, 408], ["COVID", "TEST", 412, 417], ["a structured chest computed tomography", "TEST", 454, 492], ["the disease", "PROBLEM", 509, 520], ["IMAGING", "TEST", 529, 536], ["COVID", "TEST", 540, 545], ["PULMONARY INFECTIONChest imaging", "TEST", 549, 581], ["suspected COVID-19 infection", "PROBLEM", 629, 657], ["personal protective equipment", "TREATMENT", 821, 850], ["IMAGING", "TEST", 921, 928], ["COVID", "TEST", 932, 937], ["PULMONARY INFECTION", "PROBLEM", 941, 960], ["chest imaging", "TEST", 971, 984], ["diagnostic tests", "TEST", 1039, 1055], ["the detection", "TEST", 1064, 1077], ["viral RNA", "PROBLEM", 1081, 1090], ["reverse transcription polymerase chain reaction", "PROBLEM", 1094, 1141], ["RT-PCR", "TEST", 1143, 1149], ["serological detection", "TEST", 1155, 1176], ["antibodies", "TEST", 1180, 1190], ["SARS", "TEST", 1194, 1198], ["CoV", "TEST", 1199, 1202], ["viral", "OBSERVATION_MODIFIER", 17, 22], ["infectious", "OBSERVATION", 23, 33], ["pulmonary", "ANATOMY", 78, 87], ["parenchyma", "ANATOMY_MODIFIER", 88, 98], ["myocarditis", "OBSERVATION", 116, 127], ["hypercoagulability", "OBSERVATION", 129, 147], ["acute", "OBSERVATION_MODIFIER", 156, 161], ["renal", "ANATOMY", 162, 167], ["failure", "OBSERVATION", 168, 175], ["mesenteric", "ANATOMY", 177, 187], ["lymphadenitis", "OBSERVATION", 188, 201], ["encephalitis", "OBSERVATION", 207, 219], ["chest", "ANATOMY", 274, 279], ["chest", "ANATOMY", 467, 472], ["disease", "OBSERVATION", 513, 520], ["PULMONARY", "ANATOMY", 549, 558], ["infection", "OBSERVATION", 648, 657], ["PULMONARY", "ANATOMY", 941, 950], ["INFECTION", "OBSERVATION", 951, 960], ["chest", "ANATOMY", 971, 976], ["viral RNA", "OBSERVATION", 1081, 1090]]], ["Moreover, most medical societies do not recommend the use of imaging as a method of disease screening (5-8,10).", [["imaging", "TEST", 61, 68], ["disease screening", "TEST", 84, 101]]], ["In general, it is not indicated for asymptomatic patients or those with mild symptoms of the disease.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["mild symptoms", "PROBLEM", 72, 85], ["the disease", "PROBLEM", 89, 100], ["disease", "OBSERVATION", 93, 100]]], ["Imaging should be reserved for those with moderate to severe symptoms, those with risk of progression (presence of comorbidities), and those with worsening of the respiratory condition (Figure 1).", [["respiratory", "ANATOMY", 163, 174], ["Imaging", "TEST", 0, 7], ["moderate to severe symptoms", "PROBLEM", 42, 69], ["comorbidities", "PROBLEM", 115, 128], ["the respiratory condition", "PROBLEM", 159, 184], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["respiratory condition", "OBSERVATION", 163, 184]]], ["In environments with limited resources, imaging can eventually be indicated as a method for medical triage of patients with moderate to severe clinical features and a high pre-test probability (9), in whom urgent decision-making is of primary importance.ROLE OF IMAGING IN COVID-19 PULMONARY INFECTIONNotably, there is an overlap of chest imaging findings in COVID-19 and other diseases (8).", [["chest", "ANATOMY", 333, 338], ["patients", "ORGANISM", 110, 118], ["chest", "ORGAN", 333, 338], ["patients", "SPECIES", 110, 118], ["imaging", "TEST", 40, 47], ["medical triage", "TEST", 92, 106], ["moderate to severe clinical features", "PROBLEM", 124, 160], ["a high pre-test probability", "PROBLEM", 165, 192], ["IMAGING", "TEST", 262, 269], ["chest imaging", "TEST", 333, 346], ["COVID", "TEST", 359, 364], ["other diseases", "PROBLEM", 372, 386], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["PULMONARY", "ANATOMY", 282, 291], ["INFECTIONNotably", "OBSERVATION", 292, 308], ["chest", "ANATOMY", 333, 338], ["diseases", "OBSERVATION", 378, 386]]], ["In addition, pulmonary imaging features can persist for weeks to months and should not be an objection factor for patient discharge (5), nor should it be considered as a treatment control method (6).", [["pulmonary", "ANATOMY", 13, 22], ["pulmonary", "ORGAN", 13, 22], ["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121], ["pulmonary imaging", "TEST", 13, 30], ["a treatment control method", "TREATMENT", 168, 194], ["pulmonary", "ANATOMY", 13, 22]]], ["In general, the resolution of the imaging findings is observed at approximately the 26th day of symptom onset in patients with COVID-19 pneumonia (6), but in some cases, it can take even longer.CHEST RADIOGRAPHYChest radiography is a quick and easy method, frequently requested due to its wide availability and low cost.", [["pneumonia", "DISEASE", 136, 145], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["the imaging findings", "TEST", 30, 50], ["COVID", "TEST", 127, 132], ["pneumonia", "PROBLEM", 136, 145], ["CHEST RADIOGRAPHYChest radiography", "TEST", 194, 228], ["pneumonia", "OBSERVATION", 136, 145]]], ["The advent of portable devices has allowed its use in intensive care units and field hospitals (7).CHEST RADIOGRAPHYRadiologists and clinicians should be aware of the radiography limitation of COVID-19 pneumonia due to the low sensitivity, estimated at 25% (11), especially in initial cases (Figure 2).", [["pneumonia", "DISEASE", 202, 211], ["portable devices", "TREATMENT", 14, 30], ["the radiography limitation", "TEST", 163, 189], ["COVID", "TEST", 193, 198], ["pneumonia", "PROBLEM", 202, 211], ["the low sensitivity", "PROBLEM", 219, 238], ["pneumonia", "OBSERVATION", 202, 211], ["low sensitivity", "OBSERVATION_MODIFIER", 223, 238]]], ["Therefore, it should not be considered as a screening method (7).", [["a screening method", "TEST", 42, 60]]], ["It is recommended for selected populations, such as hospitalized patients to assess disease progression (Figure 3) or to assess associated complications, such as ventilator-associated pneumonia, pleural effusion, or pneumothorax (9).CHEST RADIOGRAPHYThe main radiographic findings are lung opacities with bilateral distribution and predominance in the periphery and lower pulmonary fields (12).", [["pleural", "ANATOMY", 195, 202], ["lung opacities", "ANATOMY", 285, 299], ["periphery", "ANATOMY", 352, 361], ["lower pulmonary fields", "ANATOMY", 366, 388], ["pneumonia", "DISEASE", 184, 193], ["pleural effusion", "DISEASE", 195, 211], ["pneumothorax", "DISEASE", 216, 228], ["lung opacities", "DISEASE", 285, 299], ["patients", "ORGANISM", 65, 73], ["lung", "ORGAN", 285, 289], ["pulmonary", "ORGAN", 372, 381], ["patients", "SPECIES", 65, 73], ["disease progression", "PROBLEM", 84, 103], ["associated complications", "PROBLEM", 128, 152], ["ventilator-associated pneumonia", "PROBLEM", 162, 193], ["pleural effusion", "PROBLEM", 195, 211], ["pneumothorax", "PROBLEM", 216, 228], ["CHEST RADIOGRAPHY", "TEST", 233, 250], ["lung opacities", "PROBLEM", 285, 299], ["bilateral distribution and predominance in the periphery and lower pulmonary fields", "PROBLEM", 305, 388], ["complications", "OBSERVATION", 139, 152], ["pneumonia", "OBSERVATION", 184, 193], ["pleural", "ANATOMY", 195, 202], ["effusion", "OBSERVATION", 203, 211], ["pneumothorax", "OBSERVATION", 216, 228], ["main", "OBSERVATION_MODIFIER", 254, 258], ["lung", "ANATOMY", 285, 289], ["opacities", "OBSERVATION", 290, 299], ["bilateral", "ANATOMY_MODIFIER", 305, 314], ["distribution", "OBSERVATION_MODIFIER", 315, 327], ["predominance", "OBSERVATION_MODIFIER", 332, 344], ["periphery", "ANATOMY_MODIFIER", 352, 361], ["lower", "ANATOMY_MODIFIER", 366, 371], ["pulmonary", "ANATOMY", 372, 381], ["fields", "ANATOMY_MODIFIER", 382, 388]]], ["The disease extension can be quantified utilizing adapted scores according to the percentage of pulmonary opacity extension (12).", [["pulmonary", "ANATOMY", 96, 105], ["pulmonary", "ORGAN", 96, 105], ["The disease extension", "PROBLEM", 0, 21], ["pulmonary opacity extension", "PROBLEM", 96, 123], ["disease", "OBSERVATION", 4, 11], ["pulmonary", "ANATOMY", 96, 105], ["opacity", "OBSERVATION", 106, 113]]], ["It is noteworthy that such information can be either under-detected or underestimated when compared to CT, thus limiting the disease monitoring capability of radiography (11).CHEST COMPUTED TOMOGRAPHYIn the context of the COVID-19 pandemic, the use of CT has increased significantly, despite the aforementioned national and international recommendations.", [["CT", "TEST", 103, 105], ["the disease monitoring capability", "TEST", 121, 154], ["radiography", "TEST", 158, 169], ["the COVID", "TEST", 218, 227], ["CT", "TEST", 252, 254], ["increased", "OBSERVATION_MODIFIER", 259, 268]]], ["It should be performed in hospitalized and symptomatic patients with clinical worsening and/or patients who have comorbidities (5-8,10).", [["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 95, 103], ["comorbidities", "PROBLEM", 113, 126]]], ["In these patients, CT is indicated mainly to assess the extent of the disease and to identify complications, such as pulmonary thromboembolism or overlapping bacterial infection, and to evaluate differential diagnoses (6).CHEST COMPUTED TOMOGRAPHYWhen compared to the reference diagnostic test (RT-PCR), CT has high sensitivity (97%), but low specificity (25%) (13), and hence cannot replace it (7).", [["pulmonary", "ANATOMY", 117, 126], ["pulmonary thromboembolism", "DISEASE", 117, 142], ["bacterial infection", "DISEASE", 158, 177], ["patients", "ORGANISM", 9, 17], ["pulmonary", "ORGAN", 117, 126], ["patients", "SPECIES", 9, 17], ["CT", "TEST", 19, 21], ["the disease", "PROBLEM", 66, 77], ["complications", "PROBLEM", 94, 107], ["pulmonary thromboembolism", "PROBLEM", 117, 142], ["overlapping bacterial infection", "PROBLEM", 146, 177], ["the reference diagnostic test", "TEST", 264, 293], ["RT-PCR", "TEST", 295, 301], ["CT", "TEST", 304, 306], ["high sensitivity", "PROBLEM", 311, 327], ["disease", "OBSERVATION", 70, 77], ["pulmonary", "ANATOMY", 117, 126], ["thromboembolism", "OBSERVATION", 127, 142], ["overlapping", "OBSERVATION_MODIFIER", 146, 157], ["bacterial", "OBSERVATION_MODIFIER", 158, 167], ["infection", "OBSERVATION", 168, 177], ["low", "OBSERVATION_MODIFIER", 339, 342]]], ["The tomographic findings considered typical of COVID-19 are ground glass opacities (GGOs), consolidations and crazy-paving pattern (Figure 2) with bilateral and multifocal distribution, and a peripheral and posterior predominance (14-16).", [["GGOs", "DISEASE", 84, 88], ["COVID", "TEST", 47, 52], ["ground glass opacities (GGOs)", "PROBLEM", 60, 89], ["consolidations", "PROBLEM", 91, 105], ["crazy-paving pattern", "PROBLEM", 110, 130], ["bilateral and multifocal distribution", "PROBLEM", 147, 184], ["a peripheral and posterior predominance", "PROBLEM", 190, 229], ["ground glass opacities", "OBSERVATION", 60, 82], ["consolidations", "OBSERVATION", 91, 105], ["crazy", "OBSERVATION_MODIFIER", 110, 115], ["bilateral", "ANATOMY_MODIFIER", 147, 156], ["multifocal", "OBSERVATION_MODIFIER", 161, 171], ["distribution", "OBSERVATION_MODIFIER", 172, 184], ["peripheral", "ANATOMY_MODIFIER", 192, 202], ["posterior", "ANATOMY_MODIFIER", 207, 216], ["predominance", "OBSERVATION_MODIFIER", 217, 229]]], ["Such findings are not exclusive to COVID-19 and can be found in other viral pneumonias, connective tissue lung disease, and drug-induced lung disease (8).", [["connective tissue lung", "ANATOMY", 88, 110], ["lung", "ANATOMY", 137, 141], ["pneumonias", "DISEASE", 76, 86], ["connective tissue lung disease", "DISEASE", 88, 118], ["drug-induced lung disease", "DISEASE", 124, 149], ["COVID-19", "CHEMICAL", 35, 43], ["connective tissue lung", "CANCER", 88, 110], ["lung", "ORGAN", 137, 141], ["COVID", "TEST", 35, 40], ["other viral pneumonias", "PROBLEM", 64, 86], ["connective tissue lung disease", "PROBLEM", 88, 118], ["drug-induced lung disease", "PROBLEM", 124, 149], ["viral", "OBSERVATION_MODIFIER", 70, 75], ["pneumonias", "OBSERVATION", 76, 86], ["connective tissue", "OBSERVATION", 88, 105], ["lung", "ANATOMY", 106, 110], ["disease", "OBSERVATION", 111, 118], ["lung", "ANATOMY", 137, 141], ["disease", "OBSERVATION", 142, 149]]], ["Therefore, clinical data and temporal correlation with radiological findings are extremely important, as well as correlation with previous examination findings.", [["clinical data", "TEST", 11, 24], ["previous examination findings", "TEST", 130, 159]]], ["In addition to these findings, CT of patients with COVID-19 may also show signs of organizing pneumonia, reversed halo sign, reticular pattern, subpleural curvilinear lines, parenchymal bands, pseudocavities, and nodules, sometimes configuring the halo sign (17-19).", [["reticular", "ANATOMY", 125, 134], ["subpleural curvilinear lines", "ANATOMY", 144, 172], ["parenchymal bands", "ANATOMY", 174, 191], ["pseudocavities", "ANATOMY", 193, 207], ["nodules", "ANATOMY", 213, 220], ["pneumonia", "DISEASE", 94, 103], ["pseudocavities", "DISEASE", 193, 207], ["patients", "ORGANISM", 37, 45], ["nodules", "PATHOLOGICAL_FORMATION", 213, 220], ["patients", "SPECIES", 37, 45], ["these findings", "TEST", 15, 29], ["CT", "TEST", 31, 33], ["COVID", "TEST", 51, 56], ["organizing pneumonia", "PROBLEM", 83, 103], ["reversed halo sign", "PROBLEM", 105, 123], ["reticular pattern", "PROBLEM", 125, 142], ["subpleural curvilinear lines", "PROBLEM", 144, 172], ["parenchymal bands", "PROBLEM", 174, 191], ["pseudocavities", "PROBLEM", 193, 207], ["nodules", "PROBLEM", 213, 220], ["the halo sign", "TEST", 244, 257], ["signs of", "UNCERTAINTY", 74, 82], ["organizing", "OBSERVATION_MODIFIER", 83, 93], ["pneumonia", "OBSERVATION", 94, 103], ["halo sign", "OBSERVATION", 114, 123], ["reticular", "OBSERVATION_MODIFIER", 125, 134], ["pattern", "OBSERVATION_MODIFIER", 135, 142], ["subpleural", "ANATOMY_MODIFIER", 144, 154], ["curvilinear lines", "OBSERVATION", 155, 172], ["parenchymal", "ANATOMY_MODIFIER", 174, 185], ["bands", "OBSERVATION_MODIFIER", 186, 191], ["nodules", "OBSERVATION", 213, 220], ["halo", "OBSERVATION_MODIFIER", 248, 252]]], ["Airway centered disease such as bronchial wall thickening, centrilobular and tree in bud opacities, pleural effusion, and lymphadenopathy are not frequently encountered at the initial presentation of COVID-19 (17).CHEST COMPUTED TOMOGRAPHYCT findings also vary according to the days of symptom onset.", [["Airway", "ANATOMY", 0, 6], ["bronchial wall", "ANATOMY", 32, 46], ["centrilobular", "ANATOMY", 59, 72], ["bud opacities", "ANATOMY", 85, 98], ["pleural effusion", "ANATOMY", 100, 116], ["opacities", "DISEASE", 89, 98], ["pleural effusion", "DISEASE", 100, 116], ["lymphadenopathy", "DISEASE", 122, 137], ["COVID-19", "CHEMICAL", 200, 208], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 32, 46], ["pleural", "ORGAN", 100, 107], ["Airway centered disease", "PROBLEM", 0, 23], ["bronchial wall thickening", "PROBLEM", 32, 57], ["centrilobular and tree in bud opacities", "PROBLEM", 59, 98], ["pleural effusion", "PROBLEM", 100, 116], ["lymphadenopathy", "PROBLEM", 122, 137], ["COVID", "TEST", 200, 205], ["CHEST COMPUTED TOMOGRAPHYCT findings", "TEST", 214, 250], ["bronchial", "ANATOMY", 32, 41], ["wall", "ANATOMY_MODIFIER", 42, 46], ["thickening", "OBSERVATION", 47, 57], ["centrilobular", "OBSERVATION_MODIFIER", 59, 72], ["tree", "OBSERVATION_MODIFIER", 77, 81], ["bud", "ANATOMY_MODIFIER", 85, 88], ["opacities", "OBSERVATION", 89, 98], ["pleural", "ANATOMY", 100, 107], ["effusion", "OBSERVATION", 108, 116], ["lymphadenopathy", "OBSERVATION", 122, 137]]], ["GGOs are more common in the first few days of symptom onset and can evolve to consolidations, reaching a peak in pulmonary opacities between the 9th and 13th days after symptoms onset (6,15).CHEST COMPUTED TOMOGRAPHYThe dissociation between laboratory and tomographic findings may be seen in patients with positive RT-PCR and absence of imaging findings and those with extensive imaging findings and negative RT-PCR (7,20).CT STRUCTURED REPORT IN COVID-19During a pandemic, a more assertive interpretation of CT findings related to COVID-19 has become necessary to assist patient management.", [["pulmonary", "ANATOMY", 113, 122], ["pulmonary opacities", "DISEASE", 113, 132], ["COVID-19", "CHEMICAL", 532, 540], ["GGOs", "GENE_OR_GENE_PRODUCT", 0, 4], ["pulmonary", "ORGAN", 113, 122], ["patients", "ORGANISM", 292, 300], ["patient", "ORGANISM", 572, 579], ["patients", "SPECIES", 292, 300], ["patient", "SPECIES", 572, 579], ["consolidations", "PROBLEM", 78, 92], ["a peak in pulmonary opacities", "PROBLEM", 103, 132], ["symptoms", "PROBLEM", 169, 177], ["CHEST COMPUTED TOMOGRAPHYThe dissociation", "TEST", 191, 232], ["tomographic findings", "TEST", 256, 276], ["positive RT-PCR", "PROBLEM", 306, 321], ["imaging findings", "TEST", 337, 353], ["extensive imaging findings", "TEST", 369, 395], ["RT-PCR", "TEST", 409, 415], ["CT findings", "TEST", 509, 520], ["COVID", "TEST", 532, 537], ["patient management", "TREATMENT", 572, 590], ["more common", "OBSERVATION_MODIFIER", 9, 20], ["consolidations", "OBSERVATION", 78, 92], ["peak", "OBSERVATION_MODIFIER", 105, 109], ["pulmonary", "ANATOMY", 113, 122], ["opacities", "OBSERVATION", 123, 132], ["may be seen", "UNCERTAINTY", 277, 288]]], ["This type of report offers advantages in the context of high demand of examinations and the need for prompt decisions.", [["examinations", "TEST", 71, 83]]], ["They propose four groups of CT findings: typical, indeterminate, atypical, and negative for COVID-19 (Figure 4) and suggest ways to report them.", [["CT findings", "TEST", 28, 39], ["COVID", "TEST", 92, 97], ["indeterminate", "OBSERVATION_MODIFIER", 50, 63], ["atypical", "OBSERVATION_MODIFIER", 65, 73]]], ["In our hospital, we adapted this classification, with small reporting language changes (Table 1).CT STRUCTURED REPORT IN COVID-19The typical CT finding for COVID-19 consists of (1) peripheral, bilateral GGO with or without consolidation or visible intralobular lines (crazy-paving pattern) (Figure 5); (2) multifocal GGO of rounded morphology with or without consolidation or visible intralobular lines (crazy-paving pattern) (Figure 6); or (3) reversed halo sign or other findings of organizing pneumonia (Figure 7).", [["intralobular lines", "ANATOMY", 248, 266], ["intralobular lines", "ANATOMY", 384, 402], ["GGO", "DISEASE", 203, 206], ["pneumonia", "DISEASE", 496, 505], ["peripheral", "TISSUE", 181, 191], ["intralobular lines", "CELL", 248, 266], ["intralobular lines", "CELL", 384, 402], ["COVID-19", "DNA", 156, 164], ["COVID", "TEST", 121, 126], ["The typical CT", "TEST", 129, 143], ["COVID", "TEST", 156, 161], ["(1) peripheral, bilateral GGO", "PROBLEM", 177, 206], ["consolidation", "PROBLEM", 223, 236], ["visible intralobular lines", "PROBLEM", 240, 266], ["multifocal GGO of rounded morphology", "PROBLEM", 306, 342], ["consolidation", "PROBLEM", 359, 372], ["visible intralobular lines", "PROBLEM", 376, 402], ["reversed halo sign", "PROBLEM", 445, 463], ["organizing pneumonia", "PROBLEM", 485, 505], ["peripheral", "ANATOMY", 181, 191], ["bilateral", "ANATOMY_MODIFIER", 193, 202], ["GGO", "OBSERVATION", 203, 206], ["without", "UNCERTAINTY", 215, 222], ["consolidation", "OBSERVATION", 223, 236], ["visible", "OBSERVATION_MODIFIER", 240, 247], ["intralobular lines", "OBSERVATION", 248, 266], ["multifocal", "OBSERVATION_MODIFIER", 306, 316], ["GGO", "OBSERVATION", 317, 320], ["rounded", "OBSERVATION_MODIFIER", 324, 331], ["morphology", "OBSERVATION_MODIFIER", 332, 342], ["without", "UNCERTAINTY", 351, 358], ["consolidation", "OBSERVATION", 359, 372], ["visible", "OBSERVATION_MODIFIER", 376, 383], ["intralobular lines", "OBSERVATION", 384, 402], ["organizing", "OBSERVATION_MODIFIER", 485, 495], ["pneumonia", "OBSERVATION", 496, 505]]], ["These findings are suggestive of pneumonia and viral etiology must be included in the etiological differential diagnosis, particularly COVID-19.CT STRUCTURED REPORT IN COVID-19The indeterminate CT appearance for COVID-19 consists of diffuse (Figure 8), perihilar, or unilateral (Figure 9) GGO with or without consolidation lacking a specific distribution.", [["perihilar", "ANATOMY", 253, 262], ["pneumonia", "DISEASE", 33, 42], ["COVID-19", "DNA", 212, 220], ["pneumonia", "PROBLEM", 33, 42], ["COVID", "TEST", 135, 140], ["COVID", "TEST", 168, 173], ["COVID", "TEST", 212, 217], ["diffuse (Figure 8), perihilar, or unilateral (Figure 9) GGO", "PROBLEM", 233, 292], ["consolidation", "PROBLEM", 309, 322], ["suggestive of", "UNCERTAINTY", 19, 32], ["pneumonia", "OBSERVATION", 33, 42], ["indeterminate", "OBSERVATION_MODIFIER", 180, 193], ["diffuse", "OBSERVATION_MODIFIER", 233, 240], ["perihilar", "ANATOMY", 253, 262], ["unilateral", "ANATOMY_MODIFIER", 267, 277], ["without", "UNCERTAINTY", 301, 308], ["consolidation", "OBSERVATION", 309, 322], ["specific", "OBSERVATION_MODIFIER", 333, 341], ["distribution", "OBSERVATION_MODIFIER", 342, 354]]], ["Patients with few very small GGOs with a non-rounded and non-peripheral distribution (Figure 10) are also included in this group.", [["GGOs", "DISEASE", 29, 33], ["Patients", "ORGANISM", 0, 8], ["GGOs", "CANCER", 29, 33], ["Patients", "SPECIES", 0, 8], ["few very small GGOs", "PROBLEM", 14, 33], ["a non-rounded and non-peripheral distribution", "PROBLEM", 39, 84], ["few", "OBSERVATION_MODIFIER", 14, 17], ["very", "OBSERVATION_MODIFIER", 18, 22], ["small", "OBSERVATION_MODIFIER", 23, 28], ["GGOs", "OBSERVATION", 29, 33], ["non-peripheral", "OBSERVATION_MODIFIER", 57, 71], ["distribution", "OBSERVATION_MODIFIER", 72, 84]]], ["In these cases, the imaging findings are nonspecific and can be observed in several diseases of non-infectious and infectious origin, including viral pneumonia.", [["non-infectious and infectious origin", "DISEASE", 96, 132], ["viral pneumonia", "DISEASE", 144, 159], ["the imaging", "TEST", 16, 27], ["non-infectious and infectious origin", "PROBLEM", 96, 132], ["viral pneumonia", "PROBLEM", 144, 159], ["nonspecific", "OBSERVATION_MODIFIER", 41, 52], ["several", "OBSERVATION_MODIFIER", 76, 83], ["diseases", "OBSERVATION", 84, 92], ["non-infectious", "OBSERVATION", 96, 110], ["infectious", "OBSERVATION_MODIFIER", 115, 125], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["pneumonia", "OBSERVATION", 150, 159]]], ["Although these are not a suggestive tomographic appearance, the possibility of COVID-19 should not be ruled out, especially in severe clinical cases with extensive pulmonary opacities, or in mild cases with isolated pulmonary opacities.CT STRUCTURED REPORT IN COVID-19Patients with pulmonary infection findings different from those previously described above can be categorized into the atypical appearance (Figure 11), such as isolated lobar or segmental consolidations, discrete small nodules (centrilobular and tree-in-bud appearance), lung cavitation, and smooth interlobular septal thickening with pleural effusion (8).", [["pulmonary", "ANATOMY", 164, 173], ["pulmonary", "ANATOMY", 216, 225], ["pulmonary", "ANATOMY", 282, 291], ["lobar", "ANATOMY", 437, 442], ["nodules", "ANATOMY", 487, 494], ["centrilobular", "ANATOMY", 496, 509], ["bud", "ANATOMY", 522, 525], ["lung", "ANATOMY", 539, 543], ["smooth interlobular septal", "ANATOMY", 560, 586], ["pleural", "ANATOMY", 603, 610], ["pulmonary opacities", "DISEASE", 164, 183], ["pulmonary opacities", "DISEASE", 216, 235], ["pulmonary infection", "DISEASE", 282, 301], ["lobar or segmental consolidations", "DISEASE", 437, 470], ["lung cavitation", "DISEASE", 539, 554], ["pleural effusion", "DISEASE", 603, 619], ["pulmonary", "ORGAN", 164, 173], ["pulmonary", "ORGAN", 216, 225], ["pulmonary", "ORGAN", 282, 291], ["nodules", "CANCER", 487, 494], ["lung", "ORGAN", 539, 543], ["smooth interlobular septal", "TISSUE", 560, 586], ["COVID", "TEST", 79, 84], ["extensive pulmonary opacities", "PROBLEM", 154, 183], ["isolated pulmonary opacities", "PROBLEM", 207, 235], ["pulmonary infection findings", "PROBLEM", 282, 310], ["isolated lobar or segmental consolidations", "PROBLEM", 428, 470], ["discrete small nodules (centrilobular and tree-in-bud appearance", "PROBLEM", 472, 536], ["lung cavitation", "PROBLEM", 539, 554], ["smooth interlobular septal thickening", "PROBLEM", 560, 597], ["pleural effusion", "PROBLEM", 603, 619], ["not a suggestive", "UNCERTAINTY", 19, 35], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["extensive", "OBSERVATION_MODIFIER", 154, 163], ["pulmonary", "ANATOMY", 164, 173], ["opacities", "OBSERVATION", 174, 183], ["mild", "OBSERVATION_MODIFIER", 191, 195], ["isolated", "OBSERVATION_MODIFIER", 207, 215], ["pulmonary", "ANATOMY", 216, 225], ["opacities", "OBSERVATION", 226, 235], ["pulmonary", "ANATOMY", 282, 291], ["infection", "OBSERVATION", 292, 301], ["atypical", "OBSERVATION_MODIFIER", 387, 395], ["isolated", "OBSERVATION_MODIFIER", 428, 436], ["lobar", "OBSERVATION_MODIFIER", 437, 442], ["segmental", "ANATOMY_MODIFIER", 446, 455], ["consolidations", "OBSERVATION", 456, 470], ["discrete", "OBSERVATION_MODIFIER", 472, 480], ["small", "OBSERVATION_MODIFIER", 481, 486], ["nodules", "OBSERVATION", 487, 494], ["centrilobular", "OBSERVATION_MODIFIER", 496, 509], ["tree", "OBSERVATION_MODIFIER", 514, 518], ["bud", "ANATOMY_MODIFIER", 522, 525], ["lung", "ANATOMY", 539, 543], ["cavitation", "OBSERVATION", 544, 554], ["smooth", "OBSERVATION_MODIFIER", 560, 566], ["interlobular", "ANATOMY_MODIFIER", 567, 579], ["septal", "ANATOMY_MODIFIER", 580, 586], ["thickening", "OBSERVATION", 587, 597], ["pleural", "ANATOMY", 603, 610], ["effusion", "OBSERVATION", 611, 619]]], ["In this group, imaging findings are not usually reported in COVID-19 infection, and other etiological agents should be considered initially.CT STRUCTURED REPORT IN COVID-19The last group is that of patients without features suggestive of pneumonia.", [["infection", "DISEASE", 69, 78], ["pneumonia", "DISEASE", 238, 247], ["COVID-19", "ORGANISM", 60, 68], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["COVID-19", "SPECIES", 60, 68], ["imaging findings", "TEST", 15, 31], ["infection", "PROBLEM", 69, 78], ["COVID", "TEST", 164, 169], ["pneumonia", "PROBLEM", 238, 247], ["infection", "OBSERVATION", 69, 78], ["without features suggestive of", "UNCERTAINTY", 207, 237], ["pneumonia", "OBSERVATION", 238, 247]]], ["As already discussed, a normal chest CT does not exclude the diagnosis of COVID-19, especially in the initial days of symptoms onset.CT STRUCTURED REPORT IN COVID-19In addition to this classification, the structured report may also contain an estimate of the extent of pulmonary involvement (e.g., describing whether it involves more or less than 50% of the lung parenchyma), information that has been used as one of the criteria for hospitalization (23), and is also related to admission to intensive care units and mortality (24,25).", [["pulmonary", "ANATOMY", 269, 278], ["lung parenchyma", "ANATOMY", 358, 373], ["pulmonary", "ORGAN", 269, 278], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 358, 373], ["a normal chest CT", "TEST", 22, 39], ["COVID", "TEST", 74, 79], ["symptoms onset", "PROBLEM", 118, 132], ["pulmonary involvement", "PROBLEM", 269, 290], ["chest", "ANATOMY", 31, 36], ["extent", "OBSERVATION_MODIFIER", 259, 265], ["pulmonary", "ANATOMY", 269, 278], ["involvement", "OBSERVATION", 279, 290], ["lung", "ANATOMY", 358, 362], ["parenchyma", "ANATOMY_MODIFIER", 363, 373]]], ["Several imaging scores (by lobes or pulmonary fields) have been proposed (14,23,26,27), but all of them are difficult to apply in clinical practice and more studies are needed to validate the correlation of these quantification methods with the clinical course of the disease.ULTRASONOGRAPHYAs previously mentioned, COVID-19 alterations tend to predominate in the lung periphery, which makes lung ultrasound an option in the follow-up of hospitalized patients, especially those in intensive care units, where transfer to a CT scanner is impossible or difficult.", [["lobes", "ANATOMY", 27, 32], ["pulmonary", "ANATOMY", 36, 45], ["lung periphery", "ANATOMY", 364, 378], ["lung", "ANATOMY", 392, 396], ["lobes", "MULTI-TISSUE_STRUCTURE", 27, 32], ["pulmonary", "ORGAN", 36, 45], ["lung periphery", "MULTI-TISSUE_STRUCTURE", 364, 378], ["lung", "ORGAN", 392, 396], ["patients", "ORGANISM", 451, 459], ["patients", "SPECIES", 451, 459], ["Several imaging scores", "TEST", 0, 22], ["these quantification methods", "TEST", 207, 235], ["the disease", "PROBLEM", 264, 275], ["ULTRASONOGRAPHYAs", "TEST", 276, 293], ["COVID", "TEST", 316, 321], ["lung ultrasound", "TEST", 392, 407], ["a CT scanner", "TEST", 521, 533], ["lobes", "ANATOMY_MODIFIER", 27, 32], ["pulmonary", "ANATOMY", 36, 45], ["fields", "ANATOMY_MODIFIER", 46, 52], ["disease", "OBSERVATION", 268, 275], ["lung", "ANATOMY", 364, 368], ["periphery", "ANATOMY_MODIFIER", 369, 378], ["lung", "ANATOMY", 392, 396]]], ["However, this method should not be used as a substitute for CT (5,6,28).ULTRASONOGRAPHYIts potential use as a serial assessment tool through established protocols, such as the 12-site scanning technique (29,30) (Figure 12), allows the evaluation of the progression of inflammatory involvement of the parenchyma and identification of mild findings, such as pleural thickening and even small subpleural consolidations (Figure 13).", [["parenchyma", "ANATOMY", 300, 310], ["pleural", "ANATOMY", 356, 363], ["subpleural", "ANATOMY", 390, 400], ["pleural thickening", "DISEASE", 356, 374], ["parenchyma", "TISSUE", 300, 310], ["pleural", "PATHOLOGICAL_FORMATION", 356, 363], ["this method", "TREATMENT", 9, 20], ["CT", "TEST", 60, 62], ["a serial assessment tool", "TEST", 108, 132], ["the 12-site scanning technique", "TEST", 172, 202], ["the evaluation", "TEST", 231, 245], ["inflammatory involvement of the parenchyma", "PROBLEM", 268, 310], ["mild findings", "PROBLEM", 333, 346], ["pleural thickening", "PROBLEM", 356, 374], ["small subpleural consolidations", "PROBLEM", 384, 415], ["progression", "OBSERVATION_MODIFIER", 253, 264], ["inflammatory", "OBSERVATION", 268, 280], ["parenchyma", "ANATOMY", 300, 310], ["mild", "OBSERVATION_MODIFIER", 333, 337], ["pleural", "ANATOMY", 356, 363], ["thickening", "OBSERVATION", 364, 374], ["small", "OBSERVATION_MODIFIER", 384, 389], ["subpleural", "ANATOMY_MODIFIER", 390, 400], ["consolidations", "OBSERVATION", 401, 415]]], ["It also reduces environmental exposure as only a single doctor is needed to perform the examination at bedside (5,28).ULTRASONOGRAPHYLung ultrasound is based on artefactual lines and their patterns.", [["the examination", "TEST", 84, 99], ["ULTRASONOGRAPHYLung ultrasound", "TEST", 118, 148], ["artefactual lines", "TREATMENT", 161, 178], ["artefactual lines", "OBSERVATION", 161, 178]]], ["In patients with COVID-19, there are irregularly spaced vertical artifacts, known as B-lines, which may coalesce.", [["B-lines", "ANATOMY", 85, 92], ["patients", "ORGANISM", 3, 11], ["B-lines", "CELL", 85, 92], ["B-lines", "CELL_LINE", 85, 92], ["patients", "SPECIES", 3, 11], ["COVID", "TEST", 17, 22], ["irregularly spaced vertical artifacts", "PROBLEM", 37, 74], ["B-lines", "TREATMENT", 85, 92], ["irregularly", "OBSERVATION_MODIFIER", 37, 48], ["spaced", "OBSERVATION_MODIFIER", 49, 55], ["vertical artifacts", "OBSERVATION", 56, 74]]], ["Consolidations with or without air bronchograms may also be found in these patients (28) (Figure 13).", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["Consolidations", "PROBLEM", 0, 14], ["air bronchograms", "PROBLEM", 31, 47], ["without", "UNCERTAINTY", 23, 30], ["air bronchograms", "OBSERVATION", 31, 47], ["may also be", "UNCERTAINTY", 48, 59]]], ["B-lines represent the interlobular and/or intralobular septal thickening, most associated with pulmonary edema and interstitial disorders.", [["B-lines", "ANATOMY", 0, 7], ["interlobular", "ANATOMY", 22, 34], ["intralobular septal", "ANATOMY", 42, 61], ["pulmonary", "ANATOMY", 95, 104], ["interstitial", "ANATOMY", 115, 127], ["pulmonary edema", "DISEASE", 95, 110], ["interstitial disorders", "DISEASE", 115, 137], ["B-lines", "CELL", 0, 7], ["interlobular", "MULTI-TISSUE_STRUCTURE", 22, 34], ["intralobular septal", "TISSUE", 42, 61], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 95, 110], ["B-lines", "CELL_LINE", 0, 7], ["B-lines", "TREATMENT", 0, 7], ["the interlobular and/or intralobular septal thickening", "PROBLEM", 18, 72], ["pulmonary edema", "PROBLEM", 95, 110], ["interstitial disorders", "PROBLEM", 115, 137], ["-lines", "OBSERVATION", 1, 7], ["interlobular", "ANATOMY_MODIFIER", 22, 34], ["intralobular", "ANATOMY_MODIFIER", 42, 54], ["septal", "ANATOMY_MODIFIER", 55, 61], ["thickening", "OBSERVATION", 62, 72], ["most associated with", "UNCERTAINTY", 74, 94], ["pulmonary", "ANATOMY", 95, 104], ["edema", "OBSERVATION", 105, 110], ["interstitial", "ANATOMY_MODIFIER", 115, 127], ["disorders", "OBSERVATION", 128, 137]]], ["When coalescent, with several B-lines grouped, they correspond to GGO at the periphery of the lungs, as observed on CT (31,32).CONCLUSIONImaging should be wisely indicated in the evaluation of patients with COVID-19 to avoid unnecessary exposure of other patients and healthcare workers and rationalize the use of personal protective equipment.", [["B-lines", "ANATOMY", 30, 37], ["lungs", "ANATOMY", 94, 99], ["GGO", "DISEASE", 66, 69], ["B-lines", "CELL", 30, 37], ["lungs", "ORGAN", 94, 99], ["patients", "ORGANISM", 193, 201], ["patients", "ORGANISM", 255, 263], ["B-lines", "CELL_LINE", 30, 37], ["patients", "SPECIES", 193, 201], ["patients", "SPECIES", 255, 263], ["coalescent", "PROBLEM", 5, 15], ["several B-lines", "TREATMENT", 22, 37], ["GGO", "PROBLEM", 66, 69], ["CT", "TEST", 116, 118], ["the evaluation", "TEST", 175, 189], ["COVID", "TEST", 207, 212], ["personal protective equipment", "TREATMENT", 314, 343], ["-lines", "OBSERVATION_MODIFIER", 31, 37], ["GGO", "OBSERVATION", 66, 69], ["periphery", "ANATOMY_MODIFIER", 77, 86], ["lungs", "ANATOMY", 94, 99]]], ["Imaging should be reserved for patients with moderate to severe respiratory symptoms, risk of progression (presence of comorbidities), or worsening of the respiratory condition.", [["respiratory", "ANATOMY", 64, 75], ["respiratory", "ANATOMY", 155, 166], ["respiratory symptoms", "DISEASE", 64, 84], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Imaging", "TEST", 0, 7], ["moderate to severe respiratory symptoms", "PROBLEM", 45, 84], ["comorbidities", "PROBLEM", 119, 132], ["worsening of the respiratory condition", "PROBLEM", 138, 176], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["worsening", "OBSERVATION_MODIFIER", 138, 147], ["respiratory condition", "OBSERVATION", 155, 176]]], ["It should not be indicated for asymptomatic patients or those with mild symptoms.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["mild symptoms", "PROBLEM", 67, 80]]], ["In environments with limited testing resources, imaging can eventually be indicated as a triage method for suspected patients with high pre-test probability.CONCLUSIONChest CT is the main imaging method used in the evaluation of COVID-19 pneumonia.", [["pneumonia", "DISEASE", 238, 247], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["imaging", "TEST", 48, 55], ["a triage method", "TEST", 87, 102], ["high pre-test probability", "PROBLEM", 131, 156], ["CONCLUSIONChest CT", "TEST", 157, 175], ["the main imaging method", "TEST", 179, 202], ["the evaluation", "TEST", 211, 225], ["COVID", "TEST", 229, 234], ["pneumonia", "PROBLEM", 238, 247], ["pneumonia", "OBSERVATION", 238, 247]]], ["Typical findings include GGOs with or without consolidation, crazy-paving pattern with bilateral and multifocal distribution, peripheral and posterior predominance, multifocal GGOs of rounded morphology, and reversed halo sign.", [["GGOs", "DISEASE", 25, 29], ["GGOs", "PROBLEM", 25, 29], ["consolidation", "PROBLEM", 46, 59], ["bilateral and multifocal distribution", "PROBLEM", 87, 124], ["peripheral and posterior predominance", "PROBLEM", 126, 163], ["multifocal GGOs of rounded morphology", "PROBLEM", 165, 202], ["reversed halo sign", "PROBLEM", 208, 226], ["without", "UNCERTAINTY", 38, 45], ["consolidation", "OBSERVATION", 46, 59], ["crazy", "OBSERVATION_MODIFIER", 61, 66], ["bilateral", "ANATOMY_MODIFIER", 87, 96], ["multifocal", "OBSERVATION_MODIFIER", 101, 111], ["distribution", "OBSERVATION_MODIFIER", 112, 124], ["peripheral", "ANATOMY_MODIFIER", 126, 136], ["posterior", "ANATOMY_MODIFIER", 141, 150], ["predominance", "OBSERVATION_MODIFIER", 151, 163], ["multifocal", "OBSERVATION_MODIFIER", 165, 175], ["rounded", "OBSERVATION_MODIFIER", 184, 191], ["morphology", "OBSERVATION_MODIFIER", 192, 202], ["reversed", "OBSERVATION_MODIFIER", 208, 216], ["halo sign", "OBSERVATION", 217, 226]]], ["Additionally, CT can help evaluate the extent of pulmonary disease, presence of complications, and differential diagnosis.", [["pulmonary", "ANATOMY", 49, 58], ["pulmonary disease", "DISEASE", 49, 66], ["pulmonary", "ORGAN", 49, 58], ["CT", "TEST", 14, 16], ["pulmonary disease", "PROBLEM", 49, 66], ["complications", "PROBLEM", 80, 93], ["pulmonary", "ANATOMY", 49, 58], ["disease", "OBSERVATION", 59, 66], ["complications", "OBSERVATION", 80, 93]]], ["Despite typical CT findings in COVID-19, RT-PCR remains the gold standard for the diagnosis.CONCLUSIONStructured chest CT report standardizes the imaging findings and optimizes communication with the referring physician, thus being a useful tool in the pandemic scenario.AUTHOR CONTRIBUTIONSFarias LPG, Fonseca EKUN, Strabelli DG, Loureiro BMC, Neves YCS, and Rodrigues TP were responsible for the study conceptualization and manuscript drafting.", [["TP", "GENE_OR_GENE_PRODUCT", 370, 372], ["typical CT findings", "TEST", 8, 27], ["COVID", "TEST", 31, 36], ["RT-PCR", "TEST", 41, 47], ["chest CT", "TEST", 113, 121], ["the imaging findings", "TEST", 142, 162], ["LPG", "TEST", 298, 301], ["Fonseca", "TEST", 303, 310], ["Rodrigues TP", "PROBLEM", 360, 372], ["the study conceptualization", "TEST", 394, 421], ["chest", "ANATOMY", 113, 118]]]], "PMC7256381": [["Humans are becoming walking data factories and third-parties are tempted to use personal data for malicious purposes.", [["Humans", "ORGANISM", 0, 6]]], ["Data anonymization is therefore defined as it is the process of protecting individuals\u2019 sensitive information while preserving its type and format [12, 17].IntroductionHiding one or multiple values or even adding noise to data as an attempt to anonymize data is considered inefficient because the reconstruction of the initial information is very probable [15].", [["Data anonymization", "TEST", 0, 18]]], ["Inspired from the k-anonymization technique proposed by Sweeney [16], we aim to create micro clusters of similar objects that we code using the micro cluster\u2019s representative.", [["the k-anonymization technique", "TREATMENT", 14, 43]]], ["In this way, the distortion of the data is minimal and the usefulness of the data is maximal.", [["the data", "TEST", 31, 39], ["minimal", "OBSERVATION_MODIFIER", 43, 50]]], ["For the unsupervised methods [8], the most used approach is the clustering that allows to open a new research direction in the field of anonymization i.e. create clusters of k elements and replace the data by the prototypes of the clusters (centroids) in order to obtain a good trade-off between the information loss and the potential data identification risk.", [["k elements", "DNA", 174, 184]]], ["However, usually, these approaches are based on the use of the k-means algorithm which is prone to local optima and may give biased results.IntroductionIn this paper we answer the question of how can the introduction of discriminative information affect the quality of the anonymized datasets.", [["the k-means algorithm", "TEST", 59, 80]]], ["To this purpose, we revisited all the previously proposed approaches, and we added a second level of anonymization by incorporating the discriminative information and using Adaptive Weighting of Features to improve the quality of the anonymized data.", [["anonymization", "TREATMENT", 101, 114]]], ["The paper is organised into four sections: the first dresses the different approaches of privacy preserving using machine learning, the second sums up the previously proposed approaches, the third discusses the introduction of the discriminative information and the fourth validates the method experimentally on six different datasets.Privacy Preservation Using Machine LearningAnonymization methods for microdata rely on many mechanisms and data perturbation is the common technique binding them all.", [["machine learning", "TREATMENT", 114, 130], ["Privacy Preservation", "TREATMENT", 335, 355], ["microdata", "TREATMENT", 404, 413]]], ["Those mechanisms modify the original data to improve data privacy but inevitably at cost of some loss in data utility.", [["some loss in data utility", "PROBLEM", 92, 117]]], ["Microaggregation is a technique for disclosure limitation aimed at protecting the privacy of data subjects in microdata releases.", [["a technique", "TREATMENT", 20, 31]]], ["Unlike generalization, microaggregation perturbs the data and this additional masking freedom allows improving data utility in several ways, such as increasing data granularity, reducing the impact of outliers and avoiding discretization of numerical data [4] microaggregation.", [["increasing data granularity", "PROBLEM", 149, 176], ["numerical data", "TEST", 241, 255], ["microaggregation", "PROBLEM", 260, 276]]]], "PMC7078471": [["INTRODUCTIONHuman noroviruses (HuNoVs) are a leading cause of nonbacterial gastroenteritis worldwide.", [["nonbacterial gastroenteritis", "DISEASE", 62, 90], ["INTRODUCTIONHuman noroviruses", "ORGANISM", 0, 29], ["HuNoVs", "GENE_OR_GENE_PRODUCT", 31, 37], ["INTRODUCTIONHuman noroviruses", "PROBLEM", 0, 29], ["nonbacterial gastroenteritis", "PROBLEM", 62, 90], ["nonbacterial", "OBSERVATION_MODIFIER", 62, 74], ["gastroenteritis", "OBSERVATION", 75, 90]]], ["From the first recognition in 1968 that a virus caused an outbreak of HuNoV gastroenteritis in an elementary school in Norwalk, Ohio (1), until 2016, there was no in vitro culture system of HuNoV in intestinal epithelial cells.", [["intestinal epithelial cells", "ANATOMY", 199, 226], ["gastroenteritis", "DISEASE", 76, 91], ["HuNoV", "CHEMICAL", 190, 195], ["HuNoV", "SIMPLE_CHEMICAL", 190, 195], ["intestinal epithelial cells", "CELL", 199, 226], ["HuNoV", "PROTEIN", 190, 195], ["intestinal epithelial cells", "CELL_TYPE", 199, 226], ["HuNoV", "SPECIES", 70, 75], ["HuNoV", "SPECIES", 190, 195], ["a virus", "PROBLEM", 40, 47], ["HuNoV gastroenteritis", "PROBLEM", 70, 91], ["outbreak", "OBSERVATION_MODIFIER", 58, 66], ["HuNoV gastroenteritis", "OBSERVATION", 70, 91], ["HuNoV", "OBSERVATION", 190, 195], ["intestinal epithelial cells", "OBSERVATION", 199, 226]]], ["A novel HuNoV culture system using human intestinal enteroids (HIEs) generated from stem cells isolated from human small intestinal crypts is now available and is being used worldwide to study virus replication, inactivation, and neutralizing antibodies (2\u20139).INTRODUCTIONSecretor status is highly associated with infection and disease caused by many HuNoV strains based upon findings from human experimental infection studies and evaluation of acute gastroenteritis outbreaks (10\u201314).", [["intestinal enteroids", "ANATOMY", 41, 61], ["HIEs", "ANATOMY", 63, 67], ["stem cells", "ANATOMY", 84, 94], ["small intestinal crypts", "ANATOMY", 115, 138], ["infection", "DISEASE", 314, 323], ["infection", "DISEASE", 409, 418], ["gastroenteritis", "DISEASE", 451, 466], ["human", "ORGANISM", 35, 40], ["intestinal enteroids", "CANCER", 41, 61], ["HIEs", "CELL", 63, 67], ["stem cells", "CELL", 84, 94], ["human", "ORGANISM", 109, 114], ["intestinal crypts", "MULTI-TISSUE_STRUCTURE", 121, 138], ["human", "ORGANISM", 390, 395], ["HuNoV culture system", "CELL_LINE", 8, 28], ["stem cells", "CELL_TYPE", 84, 94], ["neutralizing antibodies", "PROTEIN", 230, 253], ["2\u20139", "PROTEIN", 255, 258], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 390, 395], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 390, 395], ["A novel HuNoV culture system", "TEST", 0, 28], ["human intestinal enteroids", "TEST", 35, 61], ["stem cells", "PROBLEM", 84, 94], ["human small intestinal crypts", "PROBLEM", 109, 138], ["neutralizing antibodies", "TEST", 230, 253], ["infection", "PROBLEM", 314, 323], ["disease", "PROBLEM", 328, 335], ["many HuNoV strains", "PROBLEM", 346, 364], ["human experimental infection studies", "TEST", 390, 426], ["evaluation", "TEST", 431, 441], ["acute gastroenteritis outbreaks", "PROBLEM", 445, 476], ["intestinal", "ANATOMY", 41, 51], ["stem cells", "OBSERVATION", 84, 94], ["small", "OBSERVATION_MODIFIER", 115, 120], ["intestinal crypts", "OBSERVATION", 121, 138], ["highly associated with", "UNCERTAINTY", 291, 313], ["infection", "OBSERVATION", 314, 323], ["HuNoV", "OBSERVATION", 351, 356], ["acute", "OBSERVATION_MODIFIER", 445, 450], ["gastroenteritis", "OBSERVATION", 451, 466]]], ["Fucosyltransferase 2 (FUT2) is an enzyme expressed in human epithelial cells that catalyzes \u03b11,2-fucosylation of the terminal galactose, preferentially on glycan type 1 chain precursors.", [["epithelial cells", "ANATOMY", 60, 76], ["galactose", "CHEMICAL", 126, 135], ["galactose", "CHEMICAL", 126, 135], ["Fucosyltransferase 2", "GENE_OR_GENE_PRODUCT", 0, 20], ["FUT2", "GENE_OR_GENE_PRODUCT", 22, 26], ["human", "ORGANISM", 54, 59], ["epithelial cells", "CELL", 60, 76], ["galactose", "SIMPLE_CHEMICAL", 126, 135], ["glycan type 1 chain", "GENE_OR_GENE_PRODUCT", 155, 174], ["Fucosyltransferase 2", "PROTEIN", 0, 20], ["FUT2", "PROTEIN", 22, 26], ["human epithelial cells", "CELL_TYPE", 54, 76], ["terminal galactose", "PROTEIN", 117, 135], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["Fucosyltransferase", "TEST", 0, 18], ["an enzyme", "TEST", 31, 40], ["human epithelial cells", "TEST", 54, 76], ["the terminal galactose", "PROBLEM", 113, 135], ["epithelial cells", "OBSERVATION", 60, 76]]], ["Glycosyltransferases coded for by FUT2 along with FUT3 and ABO genes determine the histo-blood group antigens (HBGAs) found on the epithelial cell surface (15, 16).", [["histo-blood", "ANATOMY", 83, 94], ["epithelial cell surface", "ANATOMY", 131, 154], ["FUT2", "GENE_OR_GENE_PRODUCT", 34, 38], ["FUT3", "GENE_OR_GENE_PRODUCT", 50, 54], ["ABO", "GENE_OR_GENE_PRODUCT", 59, 62], ["histo-blood group antigens", "GENE_OR_GENE_PRODUCT", 83, 109], ["HBGAs", "GENE_OR_GENE_PRODUCT", 111, 116], ["epithelial cell surface", "CELLULAR_COMPONENT", 131, 154], ["FUT2", "PROTEIN", 34, 38], ["FUT3 and ABO genes", "DNA", 50, 68], ["histo-blood group antigens", "PROTEIN", 83, 109], ["HBGAs", "PROTEIN", 111, 116], ["Glycosyltransferases", "TREATMENT", 0, 20], ["ABO genes", "TEST", 59, 68], ["the histo", "TEST", 79, 88], ["blood group antigens", "TEST", 89, 109], ["HBGAs", "TEST", 111, 116], ["the epithelial cell surface", "TEST", 127, 154], ["epithelial cell", "ANATOMY", 131, 146], ["surface", "ANATOMY_MODIFIER", 147, 154]]], ["Persons who lack functional FUT2 alleles do not express ABH HBGAs on epithelial cells, are designated nonsecretors, and are highly resistant to gastroenteritis caused by some HuNoV strains such as GII.4 viruses.", [["epithelial cells", "ANATOMY", 69, 85], ["nonsecretors", "ANATOMY", 102, 114], ["gastroenteritis", "DISEASE", 144, 159], ["Persons", "ORGANISM", 0, 7], ["FUT2", "GENE_OR_GENE_PRODUCT", 28, 32], ["ABH", "GENE_OR_GENE_PRODUCT", 56, 59], ["epithelial cells", "CELL", 69, 85], ["HuNoV", "GENE_OR_GENE_PRODUCT", 175, 180], ["FUT2 alleles", "DNA", 28, 40], ["ABH HBGAs", "PROTEIN", 56, 65], ["epithelial cells", "CELL_TYPE", 69, 85], ["Persons", "SPECIES", 0, 7], ["epithelial cells", "PROBLEM", 69, 85], ["gastroenteritis", "PROBLEM", 144, 159], ["some HuNoV strains", "PROBLEM", 170, 188], ["GII", "PROBLEM", 197, 200], ["epithelial cells", "OBSERVATION", 69, 85], ["gastroenteritis", "OBSERVATION", 144, 159], ["HuNoV strains", "OBSERVATION", 175, 188], ["viruses", "OBSERVATION", 203, 210]]], ["Similarly, HIEs derived from nonsecretor individuals are not susceptible to GII.4 HuNoV infection (2).", [["infection", "DISEASE", 88, 97], ["GII", "PROBLEM", 76, 79], ["4 HuNoV infection", "PROBLEM", 80, 97], ["HuNoV", "OBSERVATION_MODIFIER", 82, 87], ["infection", "OBSERVATION", 88, 97]]], ["HIEs and gastrointestinal epithelial cells of secretor-positive individuals also bind norovirus virus-like particles (VLPs) (17, 21).", [["HIEs", "ANATOMY", 0, 4], ["gastrointestinal epithelial cells", "ANATOMY", 9, 42], ["gastrointestinal epithelial cells", "CELL", 9, 42], ["secretor", "GENE_OR_GENE_PRODUCT", 46, 54], ["norovirus virus-like particles", "ORGANISM", 86, 116], ["VLPs", "ORGANISM", 118, 122], ["HIEs", "CELL_TYPE", 0, 4], ["gastrointestinal epithelial cells", "CELL_TYPE", 9, 42], ["norovirus virus", "SPECIES", 86, 101], ["gastrointestinal epithelial cells", "TEST", 9, 42], ["secretor", "TEST", 46, 54], ["bind norovirus virus", "PROBLEM", 81, 101], ["gastrointestinal", "ANATOMY", 9, 25], ["epithelial cells", "OBSERVATION", 26, 42], ["bind norovirus virus", "OBSERVATION", 81, 101], ["particles", "OBSERVATION_MODIFIER", 107, 116]]], ["However, while HIEs from secretors are permissive to HuNoV replication, FUT2 expression in conventional cancer-derived cell lines is not sufficient to make cells susceptible to HuNoV replication, suggesting that HBGAs function primarily as an initial attachment factor (18, 19).", [["cancer", "ANATOMY", 104, 110], ["cell lines", "ANATOMY", 119, 129], ["cells", "ANATOMY", 156, 161], ["cancer", "DISEASE", 104, 110], ["HIEs", "GENE_OR_GENE_PRODUCT", 15, 19], ["HuNoV", "GENE_OR_GENE_PRODUCT", 53, 58], ["FUT2", "GENE_OR_GENE_PRODUCT", 72, 76], ["conventional cancer-derived cell lines", "CELL", 91, 129], ["cells", "CELL", 156, 161], ["HuNoV", "GENE_OR_GENE_PRODUCT", 177, 182], ["HBGAs", "GENE_OR_GENE_PRODUCT", 212, 217], ["HIEs", "PROTEIN", 15, 19], ["FUT2", "PROTEIN", 72, 76], ["conventional cancer-derived cell lines", "CELL_LINE", 91, 129], ["HBGAs", "PROTEIN", 212, 217], ["attachment factor", "PROTEIN", 251, 268], ["HuNoV", "SPECIES", 53, 58], ["HuNoV replication", "TREATMENT", 53, 70], ["FUT2 expression in conventional cancer", "PROBLEM", 72, 110], ["derived cell lines", "TREATMENT", 111, 129], ["HuNoV replication", "TREATMENT", 177, 194], ["HBGAs function", "PROBLEM", 212, 226], ["cancer", "OBSERVATION", 104, 110], ["cell lines", "OBSERVATION", 119, 129]]], ["These data also lead to questions on whether there are additional genetically determined differences in HuNoV susceptibility in addition to secretor status.", [["HuNoV", "CANCER", 104, 109], ["HuNoV", "OBSERVATION", 104, 109]]], ["In this study, we evaluated the direct association between FUT2 function and HuNoV infectivity using HIEs with or without FUT2 expression in the same genetic background.Generation and characterization of isogenic HIE lines. ::: RESULTSWe previously showed that GII.4 viruses can replicate in HIEs derived from secretor-positive individuals and a GII.3 strain can replicate in both secretor-positive and some secretor-negative lines, recapitulating observations seen in epidemiologic studies (2).", [["secretor-negative lines", "ANATOMY", 408, 431], ["FUT2", "GENE_OR_GENE_PRODUCT", 59, 63], ["HuNoV", "GENE_OR_GENE_PRODUCT", 77, 82], ["FUT2", "GENE_OR_GENE_PRODUCT", 122, 126], ["HIE lines", "CELL", 213, 222], ["GII.4 viruses", "ORGANISM", 261, 274], ["HIEs", "GENE_OR_GENE_PRODUCT", 292, 296], ["secretor", "GENE_OR_GENE_PRODUCT", 310, 318], ["GII.3", "GENE_OR_GENE_PRODUCT", 346, 351], ["secretor", "GENE_OR_GENE_PRODUCT", 381, 389], ["secretor", "GENE_OR_GENE_PRODUCT", 408, 416], ["FUT2", "PROTEIN", 59, 63], ["FUT2", "PROTEIN", 122, 126], ["isogenic HIE lines", "CELL_LINE", 204, 222], ["secretor-positive and some secretor-negative lines", "CELL_LINE", 381, 431], ["GII.4 viruses", "SPECIES", 261, 274], ["this study", "TEST", 3, 13], ["GII.4 viruses", "PROBLEM", 261, 274], ["a GII.3 strain", "PROBLEM", 344, 358], ["epidemiologic studies", "TEST", 469, 490], ["HIE lines", "OBSERVATION", 213, 222], ["negative lines", "OBSERVATION", 417, 431]]], ["We determined the FUT2 (Se) and FUT3 (Le) genotypes of jejunal HIE lines and selected two lines (J2 and J4); both lines express FUT3, eliminating Lewis status as a variable in these studies (Table 1).", [["jejunal HIE lines", "ANATOMY", 55, 72], ["FUT2", "GENE_OR_GENE_PRODUCT", 18, 22], ["Se", "GENE_OR_GENE_PRODUCT", 24, 26], ["FUT3", "GENE_OR_GENE_PRODUCT", 32, 36], ["jejunal HIE lines", "CELL", 55, 72], ["FUT3", "GENE_OR_GENE_PRODUCT", 128, 132], ["FUT2 (Se)", "DNA", 18, 27], ["FUT3", "DNA", 32, 36], ["jejunal HIE lines", "CELL_LINE", 55, 72], ["J2", "CELL_LINE", 97, 99], ["J4", "CELL_LINE", 104, 106], ["FUT3", "PROTEIN", 128, 132], ["FUT3 (Le) genotypes of jejunal HIE lines", "TREATMENT", 32, 72], ["selected two lines (J2 and J4)", "TREATMENT", 77, 107], ["these studies", "TEST", 176, 189], ["jejunal", "ANATOMY", 55, 62], ["HIE lines", "OBSERVATION", 63, 72]]], ["The J2 cell line is heterozygous wild type (Se/se428 [J2Fut2+/\u2212]); because the Se gene is autosomal dominant, the cells are secretor positive.", [["J2 cell line", "ANATOMY", 4, 16], ["cells", "ANATOMY", 114, 119], ["Se", "CHEMICAL", 79, 81], ["J2 cell line", "CELL", 4, 16], ["Se", "GENE_OR_GENE_PRODUCT", 79, 81], ["cells", "CELL", 114, 119], ["secretor", "GENE_OR_GENE_PRODUCT", 124, 132], ["J2 cell line", "CELL_LINE", 4, 16], ["Se gene", "DNA", 79, 86], ["The J2 cell line", "TREATMENT", 0, 16], ["J2Fut2", "TEST", 54, 60], ["autosomal dominant", "PROBLEM", 90, 108], ["secretor positive", "PROBLEM", 124, 141], ["J2 cell line", "OBSERVATION", 4, 16], ["autosomal", "OBSERVATION_MODIFIER", 90, 99], ["dominant", "OBSERVATION", 100, 108]]], ["The J4 line has a homozygous se428/se428 (J4Fut2\u2212/\u2212) recessive mutation and is secretor negative (20).", [["J4 line", "ANATOMY", 4, 11], ["J4 line", "CELL", 4, 11], ["J4 line", "CELL_LINE", 4, 11], ["The J4 line", "TREATMENT", 0, 11], ["a homozygous", "TEST", 16, 28], ["J4Fut2\u2212", "TEST", 42, 49], ["recessive mutation", "PROBLEM", 53, 71], ["secretor", "TEST", 79, 87], ["J4 line", "OBSERVATION", 4, 11]]], ["No other mutations associated with loss of or decreased FUT2 enzymatic function were observed in the J2 or J4 line.", [["J4 line", "ANATOMY", 107, 114], ["FUT2", "GENE_OR_GENE_PRODUCT", 56, 60], ["J4 line", "CELL", 107, 114], ["FUT2", "PROTEIN", 56, 60], ["J2 or J4 line", "CELL_LINE", 101, 114], ["other mutations", "PROBLEM", 3, 18], ["loss of or decreased FUT2 enzymatic function", "PROBLEM", 35, 79], ["mutations", "OBSERVATION", 9, 18], ["enzymatic function", "OBSERVATION", 61, 79], ["J2", "ANATOMY", 101, 103], ["J4 line", "OBSERVATION", 107, 114]]], ["To better understand the importance of FUT2 in HuNoV infection, we generated isogenic knockout (KO) and knock-in (KI) HIE lines.", [["infection", "DISEASE", 53, 62], ["FUT2", "GENE_OR_GENE_PRODUCT", 39, 43], ["HuNoV", "GENE_OR_GENE_PRODUCT", 47, 52], ["HIE lines", "CELL", 118, 127], ["FUT2", "PROTEIN", 39, 43], ["isogenic knockout (KO) and knock-in (KI) HIE lines", "CELL_LINE", 77, 127], ["FUT2 in HuNoV infection", "PROBLEM", 39, 62]]], ["A lentivirus-delivered CRISPR/Cas9 construct with a guide RNA targeting the FUT2 coding region was used to knock out FUT2 from J2 (J2Fut2\u2212/\u2212).", [["lentivirus", "ORGANISM", 2, 12], ["Cas9", "GENE_OR_GENE_PRODUCT", 30, 34], ["FUT2", "GENE_OR_GENE_PRODUCT", 76, 80], ["FUT2", "GENE_OR_GENE_PRODUCT", 117, 121], ["lentivirus-delivered CRISPR/Cas9 construct", "DNA", 2, 44], ["FUT2 coding region", "DNA", 76, 94], ["FUT2", "PROTEIN", 117, 121], ["J2", "DNA", 127, 129], ["A lentivirus", "TREATMENT", 0, 12], ["CRISPR/Cas9 construct", "TREATMENT", 23, 44], ["a guide RNA", "TREATMENT", 50, 61], ["the FUT2 coding region", "TREATMENT", 72, 94], ["lentivirus", "OBSERVATION", 2, 12]]], ["Single cell selection under puromycin pressure was used to isolate a clonal population, and deletions of the gene in both alleles were confirmed by sequencing.", [["cell", "ANATOMY", 7, 11], ["puromycin", "CHEMICAL", 28, 37], ["puromycin", "CHEMICAL", 28, 37], ["cell", "CELL", 7, 11], ["puromycin", "SIMPLE_CHEMICAL", 28, 37], ["alleles", "DNA", 122, 129], ["Single cell selection", "TREATMENT", 0, 21], ["puromycin pressure", "TREATMENT", 28, 46], ["a clonal population", "PROBLEM", 67, 86], ["deletions of the gene in both alleles", "TREATMENT", 92, 129], ["puromycin pressure", "OBSERVATION", 28, 46]]], ["To generate the KI FUT2 line, we transduced a functional FUT2 coding sequence driven by a cytomegalovirus (CMV) promoter in a lentivirus into J4 (J4Fut2\u2212/\u2212/FUT2) cells.Generation and characterization of isogenic HIE lines. ::: RESULTSFirst, we confirmed the phenotype of the FUT2 KO and KI lines by evaluating HBGA expression using an enzyme-linked immunosorbent assay (ELISA) (Fig. 1).", [["KI FUT2 line", "ANATOMY", 16, 28], ["J4 (J4Fut2\u2212/\u2212/FUT2) cells", "ANATOMY", 142, 167], ["KI lines", "ANATOMY", 287, 295], ["KI FUT2 line", "CELL", 16, 28], ["FUT2", "GENE_OR_GENE_PRODUCT", 57, 61], ["cytomegalovirus", "ORGANISM", 90, 105], ["CMV", "ORGANISM", 107, 110], ["lentivirus", "ORGANISM", 126, 136], ["HIE lines", "CELL", 212, 221], ["FUT2", "GENE_OR_GENE_PRODUCT", 275, 279], ["KI lines", "CELL", 287, 295], ["HBGA", "GENE_OR_GENE_PRODUCT", 310, 314], ["KI FUT2 line", "CELL_LINE", 16, 28], ["FUT2 coding sequence", "DNA", 57, 77], ["cytomegalovirus (CMV) promoter", "DNA", 90, 120], ["J4 (J4Fut2\u2212/\u2212/FUT2) cells", "CELL_LINE", 142, 167], ["isogenic HIE lines", "CELL_LINE", 203, 221], ["FUT2 KO and KI lines", "CELL_LINE", 275, 295], ["HBGA", "PROTEIN", 310, 314], ["CMV", "SPECIES", 107, 110], ["lentivirus", "SPECIES", 126, 136], ["the KI FUT2 line", "TREATMENT", 12, 28], ["a functional FUT2 coding sequence", "PROBLEM", 44, 77], ["a cytomegalovirus (CMV) promoter", "PROBLEM", 88, 120], ["J4Fut2\u2212/\u2212/FUT2) cells", "TREATMENT", 146, 167], ["an enzyme", "TEST", 332, 341], ["immunosorbent assay", "TEST", 349, 368], ["cytomegalovirus", "OBSERVATION", 90, 105], ["HIE lines", "OBSERVATION", 212, 221]]], ["J2Fut2+/\u2212 cells expressed the secretor-positive glycans, Leb and B, as expected for this secretor-positive, Lewis-positive OB HIE line.", [["J2Fut2+/\u2212 cells", "ANATOMY", 0, 15], ["OB HIE line", "ANATOMY", 123, 134], ["J2Fut2", "GENE_OR_GENE_PRODUCT", 0, 6], ["secretor", "GENE_OR_GENE_PRODUCT", 30, 38], ["Leb", "GENE_OR_GENE_PRODUCT", 57, 60], ["B", "GENE_OR_GENE_PRODUCT", 65, 66], ["secretor", "GENE_OR_GENE_PRODUCT", 89, 97], ["Lewis", "GENE_OR_GENE_PRODUCT", 108, 113], ["J2Fut2+/\u2212 cells", "CELL_LINE", 0, 15], ["secretor-positive glycans", "PROTEIN", 30, 55], ["Leb", "PROTEIN", 57, 60], ["B", "PROTEIN", 65, 66], ["secretor-positive, Lewis-positive OB HIE line", "CELL_LINE", 89, 134], ["J2Fut2", "TEST", 0, 6], ["\u2212 cells", "PROBLEM", 8, 15], ["the secretor", "TEST", 26, 38], ["Leb", "TEST", 57, 60], ["this secretor", "TEST", 84, 97], ["Lewis", "TEST", 108, 113], ["positive glycans", "OBSERVATION_MODIFIER", 39, 55], ["HIE line", "OBSERVATION", 126, 134]]], ["KO of FUT2 altered the J2 phenotype such that the Leb and B glycans were no longer present, and only Lea was detected.", [["FUT2", "GENE_OR_GENE_PRODUCT", 6, 10], ["Leb", "GENE_OR_GENE_PRODUCT", 50, 53], ["B glycans", "GENE_OR_GENE_PRODUCT", 58, 67], ["FUT2", "PROTEIN", 6, 10], ["Leb", "PROTEIN", 50, 53], ["Lea", "PROTEIN", 101, 104], ["FUT2 altered the J2 phenotype", "PROBLEM", 6, 35], ["the Leb and B glycans", "PROBLEM", 46, 67], ["J2 phenotype", "OBSERVATION_MODIFIER", 23, 35], ["no longer", "UNCERTAINTY", 73, 82]]], ["J4Fut2\u2212/\u2212 cells expressed Lea but not Leb or other secretor glycans, confirming the secretor-negative genotype of this line.", [["J4Fut2\u2212/\u2212 cells", "ANATOMY", 0, 15], ["Lea", "GENE_OR_GENE_PRODUCT", 26, 29], ["Leb", "GENE_OR_GENE_PRODUCT", 38, 41], ["secretor glycans", "GENE_OR_GENE_PRODUCT", 51, 67], ["secretor", "GENE_OR_GENE_PRODUCT", 84, 92], ["J4Fut2\u2212/\u2212 cells", "CELL_LINE", 0, 15], ["Lea", "PROTEIN", 26, 29], ["Leb", "PROTEIN", 38, 41], ["secretor glycans", "PROTEIN", 51, 67], ["the secretor", "TEST", 80, 92], ["this line", "TREATMENT", 114, 123]]], ["KI of FUT2 in J4 cells led to Leb instead of Lea expression.Generation and characterization of isogenic HIE lines. ::: RESULTSWe next used immunofluorescence microscopy with fluorescently labeled Ulex europaeus agglutinin-1 (UEA-1 lectin) to detect polarized cell surface expression of terminal \u03b11,2-fucose (Fig. 2).", [["J4 cells", "ANATOMY", 14, 22], ["cell surface", "ANATOMY", 259, 271], ["\u03b11,2-fucose", "CHEMICAL", 295, 306], ["\u03b11,2-fucose", "CHEMICAL", 295, 306], ["FUT2", "GENE_OR_GENE_PRODUCT", 6, 10], ["J4 cells", "CELL", 14, 22], ["Leb", "GENE_OR_GENE_PRODUCT", 30, 33], ["Lea", "GENE_OR_GENE_PRODUCT", 45, 48], ["HIE lines", "CELL", 104, 113], ["agglutinin-1", "GENE_OR_GENE_PRODUCT", 211, 223], ["UEA-1 lectin", "GENE_OR_GENE_PRODUCT", 225, 237], ["cell", "CELL", 259, 263], ["\u03b11,2-fucose", "GENE_OR_GENE_PRODUCT", 295, 306], ["FUT2", "PROTEIN", 6, 10], ["J4 cells", "CELL_LINE", 14, 22], ["Leb", "PROTEIN", 30, 33], ["Lea", "PROTEIN", 45, 48], ["isogenic HIE lines", "CELL_LINE", 95, 113], ["Ulex europaeus agglutinin-1 (UEA-1 lectin", "PROTEIN", 196, 237], ["Ulex europaeus", "SPECIES", 196, 210], ["Ulex europaeus", "SPECIES", 196, 210], ["FUT2 in J4 cells", "PROBLEM", 6, 22], ["immunofluorescence microscopy", "TEST", 139, 168], ["fluorescently labeled Ulex europaeus agglutinin", "TEST", 174, 221], ["UEA", "TEST", 225, 228], ["polarized cell surface expression", "TEST", 249, 282], ["FUT2", "OBSERVATION", 6, 10], ["J4 cells", "OBSERVATION", 14, 22], ["Lea expression", "OBSERVATION", 45, 59], ["HIE lines", "OBSERVATION", 104, 113], ["polarized cell", "OBSERVATION", 249, 263], ["surface", "OBSERVATION_MODIFIER", 264, 271], ["terminal", "OBSERVATION_MODIFIER", 286, 294]]], ["Both J2Fut2+/\u2212 and J4Fut2\u2212/\u2212/FUT2 cells had apical staining of UEA-1 lectin.", [["J2Fut2+/\u2212", "ANATOMY", 5, 14], ["J4Fut2\u2212/\u2212/FUT2 cells", "ANATOMY", 19, 39], ["apical", "ANATOMY", 44, 50], ["J2Fut2", "GENE_OR_GENE_PRODUCT", 5, 11], ["J4Fut2\u2212", "GENE_OR_GENE_PRODUCT", 19, 26], ["UEA-1 lectin", "GENE_OR_GENE_PRODUCT", 63, 75], ["J2Fut2", "PROTEIN", 5, 11], ["J4Fut2\u2212/\u2212/FUT2 cells", "CELL_LINE", 19, 39], ["UEA-1 lectin", "PROTEIN", 63, 75], ["J2Fut2", "TEST", 5, 11], ["J4Fut2\u2212", "TEST", 19, 26], ["FUT2 cells", "PROBLEM", 29, 39], ["apical staining of UEA", "PROBLEM", 44, 66], ["apical", "ANATOMY_MODIFIER", 44, 50], ["staining", "OBSERVATION", 51, 59], ["UEA", "ANATOMY_MODIFIER", 63, 66]]], ["This apical staining was lost in J2Fut2\u2212/\u2212 and J4Fut2\u2212/\u2212 cells (Fig. 2A).", [["apical", "ANATOMY", 5, 11], ["J2Fut2\u2212/\u2212", "ANATOMY", 33, 42], ["J4Fut2\u2212/\u2212 cells", "ANATOMY", 47, 62], ["apical", "CELLULAR_COMPONENT", 5, 11], ["J2Fut2", "GENE_OR_GENE_PRODUCT", 33, 39], ["J2Fut2\u2212/\u2212 and J4Fut2\u2212/\u2212 cells", "CELL_LINE", 33, 62], ["This apical staining", "TEST", 0, 20], ["J2Fut2", "TEST", 33, 39], ["apical", "ANATOMY_MODIFIER", 5, 11], ["staining", "OBSERVATION", 12, 20]]], ["These findings indicate that, as expected, terminal fucosylation of the glycan precursor in HIEs depends on the expression of the FUT2 gene.", [["HIEs", "CANCER", 92, 96], ["FUT2", "GENE_OR_GENE_PRODUCT", 130, 134], ["FUT2 gene", "DNA", 130, 139]]], ["In the secretor-negative lines, unexpected internal cellular UEA-1 staining was present that was not observed in the secretor-positive lines.", [["secretor-negative lines", "ANATOMY", 7, 30], ["cellular", "ANATOMY", 52, 60], ["secretor-positive lines", "ANATOMY", 117, 140], ["cellular", "CELL", 52, 60], ["UEA-1", "GENE_OR_GENE_PRODUCT", 61, 66], ["secretor-negative lines", "CELL_LINE", 7, 30], ["secretor-positive lines", "CELL_LINE", 117, 140], ["unexpected internal cellular UEA", "PROBLEM", 32, 64], ["negative lines", "OBSERVATION", 16, 30], ["internal", "OBSERVATION_MODIFIER", 43, 51], ["cellular", "OBSERVATION_MODIFIER", 52, 60], ["UEA", "OBSERVATION_MODIFIER", 61, 64], ["not observed", "UNCERTAINTY", 97, 109], ["positive lines", "OBSERVATION", 126, 140]]], ["To confirm that the internal staining was due to specific UEA-1 recognition of \u03b11,2-fucose and not off-target binding due to loss of the specific ligand, we preincubated the UEA-1 lectin with l-fucose prior to staining.", [["\u03b11,2-fucose", "CHEMICAL", 79, 90], ["l-fucose", "CHEMICAL", 192, 200], ["\u03b11,2-fucose", "CHEMICAL", 79, 90], ["UEA-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["\u03b11,2-fucose", "SIMPLE_CHEMICAL", 79, 90], ["UEA-1 lectin", "GENE_OR_GENE_PRODUCT", 174, 186], ["l-fucose", "SIMPLE_CHEMICAL", 192, 200], ["UEA", "PROTEIN", 58, 61], ["UEA-1 lectin", "PROTEIN", 174, 186], ["l-fucose", "PROTEIN", 192, 200], ["the internal staining", "PROBLEM", 16, 37], ["specific UEA", "TEST", 49, 61], ["target binding", "PROBLEM", 103, 117], ["loss of the specific ligand", "PROBLEM", 125, 152], ["the UEA", "TEST", 170, 177]]], ["When UEA-1 was preincubated with 10 mM l-fucose, staining was not detected in the secretor-negative lines and was significantly reduced in the secretor-positive lines (Fig. 2B).", [["lines", "ANATOMY", 100, 105], ["secretor-positive lines", "ANATOMY", 143, 166], ["l-fucose", "CHEMICAL", 39, 47], ["l-fucose", "CHEMICAL", 39, 47], ["UEA-1", "GENE_OR_GENE_PRODUCT", 5, 10], ["l-fucose", "SIMPLE_CHEMICAL", 39, 47], ["UEA-1", "PROTEIN", 5, 10], ["secretor-negative lines", "CELL_LINE", 82, 105], ["secretor-positive lines", "CELL_LINE", 143, 166], ["UEA", "TEST", 5, 8], ["negative lines", "OBSERVATION", 91, 105], ["reduced", "OBSERVATION_MODIFIER", 128, 135], ["positive lines", "OBSERVATION", 152, 166]]], ["After preincubation with 100 mM l-fucose, UEA-1 staining was not detected in either the secretor-negative or secretor-positive lines (Fig. 2C).", [["secretor-positive lines", "ANATOMY", 109, 132], ["l-fucose", "CHEMICAL", 32, 40], ["l-fucose", "CHEMICAL", 32, 40], ["l-fucose", "GENE_OR_GENE_PRODUCT", 32, 40], ["UEA-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["secretor-negative or secretor-positive lines", "CELL_LINE", 88, 132], ["UEA", "TEST", 42, 45], ["the secretor", "TEST", 84, 96], ["positive lines", "OBSERVATION", 118, 132]]], ["Together, these data indicate that the apical and the internal staining observed with UEA-1 is due to specific interaction with \u03b11,2-fucose.", [["apical", "ANATOMY", 39, 45], ["\u03b11,2-fucose", "CHEMICAL", 128, 139], ["\u03b11,2-fucose", "CHEMICAL", 128, 139], ["apical", "CELLULAR_COMPONENT", 39, 45], ["UEA-1", "GENE_OR_GENE_PRODUCT", 86, 91], ["\u03b11,2-fucose", "SIMPLE_CHEMICAL", 128, 139], ["UEA-1", "PROTEIN", 86, 91], ["\u03b11,2", "PROTEIN", 128, 132], ["these data", "TEST", 10, 20], ["the apical and the internal staining", "PROBLEM", 35, 71], ["UEA", "TEST", 86, 89], ["apical", "ANATOMY_MODIFIER", 39, 45], ["internal", "OBSERVATION_MODIFIER", 54, 62], ["staining", "OBSERVATION", 63, 71]]], ["Table 1 summarizes the genotypic and phenotypic findings for the parental, KO and KI cell lines.Effect of FUT2 expression on replication of HuNoV strains in isogenic HIE cell lines. ::: RESULTSTo assess whether these isogenic cell lines support HuNoV replication, we evaluated virus binding and subsequent replication of GII.4, GII.3, GII.17, and GI.1 HuNoV strains that we previously demonstrated replicate in HIEs (2).", [["KI cell lines", "ANATOMY", 82, 95], ["HIE cell lines", "ANATOMY", 166, 180], ["cell lines", "ANATOMY", 226, 236], ["KO", "CELL", 75, 77], ["KI cell lines", "CELL", 82, 95], ["FUT2", "GENE_OR_GENE_PRODUCT", 106, 110], ["HuNoV", "GENE_OR_GENE_PRODUCT", 140, 145], ["HIE cell lines", "CELL", 166, 180], ["cell lines", "CELL", 226, 236], ["HuNoV", "CELL", 245, 250], ["GII.4", "ORGANISM", 321, 326], ["GII.3", "ORGANISM", 328, 333], ["GII.17", "ORGANISM", 335, 341], ["GI.1", "GENE_OR_GENE_PRODUCT", 347, 351], ["parental, KO and KI cell lines", "CELL_LINE", 65, 95], ["FUT2", "PROTEIN", 106, 110], ["isogenic HIE cell lines", "CELL_LINE", 157, 180], ["isogenic cell lines", "CELL_LINE", 217, 236], ["HuNoV", "SPECIES", 245, 250], ["KI cell lines", "TREATMENT", 82, 95], ["FUT2 expression", "PROBLEM", 106, 121], ["HuNoV strains", "PROBLEM", 140, 153], ["these isogenic cell lines", "TREATMENT", 211, 236], ["HuNoV replication", "TREATMENT", 245, 262], ["virus binding", "PROBLEM", 277, 290], ["GII", "TEST", 321, 324], ["GII", "TEST", 328, 331], ["GII", "TEST", 335, 338], ["KI cell lines", "OBSERVATION", 82, 95], ["HIE cell lines", "OBSERVATION", 166, 180], ["cell lines", "OBSERVATION", 226, 236]]], ["Since all of these viruses but GII.4 require bile for replication, all infections were performed in the presence of glycochenodeoxycholic acid (GCDCA), a bile acid that supports replication (21).Effect of FUT2 expression on replication of HuNoV strains in isogenic HIE cell lines. ::: RESULTSFirst, we assessed the effect of KO of FUT2 from J2 cells with the four HuNoV strains (Fig. 3).", [["bile", "ANATOMY", 45, 49], ["HIE cell lines", "ANATOMY", 265, 279], ["J2 cells", "ANATOMY", 341, 349], ["infections", "DISEASE", 71, 81], ["glycochenodeoxycholic acid", "CHEMICAL", 116, 142], ["GCDCA", "CHEMICAL", 144, 149], ["bile acid", "CHEMICAL", 154, 163], ["glycochenodeoxycholic acid", "CHEMICAL", 116, 142], ["GCDCA", "CHEMICAL", 144, 149], ["bile acid", "CHEMICAL", 154, 163], ["bile", "MULTI-TISSUE_STRUCTURE", 45, 49], ["glycochenodeoxycholic acid", "SIMPLE_CHEMICAL", 116, 142], ["GCDCA", "SIMPLE_CHEMICAL", 144, 149], ["bile acid", "SIMPLE_CHEMICAL", 154, 163], ["FUT2", "GENE_OR_GENE_PRODUCT", 205, 209], ["HuNoV", "GENE_OR_GENE_PRODUCT", 239, 244], ["HIE cell lines", "CELL", 265, 279], ["FUT2", "GENE_OR_GENE_PRODUCT", 331, 335], ["J2 cells", "CELL", 341, 349], ["FUT2", "PROTEIN", 205, 209], ["isogenic HIE cell lines", "CELL_LINE", 256, 279], ["FUT2", "PROTEIN", 331, 335], ["J2 cells", "CELL_LINE", 341, 349], ["GII", "PROBLEM", 31, 34], ["replication", "TREATMENT", 54, 65], ["all infections", "PROBLEM", 67, 81], ["glycochenodeoxycholic acid", "TREATMENT", 116, 142], ["a bile acid", "TEST", 152, 163], ["FUT2 expression", "PROBLEM", 205, 220], ["HuNoV strains", "PROBLEM", 239, 252], ["FUT2 from J2 cells", "TREATMENT", 331, 349], ["viruses", "OBSERVATION", 19, 26], ["bile", "ANATOMY", 45, 49], ["infections", "OBSERVATION", 71, 81], ["bile", "ANATOMY", 154, 158], ["HIE cell lines", "OBSERVATION", 265, 279]]], ["After 1 or 2 h postinfection (hpi) and washing off the inoculum, GII.4, GII.3, and GI.1 binding was significantly reduced in the J2Fut\u2212/\u2212 cells compared to the parental J2Fut2+/\u2212 cells.", [["J2Fut\u2212/\u2212 cells", "ANATOMY", 129, 143], ["J2Fut2+/\u2212 cells", "ANATOMY", 169, 184], ["GI.1", "GENE_OR_GENE_PRODUCT", 83, 87], ["J2Fut\u2212/\u2212 cells", "CELL", 129, 143], ["J2Fut2+/\u2212 cells", "CELL", 169, 184], ["J2Fut\u2212/\u2212 cells", "CELL_LINE", 129, 143], ["parental J2Fut2+/\u2212 cells", "CELL_LINE", 160, 184], ["the inoculum", "TEST", 51, 63], ["GII", "TEST", 65, 68], ["GII", "TEST", 72, 75], ["the J2Fut\u2212/\u2212 cells", "PROBLEM", 125, 143], ["the parental J2Fut2", "TEST", 156, 175], ["\u2212 cells", "OBSERVATION", 177, 184]]], ["GII.17 binding was slightly, but not significantly, reduced in several experiments.", [["reduced", "OBSERVATION_MODIFIER", 52, 59]]], ["Viral replication was completely abrogated at 24 hpi for GII.4, GII.17, and GI.1 in the J2Fut2\u2212/\u2212 HIEs.", [["Viral", "ORGANISM", 0, 5], ["J2Fut2", "GENE_OR_GENE_PRODUCT", 88, 94], ["J2Fut2", "PROTEIN", 88, 94], ["Viral replication", "PROBLEM", 0, 17], ["GII", "TEST", 57, 60], ["GII", "TEST", 64, 67]]], ["GII.3 was able to replicate in the J2Fut2\u2212/\u2212 line, consistent with our previous findings that GII.3 is able to replicate in some secretor-negative lines (2).", [["J2Fut2\u2212/\u2212 line", "ANATOMY", 35, 49], ["GII.3", "GENE_OR_GENE_PRODUCT", 94, 99], ["GII.3", "PROTEIN", 0, 5], ["J2Fut2\u2212/\u2212 line", "CELL_LINE", 35, 49], ["GII.3", "DNA", 94, 99], ["secretor-negative lines", "CELL_LINE", 129, 152], ["the J2Fut2\u2212/\u2212 line", "TREATMENT", 31, 49], ["consistent with", "UNCERTAINTY", 51, 66], ["negative lines", "OBSERVATION", 138, 152]]], ["These findings support the requirement for functional FUT2 and secretor-positive HBGAs as an initial binding factor for several strains of HuNoV that is critical for replication.Effect of FUT2 expression on replication of HuNoV strains in isogenic HIE cell lines. ::: RESULTSNext, we assayed the J4Fut2\u2212/\u2212/FUT2 line to determine whether a genetically resistant HIE line can become susceptible with the expression of FUT2.", [["HIE cell lines", "ANATOMY", 248, 262], ["J4Fut2\u2212/\u2212/FUT2 line", "ANATOMY", 296, 315], ["HIE line", "ANATOMY", 361, 369], ["FUT2", "GENE_OR_GENE_PRODUCT", 54, 58], ["secretor", "GENE_OR_GENE_PRODUCT", 63, 71], ["HBGAs", "GENE_OR_GENE_PRODUCT", 81, 86], ["HuNoV", "GENE_OR_GENE_PRODUCT", 139, 144], ["FUT2", "GENE_OR_GENE_PRODUCT", 188, 192], ["HuNoV", "GENE_OR_GENE_PRODUCT", 222, 227], ["HIE cell lines", "CELL", 248, 262], ["J4Fut2\u2212", "GENE_OR_GENE_PRODUCT", 296, 303], ["HIE line", "CELL", 361, 369], ["FUT2", "GENE_OR_GENE_PRODUCT", 416, 420], ["FUT2", "PROTEIN", 54, 58], ["secretor-positive HBGAs", "PROTEIN", 63, 86], ["HuNoV", "PROTEIN", 139, 144], ["FUT2", "PROTEIN", 188, 192], ["isogenic HIE cell lines", "CELL_LINE", 239, 262], ["J4Fut2\u2212/\u2212/FUT2 line", "CELL_LINE", 296, 315], ["genetically resistant HIE line", "CELL_LINE", 339, 369], ["FUT2", "PROTEIN", 416, 420], ["functional FUT2 and secretor-positive HBGAs", "PROBLEM", 43, 86], ["an initial binding factor", "PROBLEM", 90, 115], ["several strains of HuNoV", "PROBLEM", 120, 144], ["FUT2 expression", "PROBLEM", 188, 203], ["HuNoV strains", "PROBLEM", 222, 235], ["isogenic HIE cell lines", "TREATMENT", 239, 262], ["the J4Fut2\u2212/\u2212/FUT2 line", "TREATMENT", 292, 315], ["a genetically resistant HIE line", "PROBLEM", 337, 369], ["HIE cell lines", "OBSERVATION", 248, 262]]], ["We observed increased HuNoV binding at 1 or 2 hpi in the J4Fut2\u2212/\u2212/FUT2 line compared with the parental nonsecretor J4Fut2\u2212/\u2212 line for all four HuNoV strains (Fig. 4); however, for GII.4, the increase was not significant.", [["J4Fut2\u2212/\u2212/FUT2 line", "ANATOMY", 57, 76], ["J4Fut2\u2212/\u2212 line", "ANATOMY", 116, 130], ["HuNoV", "GENE_OR_GENE_PRODUCT", 22, 27], ["J4Fut2\u2212", "GENE_OR_GENE_PRODUCT", 57, 64], ["HuNoV", "PROTEIN", 22, 27], ["J4Fut2\u2212/\u2212/FUT2 line", "CELL_LINE", 57, 76], ["parental nonsecretor J4Fut2\u2212/\u2212 line", "CELL_LINE", 95, 130], ["increased HuNoV binding", "PROBLEM", 12, 35], ["FUT2 line", "TREATMENT", 67, 76], ["the parental nonsecretor J4Fut2\u2212/\u2212 line", "TREATMENT", 91, 130], ["GII", "PROBLEM", 181, 184], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["HuNoV", "OBSERVATION", 22, 27], ["increase", "OBSERVATION_MODIFIER", 192, 200], ["not", "UNCERTAINTY", 205, 208], ["significant", "OBSERVATION_MODIFIER", 209, 220]]], ["J4Fut2\u2212/\u2212/FUT2 was permissive to infection by all four viruses, based upon increases in viral genome equivalents (GEs) at 24 hpi.", [["infection", "DISEASE", 33, 42], ["J4Fut2\u2212", "GENE_OR_GENE_PRODUCT", 0, 7], ["\u2212", "GENE_OR_GENE_PRODUCT", 8, 9], ["FUT2", "GENE_OR_GENE_PRODUCT", 10, 14], ["J4Fut2\u2212/\u2212/FUT2", "DNA", 0, 14], ["viral genome", "DNA", 88, 100], ["FUT2", "PROBLEM", 10, 14], ["infection", "PROBLEM", 33, 42], ["all four viruses", "PROBLEM", 46, 62], ["infection", "OBSERVATION", 33, 42], ["viruses", "OBSERVATION", 55, 62], ["increases", "OBSERVATION_MODIFIER", 75, 84], ["viral genome", "OBSERVATION", 88, 100]]], ["Interestingly, although GE levels at 1 to 2 hpi were similar, we observed greater increases in GEs for GII.17 and GI.1 HuNoVs in J4Fut2\u2212/\u2212/FUT2 cells than in J2Fut2+/\u2212 cells at 24 hpi.", [["J4Fut2\u2212/\u2212/FUT2 cells", "ANATOMY", 129, 149], ["J2Fut2+/\u2212 cells", "ANATOMY", 158, 173], ["GE", "GENE_OR_GENE_PRODUCT", 24, 26], ["J2Fut2+", "CELL", 158, 165], ["J4Fut2\u2212/\u2212/FUT2 cells", "CELL_LINE", 129, 149], ["J2Fut2+/\u2212 cells", "CELL_LINE", 158, 173], ["GE levels", "TEST", 24, 33], ["GII", "PROBLEM", 103, 106], ["GI.1 HuNoVs", "TEST", 114, 125], ["FUT2 cells", "PROBLEM", 139, 149], ["J2Fut2", "TEST", 158, 164], ["greater", "OBSERVATION_MODIFIER", 74, 81], ["increases", "OBSERVATION_MODIFIER", 82, 91]]], ["This suggests that additional factors that vary between individual HIE lines, aside from secretor status, may influence the replication of these two strains.", [["HIE lines", "CELL", 67, 76], ["secretor", "GENE_OR_GENE_PRODUCT", 89, 97], ["additional factors", "PROBLEM", 19, 37], ["individual HIE lines", "TREATMENT", 56, 76], ["secretor status", "PROBLEM", 89, 104], ["these two strains", "PROBLEM", 139, 156]]], ["Taken together, these results show that functional FUT2 is sufficient and critical for replication of multiple HuNoV strains and that GII.3 is capable of infection in some secretor-negative HIE lines.DISCUSSIONPrevious studies demonstrated that the HuNoV genome is capable of productive infection in transformed cell lines (e.g., Huh-7) following transfection.", [["HIE lines", "ANATOMY", 190, 199], ["cell lines", "ANATOMY", 312, 322], ["Huh-7", "ANATOMY", 330, 335], ["GII.3", "CHEMICAL", 134, 139], ["infection", "DISEASE", 154, 163], ["HIE", "DISEASE", 190, 193], ["infection", "DISEASE", 287, 296], ["FUT2", "GENE_OR_GENE_PRODUCT", 51, 55], ["HuNoV", "GENE_OR_GENE_PRODUCT", 111, 116], ["GII.3", "GENE_OR_GENE_PRODUCT", 134, 139], ["secretor", "GENE_OR_GENE_PRODUCT", 172, 180], ["HIE lines", "CELL", 190, 199], ["HuNoV", "GENE_OR_GENE_PRODUCT", 249, 254], ["cell lines", "CELL", 312, 322], ["Huh-7", "CELL", 330, 335], ["FUT2", "PROTEIN", 51, 55], ["GII.3", "DNA", 134, 139], ["secretor-negative HIE lines", "CELL_LINE", 172, 199], ["HuNoV genome", "DNA", 249, 261], ["transformed cell lines", "CELL_LINE", 300, 322], ["Huh-7", "CELL_LINE", 330, 335], ["functional FUT2", "PROBLEM", 40, 55], ["multiple HuNoV strains", "PROBLEM", 102, 124], ["infection", "PROBLEM", 154, 163], ["DISCUSSIONPrevious studies", "TEST", 200, 226], ["productive infection", "PROBLEM", 276, 296], ["transformed cell lines", "TREATMENT", 300, 322], ["Huh", "TEST", 330, 333], ["multiple", "OBSERVATION_MODIFIER", 102, 110], ["HuNoV", "OBSERVATION", 111, 116], ["infection", "OBSERVATION", 154, 163], ["HuNoV genome", "OBSERVATION", 249, 261], ["productive", "OBSERVATION_MODIFIER", 276, 286], ["infection", "OBSERVATION", 287, 296], ["transformed cell lines", "OBSERVATION", 300, 322]]], ["Overexpression of the FUT2 gene increased virus binding to the cells but did not make them susceptible to infection (19).", [["cells", "ANATOMY", 63, 68], ["infection", "DISEASE", 106, 115], ["FUT2", "GENE_OR_GENE_PRODUCT", 22, 26], ["cells", "CELL", 63, 68], ["FUT2 gene", "DNA", 22, 31], ["the FUT2 gene increased virus binding", "PROBLEM", 18, 55], ["infection", "PROBLEM", 106, 115], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["virus", "OBSERVATION", 42, 47], ["infection", "OBSERVATION", 106, 115]]], ["These data indicated the presence of a block between virus binding and entry.", [["a block between virus binding", "PROBLEM", 37, 66]]], ["The development of the HIE HuNoV infection model identified that enterocytes in these cultures are infected with HuNoVs and allowed the performance of studies to evaluate factors important for virus infection (2).", [["enterocytes", "ANATOMY", 65, 76], ["cultures", "ANATOMY", 86, 94], ["infection", "DISEASE", 33, 42], ["infection", "DISEASE", 199, 208], ["enterocytes", "CELL", 65, 76], ["enterocytes", "CELL_TYPE", 65, 76], ["the HIE HuNoV infection", "PROBLEM", 19, 42], ["these cultures", "TEST", 80, 94], ["studies", "TEST", 151, 158], ["virus infection", "PROBLEM", 193, 208], ["HuNoV infection", "OBSERVATION", 27, 42]]], ["The current study demonstrates that FUT2 alone is necessary and sufficient for the infection and replication of the secretor-dependent GI.1, GII.4, and GII.17 HuNoVs in HIE cells.DISCUSSIONVirus attachment and entry into the infected cell are complex processes, and the exact role of fucosylated molecules in HuNoV entry remains to be determined.", [["HIE cells", "ANATOMY", 169, 178], ["cell", "ANATOMY", 234, 238], ["FUT2", "CHEMICAL", 36, 40], ["infection", "DISEASE", 83, 92], ["HIE", "DISEASE", 169, 172], ["FUT2", "GENE_OR_GENE_PRODUCT", 36, 40], ["secretor", "GENE_OR_GENE_PRODUCT", 116, 124], ["GI.1", "GENE_OR_GENE_PRODUCT", 135, 139], ["HuNoVs", "GENE_OR_GENE_PRODUCT", 159, 165], ["HIE cells", "CELL", 169, 178], ["cell", "CELL", 234, 238], ["HuNoV", "GENE_OR_GENE_PRODUCT", 309, 314], ["FUT2", "PROTEIN", 36, 40], ["HuNoVs", "PROTEIN", 159, 165], ["HIE cells", "CELL_TYPE", 169, 178], ["fucosylated molecules", "PROTEIN", 284, 305], ["The current study", "TEST", 0, 17], ["FUT2 alone", "TREATMENT", 36, 46], ["the infection", "PROBLEM", 79, 92], ["DISCUSSIONVirus attachment", "PROBLEM", 179, 205], ["fucosylated molecules", "PROBLEM", 284, 305], ["infection", "OBSERVATION", 83, 92], ["infected cell", "OBSERVATION", 225, 238]]], ["It is likely that initial binding of secretor-dependent HuNoVs to HIEs is regulated by fucosylation, with the attachment factors being fucosylated.", [["HIEs", "DISEASE", 66, 70], ["secretor", "GENE_OR_GENE_PRODUCT", 37, 45], ["HuNoVs", "GENE_OR_GENE_PRODUCT", 56, 62], ["HIEs", "GENE_OR_GENE_PRODUCT", 66, 70], ["HuNoVs", "PROTEIN", 56, 62], ["attachment factors", "PROTEIN", 110, 128], ["is likely", "UNCERTAINTY", 3, 12]]], ["However, it is unclear whether the fucosylated molecules serve only as the initial attachment factor that then facilitates interaction with a virus-specific receptor or whether the fucosylated molecules function as a virus receptor themselves; examples of both mechanisms have been described previously with nonfucosylated glycans (22).", [["fucosylated molecules", "PROTEIN", 35, 56], ["attachment factor", "PROTEIN", 83, 100], ["fucosylated molecules", "PROTEIN", 181, 202], ["the fucosylated molecules", "PROBLEM", 31, 56], ["a virus", "TREATMENT", 140, 147], ["the fucosylated molecules function", "PROBLEM", 177, 211], ["a virus receptor themselves", "PROBLEM", 215, 242]]], ["For example, reovirus binding to its proteinaceous JAM-A receptor is enhanced by initial binding to sialic acid residues (23), while human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acid receptors (24) and influenza viruses bind to terminal sialic acid receptors (25).", [["sialic acid", "CHEMICAL", 100, 111], ["9-O-acetylated sialic acid", "CHEMICAL", 175, 201], ["sialic acid", "CHEMICAL", 256, 267], ["sialic acid", "CHEMICAL", 100, 111], ["9-O-acetylated sialic acid", "CHEMICAL", 175, 201], ["sialic acid", "CHEMICAL", 256, 267], ["reovirus", "ORGANISM", 13, 21], ["JAM-A receptor", "GENE_OR_GENE_PRODUCT", 51, 65], ["sialic acid", "SIMPLE_CHEMICAL", 100, 111], ["human coronaviruses OC43", "ORGANISM", 133, 157], ["HKU1", "GENE_OR_GENE_PRODUCT", 162, 166], ["9-O-acetylated sialic acid", "SIMPLE_CHEMICAL", 175, 201], ["influenza viruses", "ORGANISM", 221, 238], ["proteinaceous JAM-A receptor", "PROTEIN", 37, 65], ["OC43", "PROTEIN", 153, 157], ["HKU1", "PROTEIN", 162, 166], ["9-O-acetylated sialic acid receptors", "PROTEIN", 175, 211], ["terminal sialic acid receptors", "PROTEIN", 247, 277], ["human", "SPECIES", 133, 138], ["human coronaviruses", "SPECIES", 133, 152], ["reovirus binding", "PROBLEM", 13, 29], ["sialic acid residues", "TEST", 100, 120], ["human coronaviruses OC43", "TEST", 133, 157], ["HKU1 bind", "TEST", 162, 171], ["acetylated sialic acid receptors", "TREATMENT", 179, 211], ["influenza viruses bind", "PROBLEM", 221, 243], ["terminal sialic acid receptors", "TREATMENT", 247, 277], ["reovirus", "OBSERVATION", 13, 21], ["proteinaceous JAM", "OBSERVATION", 37, 54]]], ["If fucosylated molecules serve only as attachment factors, then the virus receptor(s) for secretor-dependent HuNoVs is present in both secretor-positive and secretor-negative HIEs and is not expressed in other nonsusceptible, secretor-positive cancer-derived or transformed cell lines.", [["HIEs", "ANATOMY", 175, 179], ["cancer", "ANATOMY", 244, 250], ["cell lines", "ANATOMY", 274, 284], ["cancer", "DISEASE", 244, 250], ["secretor", "GENE_OR_GENE_PRODUCT", 90, 98], ["HuNoVs", "GENE_OR_GENE_PRODUCT", 109, 115], ["secretor", "GENE_OR_GENE_PRODUCT", 135, 143], ["secretor", "GENE_OR_GENE_PRODUCT", 157, 165], ["HIEs", "GENE_OR_GENE_PRODUCT", 175, 179], ["secretor", "GENE_OR_GENE_PRODUCT", 226, 234], ["cancer", "CELL", 244, 250], ["cell lines", "CELL", 274, 284], ["fucosylated molecules", "PROTEIN", 3, 24], ["attachment factors", "PROTEIN", 39, 57], ["virus receptor", "PROTEIN", 68, 82], ["secretor-dependent HuNoVs", "PROTEIN", 90, 115], ["secretor-positive and secretor-negative HIEs", "CELL_LINE", 135, 179], ["nonsusceptible, secretor-positive cancer-derived or transformed cell lines", "CELL_LINE", 210, 284], ["fucosylated molecules", "PROBLEM", 3, 24], ["attachment factors", "PROBLEM", 39, 57], ["the virus receptor", "TEST", 64, 82], ["secretor-dependent HuNoVs", "PROBLEM", 90, 115], ["positive cancer", "PROBLEM", 235, 250], ["transformed cell lines", "TREATMENT", 262, 284], ["cancer", "OBSERVATION", 244, 250], ["cell lines", "OBSERVATION", 274, 284]]], ["On the other hand, if the fucosylated molecules function as the virus receptor, it is unclear why secretor-positive cultured transformed cells derived from cancer patients are not susceptible to infection.", [["cells", "ANATOMY", 137, 142], ["cancer", "ANATOMY", 156, 162], ["cancer", "DISEASE", 156, 162], ["infection", "DISEASE", 195, 204], ["secretor", "GENE_OR_GENE_PRODUCT", 98, 106], ["cells", "CELL", 137, 142], ["cancer", "CANCER", 156, 162], ["patients", "ORGANISM", 163, 171], ["fucosylated molecules", "PROTEIN", 26, 47], ["secretor-positive cultured transformed cells", "CELL_LINE", 98, 142], ["patients", "SPECIES", 163, 171], ["the virus receptor", "TEST", 60, 78], ["cancer", "PROBLEM", 156, 162], ["infection", "PROBLEM", 195, 204], ["not susceptible to", "UNCERTAINTY", 176, 194], ["infection", "OBSERVATION", 195, 204]]], ["It is possible that transformed lines do not properly express the needed receptors or glycans or other signaling pathways essential for infection.", [["lines", "ANATOMY", 32, 37], ["infection", "DISEASE", 136, 145], ["transformed lines", "CELL_LINE", 20, 37], ["transformed lines", "TREATMENT", 20, 37], ["glycans", "TREATMENT", 86, 93], ["other signaling pathways", "PROBLEM", 97, 121], ["infection", "PROBLEM", 136, 145], ["infection", "OBSERVATION", 136, 145]]], ["Transformation may abrogate proper glycosylation in nonsusceptible cell lines compared to nontransformed HIE lines (26).DISCUSSIONWe observed a striking phenotypic difference in FUT2-expressing HIE cells compared to cells not expressing FUT2.", [["cell lines", "ANATOMY", 67, 77], ["HIE lines", "ANATOMY", 105, 114], ["FUT2-expressing HIE cells", "ANATOMY", 178, 203], ["cells", "ANATOMY", 216, 221], ["cell lines", "CELL", 67, 77], ["nontransformed HIE lines", "CELL", 90, 114], ["FUT2", "GENE_OR_GENE_PRODUCT", 178, 182], ["HIE cells", "CELL", 194, 203], ["cells", "CELL", 216, 221], ["FUT2", "GENE_OR_GENE_PRODUCT", 237, 241], ["nonsusceptible cell lines", "CELL_LINE", 52, 77], ["nontransformed HIE lines", "CELL_LINE", 90, 114], ["FUT2", "PROTEIN", 178, 182], ["HIE cells", "CELL_TYPE", 194, 203], ["FUT2", "PROTEIN", 237, 241], ["proper glycosylation", "TREATMENT", 28, 48], ["nonsusceptible cell lines", "TREATMENT", 52, 77], ["nontransformed HIE lines", "TREATMENT", 90, 114], ["a striking phenotypic difference", "PROBLEM", 142, 174], ["FUT2-expressing HIE cells", "PROBLEM", 178, 203], ["nonsusceptible cell lines", "OBSERVATION", 52, 77]]], ["UEA-1 detection of \u03b11,2-fucose was observed exclusively at the apical surface in FUT2-positive cells.", [["apical surface", "ANATOMY", 63, 77], ["FUT2-positive cells", "ANATOMY", 81, 100], ["\u03b11,2-fucose", "CHEMICAL", 19, 30], ["\u03b11,2-fucose", "CHEMICAL", 19, 30], ["UEA-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["\u03b11,2-fucose", "SIMPLE_CHEMICAL", 19, 30], ["apical surface", "CELLULAR_COMPONENT", 63, 77], ["FUT2", "GENE_OR_GENE_PRODUCT", 81, 85], ["FUT2-positive cells", "CELL_LINE", 81, 100], ["UEA", "TEST", 0, 3], ["apical", "ANATOMY_MODIFIER", 63, 69], ["surface", "ANATOMY_MODIFIER", 70, 77], ["positive cells", "OBSERVATION", 86, 100]]], ["Unexpectedly, in the secretor-negative lines, there was internal cellular staining by UEA-1.", [["secretor-negative lines", "ANATOMY", 21, 44], ["cellular", "ANATOMY", 65, 73], ["cellular", "CELL", 65, 73], ["UEA-1", "GENE_OR_GENE_PRODUCT", 86, 91], ["secretor-negative lines", "CELL_LINE", 21, 44], ["UEA", "PROTEIN", 86, 89], ["internal cellular staining", "PROBLEM", 56, 82], ["UEA", "TEST", 86, 89], ["negative lines", "OBSERVATION", 30, 44], ["internal", "OBSERVATION_MODIFIER", 56, 64], ["cellular staining", "OBSERVATION", 65, 82]]], ["The staining was due to UEA-1-specific interactions with \u03b11,2-fucose, indicating that these glycan structures are present but unable to transit to the surfaces of the secretor-negative HIE cultures.", [["\u03b11,2-fucose", "CHEMICAL", 57, 68], ["\u03b11,2-fucose", "CHEMICAL", 57, 68], ["UEA-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["\u03b11,2-fucose", "SIMPLE_CHEMICAL", 57, 68], ["secretor", "GENE_OR_GENE_PRODUCT", 167, 175], ["secretor-negative HIE cultures", "CELL_LINE", 167, 197], ["The staining", "TEST", 0, 12], ["UEA", "TEST", 24, 27], ["these glycan structures", "PROBLEM", 86, 109], ["HIE cultures", "TEST", 185, 197]]], ["There is evidence that FUT2 expression leads to surface expression of \u03b11,2-fucosylated molecules.", [["surface", "ANATOMY", 48, 55], ["FUT2", "GENE_OR_GENE_PRODUCT", 23, 27], ["surface", "CELLULAR_COMPONENT", 48, 55], ["\u03b11,2-fucosylated", "GENE_OR_GENE_PRODUCT", 70, 86], ["FUT2", "PROTEIN", 23, 27], ["\u03b11,2", "PROTEIN", 70, 74], ["fucosylated molecules", "PROTEIN", 75, 96], ["FUT2 expression", "PROBLEM", 23, 38], ["\u03b11,2-fucosylated molecules", "PROBLEM", 70, 96], ["FUT2 expression", "OBSERVATION", 23, 38], ["surface", "OBSERVATION_MODIFIER", 48, 55], ["expression", "OBSERVATION_MODIFIER", 56, 66], ["fucosylated molecules", "OBSERVATION", 75, 96]]], ["This was shown in specific-pathogen-free mice, where the lumen of the small intestine is mostly lacking in surface fucosylation, and intraperitoneal injection of lipopolysaccharide (LPS) stimulates expression of \u03b11,2-fucosylated molecules at the surface in a FUT2-dependent manner (27, 28).", [["lumen", "ANATOMY", 57, 62], ["small intestine", "ANATOMY", 70, 85], ["surface", "ANATOMY", 107, 114], ["intraperitoneal", "ANATOMY", 133, 148], ["surface", "ANATOMY", 246, 253], ["lipopolysaccharide", "CHEMICAL", 162, 180], ["LPS", "CHEMICAL", 182, 185], ["mice", "ORGANISM", 41, 45], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 62], ["small intestine", "ORGAN", 70, 85], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 133, 148], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 162, 180], ["LPS", "SIMPLE_CHEMICAL", 182, 185], ["\u03b11,2-fucosylated", "GENE_OR_GENE_PRODUCT", 212, 228], ["surface", "CELLULAR_COMPONENT", 246, 253], ["FUT2", "GENE_OR_GENE_PRODUCT", 259, 263], ["\u03b11,2-fucosylated molecules", "PROTEIN", 212, 238], ["FUT2", "PROTEIN", 259, 263], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["surface fucosylation", "TREATMENT", 107, 127], ["intraperitoneal injection of lipopolysaccharide (LPS)", "TREATMENT", 133, 186], ["\u03b11,2-fucosylated molecules", "PROBLEM", 212, 238], ["free mice", "OBSERVATION", 36, 45], ["lumen", "ANATOMY_MODIFIER", 57, 62], ["small intestine", "ANATOMY", 70, 85], ["intraperitoneal", "ANATOMY", 133, 148], ["fucosylated molecules", "OBSERVATION", 217, 238], ["surface", "ANATOMY_MODIFIER", 246, 253], ["FUT2-dependent", "OBSERVATION_MODIFIER", 259, 273]]], ["There may be additional fucosyltransferase enzymes present in our HIEs capable of adding fucose to glycoproteins or glycolipids in the absence of FUT2 activity.", [["fucose", "CHEMICAL", 89, 95], ["fucose", "SIMPLE_CHEMICAL", 89, 95], ["FUT2", "GENE_OR_GENE_PRODUCT", 146, 150], ["fucosyltransferase enzymes", "PROTEIN", 24, 50], ["FUT2", "PROTEIN", 146, 150], ["additional fucosyltransferase enzymes", "TEST", 13, 50], ["fucose to glycoproteins", "TREATMENT", 89, 112], ["glycolipids", "TREATMENT", 116, 127], ["FUT2 activity", "PROBLEM", 146, 159]]], ["However, these alternatively fucosylated molecules are unable to transit to the cell surface.", [["cell surface", "ANATOMY", 80, 92], ["cell surface", "CELLULAR_COMPONENT", 80, 92], ["these alternatively fucosylated molecules", "PROBLEM", 9, 50], ["fucosylated molecules", "OBSERVATION", 29, 50], ["cell", "OBSERVATION_MODIFIER", 80, 84], ["surface", "OBSERVATION_MODIFIER", 85, 92]]], ["Fucosyltransferase 1 (FUT1), expressed in erythroid cells and some other tissues, is also capable of adding \u03b11,2-fucose, although preferentially on glycan chains other than those found in intestinal epithelia.", [["erythroid cells", "ANATOMY", 42, 57], ["tissues", "ANATOMY", 73, 80], ["intestinal epithelia", "ANATOMY", 188, 208], ["\u03b11,2-fucose", "CHEMICAL", 108, 119], ["\u03b11,2-fucose", "CHEMICAL", 108, 119], ["Fucosyltransferase 1", "GENE_OR_GENE_PRODUCT", 0, 20], ["FUT1", "GENE_OR_GENE_PRODUCT", 22, 26], ["erythroid cells", "CELL", 42, 57], ["tissues", "TISSUE", 73, 80], ["\u03b11,2-fucose", "SIMPLE_CHEMICAL", 108, 119], ["intestinal epithelia", "TISSUE", 188, 208], ["Fucosyltransferase 1", "PROTEIN", 0, 20], ["FUT1", "PROTEIN", 22, 26], ["erythroid cells", "CELL_TYPE", 42, 57], ["Fucosyltransferase", "TEST", 0, 18], ["erythroid cells", "TREATMENT", 42, 57], ["glycan chains", "TREATMENT", 148, 161], ["erythroid cells", "OBSERVATION", 42, 57], ["intestinal epithelia", "ANATOMY", 188, 208]]], ["In the parental J2 enteroid line used in this study, FUT1 transcripts are expressed by transcriptome sequencing (RNA-seq), and the fragment per kilobase per million (FPKM) value is \u223c60-fold lower than that of FUT2.", [["enteroid line", "ANATOMY", 19, 32], ["J2 enteroid line", "CELL", 16, 32], ["FUT1", "GENE_OR_GENE_PRODUCT", 53, 57], ["FUT2", "GENE_OR_GENE_PRODUCT", 209, 213], ["parental J2 enteroid line", "CELL_LINE", 7, 32], ["FUT1 transcripts", "RNA", 53, 69], ["FUT2", "PROTEIN", 209, 213], ["the parental J2 enteroid line", "TREATMENT", 3, 32], ["this study", "TEST", 41, 51], ["FUT1 transcripts", "TREATMENT", 53, 69], ["transcriptome sequencing", "TEST", 87, 111], ["J2", "ANATOMY", 16, 18], ["fragment", "OBSERVATION_MODIFIER", 131, 139]]], ["In bovine coronary venular endothelial cells, a lotus lectin (LTL) that also recognizes \u03b11,2-fucosylated molecules detects cytoplasmic tubule structures, and this staining is lost after depletion of both FUT1 and FUT2 (29).", [["coronary venular endothelial cells", "ANATOMY", 10, 44], ["cytoplasmic tubule structures", "ANATOMY", 123, 152], ["bovine", "ORGANISM", 3, 9], ["coronary venular endothelial cells", "CELL", 10, 44], ["lotus lectin", "GENE_OR_GENE_PRODUCT", 48, 60], ["LTL", "GENE_OR_GENE_PRODUCT", 62, 65], ["\u03b11,2-fucosylated", "GENE_OR_GENE_PRODUCT", 88, 104], ["cytoplasmic tubule structures", "TISSUE", 123, 152], ["FUT1", "GENE_OR_GENE_PRODUCT", 204, 208], ["FUT2", "GENE_OR_GENE_PRODUCT", 213, 217], ["bovine coronary venular endothelial cells", "CELL_TYPE", 3, 44], ["lotus lectin", "PROTEIN", 48, 60], ["LTL", "PROTEIN", 62, 65], ["\u03b11,2", "PROTEIN", 88, 92], ["fucosylated molecules", "PROTEIN", 93, 114], ["FUT1", "PROTEIN", 204, 208], ["FUT2", "PROTEIN", 213, 217], ["bovine", "SPECIES", 3, 9], ["bovine", "SPECIES", 3, 9], ["a lotus lectin", "TEST", 46, 60], ["cytoplasmic tubule structures", "PROBLEM", 123, 152], ["this staining", "TEST", 158, 171], ["bovine", "ANATOMY_MODIFIER", 3, 9], ["coronary venular", "ANATOMY", 10, 26], ["endothelial cells", "OBSERVATION", 27, 44], ["lotus", "OBSERVATION_MODIFIER", 48, 53], ["lectin", "OBSERVATION_MODIFIER", 54, 60], ["fucosylated molecules", "OBSERVATION", 93, 114], ["cytoplasmic tubule structures", "OBSERVATION", 123, 152]]], ["Further studies showed that LTL costained with a Golgi marker in newly derived primary human fibroblasts from oral mucosa, but this Golgi colocalization was lost and LTL was instead detected in tubule structures as the fibroblasts were passaged.", [["Golgi", "ANATOMY", 49, 54], ["fibroblasts", "ANATOMY", 93, 104], ["oral mucosa", "ANATOMY", 110, 121], ["Golgi", "ANATOMY", 132, 137], ["tubule structures", "ANATOMY", 194, 211], ["fibroblasts", "ANATOMY", 219, 230], ["LTL", "GENE_OR_GENE_PRODUCT", 28, 31], ["Golgi", "CELLULAR_COMPONENT", 49, 54], ["human", "ORGANISM", 87, 92], ["fibroblasts", "CELL", 93, 104], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 110, 121], ["Golgi", "CELLULAR_COMPONENT", 132, 137], ["LTL", "GENE_OR_GENE_PRODUCT", 166, 169], ["tubule structures", "TISSUE", 194, 211], ["fibroblasts", "CELL", 219, 230], ["LTL", "PROTEIN", 28, 31], ["primary human fibroblasts", "CELL_TYPE", 79, 104], ["LTL", "PROTEIN", 166, 169], ["fibroblasts", "CELL_TYPE", 219, 230], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["Further studies", "TEST", 0, 15], ["this Golgi colocalization", "TEST", 127, 152], ["LTL", "TEST", 166, 169], ["Golgi marker", "OBSERVATION", 49, 61], ["primary human fibroblasts", "OBSERVATION", 79, 104], ["oral mucosa", "ANATOMY", 110, 121], ["fibroblasts", "ANATOMY", 219, 230]]], ["In our system, the presence of some FUT1 expression may allow for \u03b11,2-fucose-containing structures intracellularly.", [["\u03b11,2-fucose", "CHEMICAL", 66, 77], ["\u03b11,2-fucose", "CHEMICAL", 66, 77], ["FUT1", "GENE_OR_GENE_PRODUCT", 36, 40], ["\u03b11,2-fucose", "SIMPLE_CHEMICAL", 66, 77], ["FUT1", "PROTEIN", 36, 40], ["some FUT1 expression", "PROBLEM", 31, 51], ["FUT1 expression", "OBSERVATION", 36, 51]]], ["Future studies will determine the identity and subcellular location of the fucosylated molecules present in the FUT2-negative HIE lines and whether FUT1 is required for their presence.DISCUSSIONHIEs provide an excellent tool for future studies on intestinal enzymes involved in glycosylation and how glycosylation alters glycoprotein localization.", [["subcellular", "ANATOMY", 47, 58], ["FUT2-negative HIE lines", "ANATOMY", 112, 135], ["intestinal", "ANATOMY", 247, 257], ["FUT2", "GENE_OR_GENE_PRODUCT", 112, 116], ["FUT1", "GENE_OR_GENE_PRODUCT", 148, 152], ["intestinal", "ORGAN", 247, 257], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 321, 333], ["fucosylated molecules", "PROTEIN", 75, 96], ["FUT2-negative HIE lines", "CELL_LINE", 112, 135], ["FUT1", "PROTEIN", 148, 152], ["intestinal enzymes", "PROTEIN", 247, 265], ["Future studies", "TEST", 0, 14], ["the fucosylated molecules", "PROBLEM", 71, 96], ["future studies", "TEST", 229, 243], ["intestinal enzymes", "TEST", 247, 265], ["glycosylation", "TREATMENT", 278, 291], ["fucosylated molecules", "OBSERVATION", 75, 96]]], ["An association of enteric commensals and pathogens with host secretor status has led to increased recognition of secretor glycans being susceptibility factors important in infection and disease outcomes (30, 31).", [["infection", "DISEASE", 172, 181], ["secretor glycans", "GENE_OR_GENE_PRODUCT", 113, 129], ["susceptibility factors", "PROTEIN", 136, 158], ["enteric commensals", "PROBLEM", 18, 36], ["host secretor status", "PROBLEM", 56, 76], ["secretor glycans", "PROBLEM", 113, 129], ["susceptibility factors", "PROBLEM", 136, 158], ["infection and disease outcomes", "PROBLEM", 172, 202], ["enteric commensals", "OBSERVATION_MODIFIER", 18, 36], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["infection", "OBSERVATION", 172, 181]]], ["The exact role played by the glycans in these infections is not fully understood.", [["infections", "DISEASE", 46, 56], ["infections", "OBSERVATION", 46, 56]]], ["Our isogenic, physiologically active HIE lines should be helpful to determine whether fucosylation plays a role in microbe binding, entry, or postentry processes that may affect the epithelial responses to infection, and it will be interesting to understand different outcomes of infection with the different microbes.Plasmid constructs. ::: MATERIALS AND METHODSThe cDNA of FUT2, obtained from J2 human intestinal enteroid (HIE) total RNA, was amplified with specific gene primers (Table 2) and cloned into the lentiviral expression vector pLVSIN-IRES-puromycin (32) using In-Fusion cloning kit (TaKaRa-Clontech) according to the manufacturer\u2019s instructions.", [["HIE lines", "ANATOMY", 37, 46], ["epithelial", "ANATOMY", 182, 192], ["intestinal", "ANATOMY", 404, 414], ["infection", "DISEASE", 206, 215], ["infection", "DISEASE", 280, 289], ["pLVSIN-IRES-puromycin", "CHEMICAL", 541, 562], ["puromycin", "CHEMICAL", 553, 562], ["HIE lines", "CELL", 37, 46], ["epithelial", "TISSUE", 182, 192], ["FUT2", "GENE_OR_GENE_PRODUCT", 375, 379], ["human", "ORGANISM", 398, 403], ["intestinal enteroid", "CANCER", 404, 423], ["lentiviral", "ORGANISM", 512, 522], ["puromycin", "SIMPLE_CHEMICAL", 553, 562], ["HIE lines", "CELL_LINE", 37, 46], ["Plasmid constructs", "DNA", 318, 336], ["FUT2", "DNA", 375, 379], ["J2 human intestinal enteroid (HIE) total RNA", "RNA", 395, 439], ["specific gene primers", "DNA", 460, 481], ["lentiviral expression vector", "DNA", 512, 540], ["pLVSIN", "DNA", 541, 547], ["IRES", "DNA", 548, 552], ["TaKaRa-Clontech", "DNA", 597, 612], ["human", "SPECIES", 398, 403], ["human", "SPECIES", 398, 403], ["HIE lines", "TREATMENT", 37, 46], ["microbe binding", "PROBLEM", 115, 130], ["infection", "PROBLEM", 206, 215], ["infection", "PROBLEM", 280, 289], ["Plasmid constructs", "TREATMENT", 318, 336], ["FUT2", "PROBLEM", 375, 379], ["J2 human intestinal enteroid (HIE) total RNA", "TREATMENT", 395, 439], ["specific gene primers", "TREATMENT", 460, 481], ["puromycin", "TREATMENT", 553, 562], ["In-Fusion cloning kit (TaKaRa-Clontech)", "TREATMENT", 574, 613], ["active", "OBSERVATION_MODIFIER", 30, 36], ["infection", "OBSERVATION", 206, 215], ["infection", "OBSERVATION", 280, 289], ["intestinal", "ANATOMY", 404, 414]]], ["A Cas9-expressing lentiviral vector (lentiCas9-BLAST; plasmid no. 52962) and single guide RNA (sgRNA) expression vector (lentiGuide-puro; plasmid no. 52963) were purchased from Addgene.", [["Cas9", "GENE_OR_GENE_PRODUCT", 2, 6], ["lentiviral", "ORGANISM", 18, 28], ["single guide RNA", "GENE_OR_GENE_PRODUCT", 77, 93], ["Addgene", "GENE_OR_GENE_PRODUCT", 177, 184], ["Cas9-expressing lentiviral vector", "DNA", 2, 35], ["lentiCas9-BLAST; plasmid no. 52962", "DNA", 37, 71], ["single guide RNA (sgRNA) expression vector", "DNA", 77, 119], ["lentiGuide-puro; plasmid no. 52963", "DNA", 121, 155], ["Addgene", "DNA", 177, 184], ["A Cas9", "TREATMENT", 0, 6]]], ["The sgRNA sequence targeting the human FUT2 gene (5\u2032-CCAGCCAGCTCAGGGGGATG-3\u2032) was cloned into the lentiGuide-puro vector following the manufacturer\u2019s protocol.Lentivirus packaging and production. ::: MATERIALS AND METHODSA third-generation lentivirus carrying the FUT2 gene (Lv-FUT2) was produced by cotransfecting HEK293T cells with a combination of a lentivirus plasmid (pLVSIN-FUT2-IRES-puro, lentiCas9-BLAST, or lentiGuide puro) and three packaging plasmids (pMDLg/pRRE [plasmid no. 12251; Addgene], envelope plasmid pMD2.G [plasmid no. 12259; Addgene], and pRSV-Rev [plasmid no. 12253; Addgene]) at a ratio of 3.5:2:1:1, respectively, using polyethylenimine HCl Max molecular weight (MW) 40,000 (Polysciences) (32).", [["HEK293T cells", "ANATOMY", 315, 328], ["plasmids", "ANATOMY", 453, 461], ["plasmid", "ANATOMY", 513, 520], ["polyethylenimine HCl", "CHEMICAL", 646, 666], ["polyethylenimine", "CHEMICAL", 646, 662], ["HCl", "CHEMICAL", 663, 666], ["human", "ORGANISM", 33, 38], ["FUT2", "GENE_OR_GENE_PRODUCT", 39, 43], ["5\u2032-CCAGCCAGCTCAGGGGGATG-3", "GENE_OR_GENE_PRODUCT", 50, 75], ["Lentivirus", "ORGANISM", 159, 169], ["lentivirus", "ORGANISM", 240, 250], ["FUT2", "GENE_OR_GENE_PRODUCT", 264, 268], ["Lv-FUT2", "GENE_OR_GENE_PRODUCT", 275, 282], ["HEK293T cells", "CELL", 315, 328], ["lentivirus", "ORGANISM", 353, 363], ["pLVSIN-FUT2", "GENE_OR_GENE_PRODUCT", 373, 384], ["lentiCas9", "GENE_OR_GENE_PRODUCT", 396, 405], ["lentiGuide puro", "GENE_OR_GENE_PRODUCT", 416, 431], ["Addgene", "GENE_OR_GENE_PRODUCT", 494, 501], ["Addgene", "GENE_OR_GENE_PRODUCT", 548, 555], ["pRSV-Rev", "GENE_OR_GENE_PRODUCT", 562, 570], ["Addgene", "GENE_OR_GENE_PRODUCT", 591, 598], ["sgRNA sequence", "DNA", 4, 18], ["human FUT2 gene", "DNA", 33, 48], ["5\u2032-CCAGCCAGCTCAGGGGGATG-3\u2032", "DNA", 50, 76], ["lentiGuide-puro vector", "DNA", 98, 120], ["FUT2 gene", "DNA", 264, 273], ["Lv-FUT2", "DNA", 275, 282], ["HEK293T cells", "CELL_LINE", 315, 328], ["lentivirus plasmid", "DNA", 353, 371], ["pLVSIN", "DNA", 373, 379], ["FUT2", "DNA", 380, 384], ["IRES", "DNA", 385, 389], ["puro", "DNA", 390, 394], ["lentiCas9", "DNA", 396, 405], ["BLAST", "DNA", 406, 411], ["lentiGuide puro", "DNA", 416, 431], ["packaging plasmids", "DNA", 443, 461], ["pMDLg", "DNA", 463, 468], ["pRRE", "DNA", 469, 473], ["plasmid no. 12251", "DNA", 475, 492], ["Addgene", "DNA", 494, 501], ["envelope plasmid pMD2", "DNA", 504, 525], ["pRSV", "DNA", 562, 566], ["Rev", "DNA", 567, 570], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["Lentivirus", "SPECIES", 159, 169], ["lentivirus", "SPECIES", 240, 250], ["lentivirus", "SPECIES", 353, 363], ["The sgRNA sequence", "TEST", 0, 18], ["5\u2032-CCAGCCAGCTCAGGGGGATG", "TEST", 50, 73], ["the manufacturer\u2019s protocol", "TREATMENT", 131, 158], ["Lentivirus packaging", "TREATMENT", 159, 179], ["METHODSA third-generation lentivirus", "TREATMENT", 214, 250], ["a lentivirus plasmid", "TREATMENT", 351, 371], ["pLVSIN", "TEST", 373, 379], ["FUT2", "TEST", 380, 384], ["IRES", "TEST", 385, 389], ["lentiCas9", "TEST", 396, 405], ["lentiGuide puro", "TREATMENT", 416, 431], ["three packaging plasmids", "TREATMENT", 437, 461], ["envelope plasmid pMD2", "TREATMENT", 504, 525], ["polyethylenimine HCl", "TREATMENT", 646, 666]]], ["The culture supernatant was harvested 60 to 72 h posttransfection, passed through a 0.45-\u03bcm filter, concentrated by using LentiX-concentrator (TaKaRa-Clontech) according to the manufacturer\u2019s protocol, and suspended in CMGF(+) medium for transduction.Lentiviral transduction of HIEs. ::: MATERIALS AND METHODSA cell suspension was prepared from three-dimensional (3D) undifferentiated jejunal HIEs cultivated as previously described (2, 33).", [["supernatant", "ANATOMY", 12, 23], ["cell", "ANATOMY", 311, 315], ["jejunal HIEs", "ANATOMY", 385, 397], ["CMGF", "CHEMICAL", 219, 223], ["CMGF(+)", "CHEMICAL", 219, 226], ["CMGF", "SIMPLE_CHEMICAL", 219, 223], ["Lentiviral", "ORGANISM", 251, 261], ["METHODSA cell", "CELL", 302, 315], ["jejunal HIEs", "CELL", 385, 397], ["The culture supernatant", "TEST", 0, 23], ["a 0.45-\u03bcm filter", "TREATMENT", 82, 98], ["LentiX-concentrator (TaKaRa-Clontech)", "TREATMENT", 122, 159], ["METHODSA cell suspension", "TREATMENT", 302, 326], ["METHODSA cell suspension", "OBSERVATION", 302, 326], ["jejunal", "ANATOMY", 385, 392]]], ["After trypsinization and pelleting of the cells at 300 \u00d7 g, the resulting cell pellet was suspended at a concentration of 3 \u00d7 105 cells per ml of concentrated lentivirus supplemented with 10 \u03bcM Rho-associated protein kinase (ROCK) inhibitor Y-27632 (catalog no. Y0503; Sigma) and 8 \u03bcg/ml Polybrene (catalog no. TR-1003-G; EMD Millipore).", [["cells", "ANATOMY", 42, 47], ["cell pellet", "ANATOMY", 74, 85], ["cells", "ANATOMY", 130, 135], ["Y-27632", "CHEMICAL", 241, 248], ["Polybrene", "CHEMICAL", 288, 297], ["Y-27632", "CHEMICAL", 241, 248], ["Polybrene", "CHEMICAL", 288, 297], ["cells", "CELL", 42, 47], ["cell", "CELL", 74, 78], ["cells", "CELL", 130, 135], ["lentivirus", "ORGANISM", 159, 169], ["\u03bcM Rho-associated protein kinase", "GENE_OR_GENE_PRODUCT", 191, 223], ["ROCK", "GENE_OR_GENE_PRODUCT", 225, 229], ["Y-27632", "SIMPLE_CHEMICAL", 241, 248], ["Polybrene", "SIMPLE_CHEMICAL", 288, 297], ["ROCK", "PROTEIN", 225, 229], ["TR", "PROTEIN", 311, 313], ["Y-27632", "SPECIES", 241, 248], ["trypsinization", "TREATMENT", 6, 20], ["the resulting cell pellet", "TEST", 60, 85], ["concentrated lentivirus", "TREATMENT", 146, 169], ["TR", "TEST", 311, 313], ["cell pellet", "OBSERVATION", 74, 85]]], ["The mixture was plated in one well of a 48-well plate.", [["The mixture", "TREATMENT", 0, 11]]], ["The plate was then centrifuged for 1 h at 300 \u00d7 g at room temperature (RT).", [["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["After spinoculation, the lentivirus solution was removed, the cells were washed once with CMGF(\u2212) medium, centrifuged again, embedded in 30-\u03bcl Matrigel plug, and incubated at 37\u00b0C and 5% CO2 in the presence of CMGF(+) medium with ROCK inhibitor for recovery.", [["cells", "ANATOMY", 62, 67], ["CMGF", "CHEMICAL", 90, 94], ["CO2", "CHEMICAL", 187, 190], ["CMGF", "CHEMICAL", 210, 214], ["CO2", "CHEMICAL", 187, 190], ["CMGF(+)", "CHEMICAL", 210, 217], ["lentivirus", "ORGANISM", 25, 35], ["cells", "CELL", 62, 67], ["CMGF", "SIMPLE_CHEMICAL", 90, 94], ["CO2", "SIMPLE_CHEMICAL", 187, 190], ["CMGF", "SIMPLE_CHEMICAL", 210, 214], ["ROCK", "GENE_OR_GENE_PRODUCT", 230, 234], ["ROCK", "PROTEIN", 230, 234], ["lentivirus", "SPECIES", 25, 35], ["spinoculation", "TREATMENT", 6, 19], ["the lentivirus solution", "TREATMENT", 21, 44], ["the cells", "TREATMENT", 58, 67], ["CMGF", "TEST", 210, 214], ["ROCK inhibitor", "TREATMENT", 230, 244]]], ["Five days postransduction, the cells were treated with puromycin (2 \u03bcg/ml) or Blasticidin S (5 \u03bcg/ml) until mock-treated cells were completely dead.", [["cells", "ANATOMY", 31, 36], ["cells", "ANATOMY", 121, 126], ["puromycin", "CHEMICAL", 55, 64], ["Blasticidin S", "CHEMICAL", 78, 91], ["puromycin", "CHEMICAL", 55, 64], ["Blasticidin S", "CHEMICAL", 78, 91], ["cells", "CELL", 31, 36], ["puromycin", "SIMPLE_CHEMICAL", 55, 64], ["Blasticidin S", "SIMPLE_CHEMICAL", 78, 91], ["cells", "CELL", 121, 126], ["mock-treated cells", "CELL_LINE", 108, 126], ["puromycin", "TREATMENT", 55, 64], ["Blasticidin S", "TREATMENT", 78, 91]]], ["Single cells were isolated by serial dilution in 96-well plates for sgRNA-transduced HIEs, and deletion of the gene was confirmed by sequencing of genomic DNA from each single cell clone using primers BO-119 and BO-120 (Table 2) that amplified the portion of the FUT2 gene targeted by the sgRNA.HIE HBGA phenotyping. ::: MATERIALS AND METHODSDifferentiated HIE cells were suspended in phosphate-buffered saline (PBS) and boiled for 5 min.", [["cells", "ANATOMY", 7, 12], ["HIEs", "ANATOMY", 85, 89], ["cell", "ANATOMY", 176, 180], ["HIE cells", "ANATOMY", 357, 366], ["phosphate", "CHEMICAL", 385, 394], ["phosphate", "CHEMICAL", 385, 394], ["Single cells", "CELL", 0, 12], ["sgRNA", "GENE_OR_GENE_PRODUCT", 68, 73], ["HIEs", "CANCER", 85, 89], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["cell clone", "CELL", 176, 186], ["BO-120", "GENE_OR_GENE_PRODUCT", 212, 218], ["FUT2", "GENE_OR_GENE_PRODUCT", 263, 267], ["HIE cells", "CELL", 357, 366], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 385, 410], ["sgRNA-transduced HIEs", "DNA", 68, 89], ["genomic DNA", "DNA", 147, 158], ["BO-120", "DNA", 212, 218], ["FUT2 gene", "DNA", 263, 272], ["sgRNA", "DNA", 289, 294], ["METHODSDifferentiated HIE cells", "CELL_LINE", 335, 366], ["serial dilution", "TEST", 30, 45], ["sgRNA", "TEST", 68, 73], ["deletion of the gene", "PROBLEM", 95, 115], ["genomic DNA", "PROBLEM", 147, 158], ["primers BO", "TEST", 193, 203], ["BO", "TEST", 212, 214], ["the FUT2 gene", "TREATMENT", 259, 272], ["the sgRNA", "PROBLEM", 285, 294], ["HIE HBGA phenotyping", "TEST", 295, 315], ["METHODSDifferentiated HIE cells", "TREATMENT", 335, 366], ["phosphate-buffered saline (PBS)", "TREATMENT", 385, 416], ["sgRNA", "OBSERVATION", 289, 294]]], ["After incubation of the boiled supernatants on vinyl, flat-bottomed, 96-well plates (ThermoFisher Scientific) for 4 h at RT and blocking with 10% Carnation instant nonfat dry milk overnight at 4\u00b0C, anti-Lea Gamma-clone (Immucor), anti-Leb (BG-6; Biolegend), anti-A type Gamma-clone (Immucor), or anti-B type Gamma-clone (Immucor) was used as the primary antibody, and horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Sigma) was used as the secondary antibody.", [["supernatants", "ANATOMY", 31, 43], ["vinyl", "CHEMICAL", 47, 52], ["vinyl", "CHEMICAL", 47, 52], ["vinyl", "SIMPLE_CHEMICAL", 47, 52], ["milk", "ORGANISM_SUBSTANCE", 175, 179], ["Immucor", "SIMPLE_CHEMICAL", 220, 227], ["Biolegend", "GENE_OR_GENE_PRODUCT", 246, 255], ["Gamma-clone", "GENE_OR_GENE_PRODUCT", 270, 281], ["Immucor", "ORGANISM", 283, 290], ["Gamma-clone", "GENE_OR_GENE_PRODUCT", 308, 319], ["Immucor", "ORGANISM", 321, 328], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 368, 390], ["HRP", "SIMPLE_CHEMICAL", 392, 395], ["goat", "ORGANISM", 408, 412], ["anti-mouse IgG", "SIMPLE_CHEMICAL", 413, 427], ["Sigma", "SIMPLE_CHEMICAL", 429, 434], ["BG", "PROTEIN", 240, 242], ["Biolegend", "PROTEIN", 246, 255], ["anti-A type Gamma-clone", "CELL_LINE", 258, 281], ["Immucor", "PROTEIN", 283, 290], ["anti-B type Gamma-clone", "CELL_LINE", 296, 319], ["Immucor", "PROTEIN", 321, 328], ["primary antibody", "PROTEIN", 346, 362], ["horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG", "PROTEIN", 368, 427], ["Sigma", "PROTEIN", 429, 434], ["secondary antibody", "PROTEIN", 452, 470], ["horseradish", "SPECIES", 368, 379], ["goat", "SPECIES", 408, 412], ["anti-mouse", "SPECIES", 413, 423], ["goat", "SPECIES", 408, 412], ["the boiled supernatants", "TREATMENT", 20, 43], ["vinyl", "TREATMENT", 47, 52], ["anti-Leb", "TREATMENT", 230, 238], ["BG", "TEST", 240, 242], ["Biolegend", "TEST", 246, 255], ["clone (Immucor)", "TREATMENT", 314, 329], ["the primary antibody", "TEST", 342, 362], ["horseradish peroxidase", "TEST", 368, 390], ["HRP", "TEST", 392, 395], ["conjugated goat anti-mouse IgG", "TREATMENT", 397, 427], ["secondary antibody", "OBSERVATION", 452, 470]]], ["3,3\u2032,5,5\u2032-Tetramethylbenzidine (TMB) (KPL) was used as a HRP substrate, and the reaction was stopped with 1 M phosphoric acid (Fisher Scientific) after a 10-min incubation at RT.", [["3,3\u2032,5,5\u2032-Tetramethylbenzidine", "CHEMICAL", 0, 30], ["TMB", "CHEMICAL", 32, 35], ["KPL", "CHEMICAL", 38, 41], ["phosphoric acid", "CHEMICAL", 110, 125], ["3,3\u2032,5,5\u2032-Tetramethylbenzidine", "CHEMICAL", 0, 30], ["TMB", "CHEMICAL", 32, 35], ["KPL", "CHEMICAL", 38, 41], ["phosphoric acid", "CHEMICAL", 110, 125], ["3,3\u2032,5,5\u2032-Tetramethylbenzidine", "SIMPLE_CHEMICAL", 0, 30], ["TMB", "SIMPLE_CHEMICAL", 32, 35], ["KPL", "SIMPLE_CHEMICAL", 38, 41], ["HRP", "SIMPLE_CHEMICAL", 57, 60], ["phosphoric acid", "SIMPLE_CHEMICAL", 110, 125], ["Tetramethylbenzidine (TMB) (KPL)", "TREATMENT", 10, 42], ["a HRP substrate", "TREATMENT", 55, 70], ["the reaction", "PROBLEM", 76, 88], ["1 M phosphoric acid", "TREATMENT", 106, 125]]], ["The absorbance was determined at 450 nm with a Spectramax 190 plate reader (Molecular Devices).", [["a Spectramax 190 plate reader (Molecular Devices", "TREATMENT", 45, 93]]], ["Pooled saliva samples from persons who collectively express each histo-blood group antigen (HBGA) type evaluated was used as a positive control (34).", [["saliva samples", "ANATOMY", 7, 21], ["blood", "ANATOMY", 71, 76], ["saliva samples", "ORGANISM_SUBSTANCE", 7, 21], ["persons", "ORGANISM", 27, 34], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["histo-blood group antigen", "PROTEIN", 65, 90], ["HBGA", "PROTEIN", 92, 96], ["persons", "SPECIES", 27, 34], ["blood group antigen", "TEST", 71, 90]]], ["Saliva from an individual negative for the HBGAs was used as a negative control.HIE HBGA genotyping. ::: MATERIALS AND METHODSDNA was extracted from HIEs and primers (Table 2) targeting exons 6 and 7 of the ABO gene, the FUT2 (secretor) gene, and the FUT3 (Lewis) gene were used to generate amplicons that were purified using the GeneJET PCR purification kit (ThermoFisher Scientific) and sequenced (GeneWiz).", [["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["HBGAs", "CANCER", 43, 48], ["ABO", "GENE_OR_GENE_PRODUCT", 207, 210], ["FUT2", "GENE_OR_GENE_PRODUCT", 221, 225], ["secretor", "GENE_OR_GENE_PRODUCT", 227, 235], ["FUT3", "GENE_OR_GENE_PRODUCT", 251, 255], ["HIEs", "DNA", 149, 153], ["exons 6 and 7", "DNA", 186, 199], ["ABO gene", "DNA", 207, 215], ["FUT2 (secretor) gene", "DNA", 221, 241], ["FUT3 (Lewis) gene", "DNA", 251, 268], ["the HBGAs", "TEST", 39, 48], ["HIE HBGA genotyping", "TEST", 80, 99], ["exons", "TEST", 186, 191], ["the ABO gene", "TEST", 203, 215], ["the FUT3 (Lewis) gene", "TREATMENT", 247, 268], ["the GeneJET PCR purification", "TREATMENT", 326, 354]]], ["Chromatograms were examined to identify single nucleotide polymorphisms associated with loss of function (for FUT2.", [["nucleotide", "CHEMICAL", 47, 57], ["FUT2", "GENE_OR_GENE_PRODUCT", 110, 114], ["FUT2", "PROTEIN", 110, 114], ["Chromatograms", "TEST", 0, 13], ["single nucleotide polymorphisms", "PROBLEM", 40, 71], ["loss of function", "PROBLEM", 88, 104]]], ["A385T, G428A, C571T, and C628T; for FUT3, T59G, T202C, C314T, G484A, G508A, G667A, G808A, and T1067A or A, B, or O genotype (for exon 6, nucleotides 261 and 297; for exon 7, nucleotides 657, 703, 771, 796, 803, 829, and 930).Immunofluorescence and quantitation. ::: MATERIALS AND METHODSHIE monolayers were grown in glass bottom plates (catalog no. 655892; Greiner Bio-One), differentiated for 5 days, and fixed with 4% paraformaldehyde (PFA) for 20 min at RT.", [["monolayers", "ANATOMY", 291, 301], ["nucleotides", "CHEMICAL", 174, 185], ["paraformaldehyde", "CHEMICAL", 420, 436], ["PFA", "CHEMICAL", 438, 441], ["A385T", "GENE_OR_GENE_PRODUCT", 0, 5], ["FUT3", "GENE_OR_GENE_PRODUCT", 36, 40], ["B", "GENE_OR_GENE_PRODUCT", 107, 108], ["METHODSHIE monolayers", "CELL", 280, 301], ["paraformaldehyde", "SIMPLE_CHEMICAL", 420, 436], ["PFA", "SIMPLE_CHEMICAL", 438, 441], ["exon 6", "DNA", 129, 135], ["nucleotides 261 and 297", "DNA", 137, 160], ["exon 7", "DNA", 166, 172], ["METHODSHIE monolayers", "CELL_LINE", 280, 301], ["C571T", "TEST", 14, 19], ["C628T", "TEST", 25, 30], ["FUT3", "TEST", 36, 40], ["T59G", "TEST", 42, 46], ["T202C", "TEST", 48, 53], ["C314T", "TEST", 55, 60], ["exon", "TEST", 129, 133], ["nucleotides", "TEST", 137, 148], ["exon", "TEST", 166, 170], ["nucleotides", "TEST", 174, 185], ["Immunofluorescence", "TEST", 225, 243], ["METHODSHIE monolayers", "TEST", 280, 301], ["4% paraformaldehyde (PFA", "TREATMENT", 417, 441]]], ["HIE monolayers were permeabilized and blocked with 5% bovine serum albumin (BSA) in 0.1% Triton X-100 in PBS for 30 min at RT.", [["monolayers", "ANATOMY", 4, 14], ["serum", "ANATOMY", 61, 66], ["Triton X-100", "CHEMICAL", 89, 101], ["HIE monolayers", "CELL", 0, 14], ["bovine", "ORGANISM", 54, 60], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["albumin", "SIMPLE_CHEMICAL", 67, 74], ["BSA", "SIMPLE_CHEMICAL", 76, 79], ["Triton X-100", "SIMPLE_CHEMICAL", 89, 101], ["bovine", "SPECIES", 54, 60], ["HIE monolayers", "TEST", 0, 14], ["5% bovine serum albumin (BSA)", "TREATMENT", 51, 80]]], ["All the subsequent steps were performed in PBS plus 0.1% Triton X-100.", [["Triton X-100", "CHEMICAL", 57, 69], ["Triton X-100", "CHEMICAL", 57, 69], ["Triton X-100", "SIMPLE_CHEMICAL", 57, 69]]], ["HBGAs and cell boundaries were detected after overnight incubation at 4\u00b0C with rhodamine-labeled Ulex europaeus agglutinin-1 (UEA-1) (1:1,000) (catalog no. RL-1062; Vector Laboratories) and Alexa Fluor 647 phalloidin (ThermoFisher Scientific), respectively.", [["cell", "ANATOMY", 10, 14], ["rhodamine", "CHEMICAL", 79, 88], ["RL-1062", "CHEMICAL", 156, 163], ["rhodamine", "CHEMICAL", 79, 88], ["RL-1062", "CHEMICAL", 156, 163], ["Alexa Fluor 647 phalloidin", "CHEMICAL", 190, 216], ["HBGAs", "SIMPLE_CHEMICAL", 0, 5], ["cell", "CELL", 10, 14], ["rhodamine", "SIMPLE_CHEMICAL", 79, 88], ["Ulex europaeus agglutinin-1", "SIMPLE_CHEMICAL", 97, 124], ["UEA-1", "GENE_OR_GENE_PRODUCT", 126, 131], ["Alexa Fluor 647 phalloidin", "SIMPLE_CHEMICAL", 190, 216], ["UEA", "PROTEIN", 126, 129], ["Ulex europaeus", "SPECIES", 97, 111], ["Ulex europaeus", "SPECIES", 97, 111], ["Alexa Fluor 647", "SPECIES", 190, 205], ["HBGAs", "TEST", 0, 5], ["cell boundaries", "TEST", 10, 25], ["rhodamine", "TEST", 79, 88], ["agglutinin", "TEST", 112, 122], ["UEA", "TEST", 126, 129], ["RL", "TEST", 156, 158], ["Vector Laboratories", "TEST", 165, 184], ["Alexa Fluor", "TEST", 190, 201], ["cell boundaries", "OBSERVATION", 10, 25]]], ["For the fucose inhibition assay, the UEA-I was incubated with different concentrations of l-fucose at RT for 1 h prior to staining.", [["l-fucose", "CHEMICAL", 90, 98], ["fucose", "CHEMICAL", 8, 14], ["l-fucose", "CHEMICAL", 90, 98], ["fucose", "SIMPLE_CHEMICAL", 8, 14], ["UEA-I", "GENE_OR_GENE_PRODUCT", 37, 42], ["l-fucose", "SIMPLE_CHEMICAL", 90, 98], ["UEA-I", "PROTEIN", 37, 42], ["the fucose inhibition assay", "TEST", 4, 31], ["l-fucose at RT", "TREATMENT", 90, 104]]], ["Nuclei were stained with 4\u2032,6\u2032-diamidino-2-phenylindole (DAPI) (300 nM) for 5 min at RT.", [["Nuclei", "ANATOMY", 0, 6], ["4\u2032,6\u2032-diamidino-2-phenylindole", "CHEMICAL", 25, 55], ["DAPI", "CHEMICAL", 57, 61], ["4\u2032,6\u2032-diamidino-2-phenylindole", "CHEMICAL", 25, 55], ["DAPI", "CHEMICAL", 57, 61], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["4\u2032,6\u2032-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 25, 55], ["DAPI", "SIMPLE_CHEMICAL", 57, 61], ["Nuclei", "TEST", 0, 6], ["diamidino", "TREATMENT", 31, 40]]], ["Orthogonal 5-\u03bcm-thick sections of the sample were captured using a Zeiss LSM 510 confocal microscope.", [["sections", "ANATOMY", 22, 30], ["sample", "ANATOMY", 38, 44], ["sections", "MULTI-TISSUE_STRUCTURE", 22, 30], ["confocal microscope", "TEST", 81, 100]]], ["For quantifying fluorescence intensity, five fields per well were analyzed.", [["quantifying fluorescence intensity", "PROBLEM", 4, 38]]], ["The fluorescence threshold in these images was set in Image J. Mean fluorescence data from 15 identical regions of interest (ROIs) per field were collected.", [["The fluorescence threshold", "TEST", 0, 26], ["these images", "TEST", 30, 42], ["Mean fluorescence data", "TEST", 63, 85]]], ["P values of <0.05 were considered statistically significant.In vitro HuNoV infection. ::: MATERIALS AND METHODSJejunal HIE monolayers in 96-well plates were differentiated for 5 days in commercial Intesticult (INT) human organoid growth medium (Stem Cell Technologies) and inoculated with the indicated positive HuNoV stool filtrates at 37\u00b0C for 1 h (GII/Hu/US/2012/GII.4 Sydney [P31]/TCH12-580, 9 \u00d7 105 genome equivalents [GEs]/well; GII/Hu/US/2004/GII.3 [P21]/TCH04-577, 4.3 \u00d7 105 GEs/well; GII/Hu/US/2014/GII.17 [P38]/TCH14-385, 1.8 \u00d7 106 GEs/well) or for 2 h (GI/Hu/US/2006/GI.1 Norwalk [P1]/BCM723-02, 6.9 \u00d7 105 GEs/well) as described previously (2).", [["METHODSJejunal HIE monolayers", "ANATOMY", 104, 133], ["Cell", "ANATOMY", 250, 254], ["HuNoV infection", "DISEASE", 69, 84], ["TCH14-385", "CHEMICAL", 521, 530], ["METHODSJejunal HIE monolayers", "CELL", 104, 133], ["human", "ORGANISM", 215, 220], ["Stem Cell", "CELL", 245, 254], ["P38", "PROTEIN", 516, 519], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["HuNoV", "SPECIES", 312, 317], ["GII/Hu/US/2012/GII.4 Sydney [P31]/TCH12-580", "SPECIES", 351, 394], ["GI/Hu/US/2006/GI.1 Norwalk [P1]/BCM723-02", "SPECIES", 564, 605], ["P values", "TEST", 0, 8], ["vitro HuNoV infection", "PROBLEM", 63, 84], ["METHODSJejunal HIE monolayers", "TEST", 104, 133], ["positive HuNoV stool filtrates", "PROBLEM", 303, 333], ["TCH12", "TEST", 385, 390], ["genome equivalents", "TEST", 404, 422], ["GII", "TEST", 435, 438], ["Hu/US", "TEST", 439, 444], ["P21", "TEST", 457, 460], ["TCH04", "TEST", 462, 467], ["GEs", "TEST", 483, 486], ["GII", "TEST", 493, 496], ["Hu/US", "TEST", 497, 502], ["GII.17", "TEST", 508, 514], ["P38", "TEST", 516, 519], ["TCH14", "TEST", 521, 526], ["GI/Hu/US", "TEST", 564, 572], ["P1", "TEST", 592, 594], ["BCM723", "TEST", 596, 602], ["HuNoV infection", "OBSERVATION", 69, 84]]], ["Each infection was performed in triplicate wells for each time point, and conditions were tested in at least two independent experiments.", [["infection", "DISEASE", 5, 14], ["Each infection", "PROBLEM", 0, 14], ["infection", "OBSERVATION", 5, 14]]], ["Inocula were removed, and monolayers were washed twice with CMGF(\u2212) medium to remove unbound virus.", [["monolayers", "ANATOMY", 26, 36], ["CMGF", "CHEMICAL", 60, 64], ["monolayers", "CELL", 26, 36], ["CMGF", "SIMPLE_CHEMICAL", 60, 64], ["Inocula", "TREATMENT", 0, 7], ["CMGF(\u2212) medium", "TREATMENT", 60, 74], ["unbound virus", "PROBLEM", 85, 98]]], ["Differentiation INT medium (100 \u03bcl supplemented with 500 \u03bcM glycochenodeoxycholic acid [GCDCA] [Sigma]) was then added to each well, and the cultures were incubated at 37\u00b0C for the indicated time points.", [["glycochenodeoxycholic acid", "CHEMICAL", 60, 86], ["GCDCA", "CHEMICAL", 88, 93], ["glycochenodeoxycholic acid", "CHEMICAL", 60, 86], ["GCDCA", "CHEMICAL", 88, 93], ["glycochenodeoxycholic acid", "SIMPLE_CHEMICAL", 60, 86], ["GCDCA", "SIMPLE_CHEMICAL", 88, 93], ["C", "GENE_OR_GENE_PRODUCT", 171, 172], ["500 \u03bcM glycochenodeoxycholic acid [GCDCA] [Sigma])", "TREATMENT", 53, 103], ["the cultures", "TEST", 137, 149]]], ["RNA was extracted from each well using the KingFisher Flex Purification system and MAgMAX-96 viral RNA isolation kit.", [["RNA", "RNA", 0, 3], ["MAgMAX-96", "SPECIES", 83, 92], ["the KingFisher Flex Purification system", "TREATMENT", 39, 78], ["MAgMAX", "TEST", 83, 89], ["viral RNA isolation kit", "TREATMENT", 93, 116]]], ["RNA extracted at 1 to 2 hpi was used as a baseline to determine the amount of input virus that remained associated with cells after the infected cultures were washed to remove unbound virus.", [["cells", "ANATOMY", 120, 125], ["cultures", "ANATOMY", 145, 153], ["cells", "CELL", 120, 125], ["RNA", "RNA", 0, 3], ["RNA extracted", "PROBLEM", 0, 13], ["input virus", "PROBLEM", 78, 89], ["the infected cultures", "PROBLEM", 132, 153], ["unbound virus", "PROBLEM", 176, 189]]], ["Replication of virus was determined by HuNoV RNA levels, which were quantified using a standard curve based on a recombinant HuNoV RNA transcript, and replication of virus was determined by assessing changes in virus GE levels at 24 hpi from baseline.Statistics. ::: MATERIALS AND METHODSAll statistical analyses were performed on GraphPad Prism (GraphPad Software, La Jolla, California USA).", [["HuNoV", "GENE_OR_GENE_PRODUCT", 39, 44], ["HuNoV", "GENE_OR_GENE_PRODUCT", 125, 130], ["HuNoV RNA", "RNA", 39, 48], ["recombinant HuNoV RNA transcript", "RNA", 113, 145], ["HuNoV", "SPECIES", 125, 130], ["Replication of virus", "PROBLEM", 0, 20], ["a standard curve", "TREATMENT", 85, 101], ["a recombinant HuNoV RNA transcript", "TREATMENT", 111, 145], ["replication of virus", "PROBLEM", 151, 171], ["changes in virus GE levels", "PROBLEM", 200, 226], ["METHODSAll statistical analyses", "TEST", 281, 312], ["GraphPad Prism", "TEST", 331, 345], ["virus", "OBSERVATION", 15, 20]]], ["Samples with RNA levels below the limit of detection of the reverse transcription-quantitative PCR (RT-qPCR) assay were assigned a value that is one-half the limit of detection of the assay.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["RNA levels", "TEST", 13, 23], ["the reverse transcription", "TEST", 56, 81], ["quantitative PCR", "TEST", 82, 98], ["the assay", "TEST", 180, 189]]], ["Comparisons between infection time point groups or infected cell lines were made using two-way analysis of variance (ANOVA) with Tukey\u2019s test for post hoc analyses.", [["cell lines", "ANATOMY", 60, 70], ["infection", "DISEASE", 20, 29], ["cell lines", "CELL", 60, 70], ["infected cell lines", "CELL_LINE", 51, 70], ["infection time point groups", "TREATMENT", 20, 47], ["infected cell lines", "TREATMENT", 51, 70], ["Tukey\u2019s test", "TEST", 129, 141], ["post hoc analyses", "TEST", 146, 163], ["infected cell lines", "OBSERVATION", 51, 70]]], ["P values of <0.05 were considered statistically significant.", [["P values", "TEST", 0, 8]]]], "PMC7480895": [["Coronavirus disease 2019 (COVID-19) was emerged in the Wuhan City, Hubei Province of Central China in December 2019 and subsequently has rapidly spread to most of the countries worldwide [1].", [["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 26, 34], ["Coronavirus disease 2019 (COVID-19", "SPECIES", 0, 34], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 26, 31]]], ["To date (2nd August, 2020), Covid-19 caused 17,680,523 confirmed cases and 680,894 deaths in 216 countries as per WHO report as well as also declared as a Public Health Emergency of International Concern (PHEIC).", [["deaths", "DISEASE", 83, 89], ["Covid", "TEST", 28, 33]]], ["Strikingly, no vaccine as well as effective therapeutic drugs are available in the International market.", [["vaccine", "TREATMENT", 15, 22], ["effective therapeutic drugs", "TREATMENT", 34, 61]]], ["In view of these facts, there is an urgent need for a better understanding of SARS-COV-2 virus [severe acute respiratory syndrome; previously known as 2019 novel coronavirus (2019-nCoV)] in order to develop any effective vaccines or molecules against COVID-19.", [["SARS", "DISEASE", 78, 82], ["acute respiratory syndrome", "DISEASE", 103, 129], ["SARS-COV-2 virus", "ORGANISM", 78, 94], ["SARS-COV-2 virus", "SPECIES", 78, 94], ["SARS", "PROBLEM", 78, 82], ["COV-2 virus", "PROBLEM", 83, 94], ["severe acute respiratory syndrome", "PROBLEM", 96, 129], ["novel coronavirus", "PROBLEM", 156, 173], ["any effective vaccines", "TREATMENT", 207, 229], ["COVID", "TEST", 251, 256], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory syndrome", "OBSERVATION", 109, 129]]]], "PMC7462965": [["Payment ReformDuring the last decade, US health policy has gradually transitioned to VBC, shifting from fee-for-service to alternative payment models (APMs).", [["VBC", "TREATMENT", 85, 88]]], ["Thirty-four percent of total US health care payments were associated with APMs in 2017,2 with goals of 50% of Medicare and 25% of commercial by 2022.3,4 Practices that remain in fee-for-service without adoption of VBC can expect reduced future revenues and negative payment adjustments.Payment ReformThe Medicare Access and CHIP Reauthorization Act of 2015 created the Quality Payment Program, which established the Merit-Based Incentive Payment System and Advanced APM pathways.", [["APMs", "DISEASE", 74, 78], ["Medicare", "TREATMENT", 110, 118], ["VBC", "TREATMENT", 214, 217], ["Incentive Payment System", "TREATMENT", 428, 452], ["Advanced APM pathways", "TREATMENT", 457, 478]]], ["APM programs, such as Accountable Care Organizations (ACO) and the Oncology Care Model (OCM), were established as advanced APMs.5 In both the ACO and OCM models, the participating organization is responsible for the total cost of care (TCOC), such as outpatient (including radiation oncology), inpatient, radiology, laboratory, and pharmaceuticals, for all patients attributed to the organization during a performance period.", [["patients", "ORGANISM", 357, 365], ["patients", "SPECIES", 357, 365], ["ACO", "OBSERVATION_MODIFIER", 142, 145]]], ["The benefits of participating in an advanced APM model include a 5% incentive payment bonus, eligibility for APM-specific rewards, and exclusion from Merit-Based Incentive Payment System requirements.Payment ReformQuantifying performance in these APMs is complex and multifactorial.", [["APMs", "DISEASE", 247, 251], ["APMs", "CANCER", 247, 251], ["an advanced APM model", "TREATMENT", 33, 54], ["a 5% incentive payment bonus", "TREATMENT", 63, 91]]], ["APMs begin with a benchmark cost, which reflects risk-adjusted historical costs.", [["a benchmark cost", "TREATMENT", 16, 32]]], ["If actual expenditures (aggregated over all patients attributed to the organization during a performance period) were below the target price, the organization may share in a percentage of those savings based on quality measure performance (shared savings).", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["actual expenditures", "PROBLEM", 3, 22]]], ["Eventually, organizations have transitioned, either voluntarily or by mandate, into a 2-sided risk arrangement that includes downside risk, in which organizations would be obligated to make payments to CMS if expenditures exceed benchmarks.Payment ReformIn 2019, CMS proposed a mandatory 2-sided risk episode-based Radiation Oncology APM (RO-APM) that would qualify as an advanced APM.6 The RO-APM focuses exclusively on radiation therapy\u2013related costs and would not be a TCOC program.", [["a 2-sided risk arrangement", "TREATMENT", 84, 110], ["sided risk episode", "PROBLEM", 290, 308], ["an advanced APM", "TREATMENT", 369, 384], ["radiation therapy\u2013related costs", "TREATMENT", 421, 452]]], ["RO-APM participants could also be participants within an OCM or ACO organization.", [["participants", "SPECIES", 7, 19], ["participants", "SPECIES", 34, 46]]], ["RO-APM episode payment calculation begins with a national base rate that is then adjusted by a trend factor (based on episode costs outside the model), case mix, historical episode costs, discount factors, withholds for quality and incorrect payments, geography, and sequestration, as previously described.7 The RO-APM was proposed to begin in 2020.Impact of COVID-19 on APMsDespite this momentum toward VBC, COVID-19 has threatened the long-term adoption of APMs.", [["RO", "CHEMICAL", 312, 314], ["COVID-19", "CHEMICAL", 409, 417], ["COVID-19", "CHEMICAL", 359, 367], ["APMs", "PATHOLOGICAL_FORMATION", 459, 463], ["payment calculation", "TEST", 15, 34], ["a national base rate", "TEST", 47, 67], ["COVID", "TREATMENT", 359, 364], ["VBC", "TEST", 404, 407], ["COVID", "TEST", 409, 414], ["sequestration", "OBSERVATION", 267, 280]]], ["The financial impact of COVID-19, which is likely outside the purview of the participating organization, will place a burden on health care organizations that participate in 2-sided risk models linked to TCOC.", [["TCOC", "DISEASE", 204, 208], ["TCOC", "CANCER", 204, 208], ["COVID", "TEST", 24, 29], ["health care organizations", "TREATMENT", 128, 153]]], ["In hotspots, practices in APMs have needed to divert resources from APM-related nurse navigation, social work, and quality data reporting to the clinical frontlines for managing COVID-19.", [["managing COVID", "TEST", 169, 183]]], ["Some APM programs have mitigation strategies for shared losses (eg, up to a percentage of revenue [stop-loss]) and adjustments for quality metrics (including the \u201cextreme and uncontrollable circumstances\u201d exception), but none has adjustments for benchmarks or expenditures.", [["Some APM programs", "TREATMENT", 0, 17], ["mitigation strategies", "TREATMENT", 23, 44], ["shared losses (eg", "PROBLEM", 49, 66]]], ["COVID-19\u2013related expenditures will skew actual episode expenditures and compromise future financial benchmarks that are tied to historical costs and target prices.", [["COVID", "TEST", 0, 5], ["skew actual episode expenditures", "PROBLEM", 35, 67]]], ["Quality-measure performance and benchmarks, such as hospitalizations, pain/depression score screening, and patient surveys, may also be affected if responses reflect care for COVID-19.Impact of COVID-19 on APMsThe RO-APM final rule was expected to be released earlier this year but has been delayed due to COVID-19.", [["pain", "DISEASE", 70, 74], ["depression", "DISEASE", 75, 85], ["patient", "ORGANISM", 107, 114], ["RO-APM", "GENE_OR_GENE_PRODUCT", 214, 220], ["patient", "SPECIES", 107, 114], ["pain", "PROBLEM", 70, 74], ["depression score screening", "TEST", 75, 101], ["COVID", "TEST", 175, 180], ["COVID", "TREATMENT", 194, 199], ["COVID", "TEST", 306, 311]]], ["Professional societies, including the American Society for Radiation Oncology and American College of Radiology, have recently recommended a start date no earlier than January 1, 2021, given the upfront costs required to establish quality metric data collection, time to retool electronic health records, and inability of practices (that are already experiencing \u223c30% treatment volume declines and greater than 10% revenue declines8) to predict mandatory 2-sided risk model performance in an unstable environment.", [["30% treatment volume declines", "TREATMENT", 364, 393], ["unstable", "OBSERVATION", 492, 500]]], ["Although the RO-APM, which only includes radiation therapy costs, is better positioned in the post\u2013COVID-19 era than TCOC models, COVID-19\u2013related reductions in patient volumes and increase in hypofractionation and active surveillance in 2020 will alter future payment calculations.", [["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["radiation therapy costs", "TREATMENT", 41, 64], ["COVID", "TEST", 130, 135], ["\u2013related reductions in patient volumes", "TREATMENT", 138, 176], ["increase in hypofractionation", "TREATMENT", 181, 210], ["radiation therapy", "OBSERVATION", 41, 58], ["increase", "OBSERVATION_MODIFIER", 181, 189]]], ["Incorporating 2020 data into the trend factor, which incorporates costs outside the RO-APM to update RO-APM payments, may not accurately adjust episode prices, particularly if the 2020 trends represent only a temporary response to the pandemic and not a permanent shift in practice patterns.Impact of COVID-19 on APMsAdditionally, delays in cancer diagnostic testing due to COVID-19 may ultimately lead to fewer patients presenting with early stage disease.9,10 The RO-APM\u2019s practice-specific historical case mix methodology will not recognize this change, as COVID-19 may ultimately shift actual case mix toward more advanced disease requiring more complex treatments.Solutions and Implications for Radiation OncologySeveral immediate solutions can be adopted by CMS and other payers, whereas other solutions will require longer-term collaborations and technological innovations.", [["cancer", "ANATOMY", 341, 347], ["COVID-19", "CHEMICAL", 301, 309], ["cancer", "DISEASE", 341, 347], ["COVID-19", "CHEMICAL", 374, 382], ["COVID-19", "CHEMICAL", 374, 382], ["cancer", "CANCER", 341, 347], ["patients", "ORGANISM", 412, 420], ["patients", "SPECIES", 412, 420], ["COVID", "TREATMENT", 301, 306], ["diagnostic testing", "TEST", 348, 366], ["COVID", "TEST", 374, 379], ["early stage disease", "PROBLEM", 437, 456], ["more advanced disease", "PROBLEM", 613, 634], ["more complex treatments", "TREATMENT", 645, 668], ["Radiation OncologySeveral immediate solutions", "TREATMENT", 700, 745], ["longer-term collaborations", "TREATMENT", 823, 849], ["early stage", "OBSERVATION_MODIFIER", 437, 448], ["disease", "OBSERVATION", 449, 456], ["advanced", "OBSERVATION_MODIFIER", 618, 626], ["disease", "OBSERVATION", 627, 634]]], ["On June 3, 2020, CMS released model-specific adjustments to current APMs.11 In general, CMS will create an option for practices in APMs to forgo 1-sided or 2-sided risk during the public health emergency.", [["current APMs", "TREATMENT", 60, 72], ["practices in APMs", "TREATMENT", 118, 135]]], ["For practices that elect to remain in their risk arrangement, CMS will work to remove COVID-19\u2013related episodes during reconciliation for those performance periods.", [["COVID", "TREATMENT", 86, 91]]], ["CMS will also allow reporting of quality measures and clinical/staging data to be optional for the affected periods and will remove upcoming deadlines for cost and resource use reporting.", [["clinical/staging data", "TEST", 54, 75], ["the affected periods", "PROBLEM", 95, 115]]], ["CMS has also extended the timeline for APMs, such as the OCM, for an additional year.", [["APMs", "DISEASE", 39, 43]]], ["Depending on future changes to the public health emergency, implementation of new APMs could be further delayed, but no specific details regarding the proposed RO-APM were released.Solutions and Implications for Radiation OncologyAlthough these adjustments will be beneficial, there are several additional immediate solutions to consider.", [["RO", "CHEMICAL", 160, 162], ["RO-APM", "GENE_OR_GENE_PRODUCT", 160, 166], ["Radiation", "TREATMENT", 212, 221], ["additional immediate solutions", "TREATMENT", 295, 325]]], ["First, 2020 data could be removed from benchmark and trend factor calculations for future payment rate calculations, unless filtered data meet stringent inclusion criteria consistent with historical trends.", [["future payment rate calculations", "TREATMENT", 83, 115]]], ["Similarly, practice-specific case mix methodology will need to be modified to account for more advanced disease requiring more complex care as a result of delays.", [["more advanced disease", "PROBLEM", 90, 111]]], ["Additionally, radiation oncology practices selected for the RO-APM should be provided with upfront financial support to maximize the probability of successfully entering into a risk-bearing APM arrangement\u2014financial resources will be depleted for many radiation oncology practices due to COVID-19.", [["COVID-19", "DNA", 288, 296], ["radiation oncology practices", "TREATMENT", 14, 42], ["upfront financial support", "TREATMENT", 91, 116], ["COVID", "TEST", 288, 293]]], ["CMS and other payers should also consider more flexibility and extension of timelines for future APMs.Solutions and Implications for Radiation OncologyIn the longer term, population health management with Big Data, artificial intelligence, and predictive analytics will need to play a pivotal role in understanding the spread of disease, the effectiveness of clinical responses, impact on cost, and trend predictions.", [["APMs", "DISEASE", 97, 101], ["APMs", "PATHOLOGICAL_FORMATION", 97, 101], ["future APMs", "PROBLEM", 90, 101], ["Radiation Oncology", "TREATMENT", 133, 151], ["population health management", "TREATMENT", 171, 199], ["disease", "PROBLEM", 329, 336]]], ["Population health experts are already working on integrated analytics approaches with aggregate polygenic (genetic risk) and polysocial (health and nonhealth sectors such as justice, transportation, housing, employment, environment, education, and sanitation) risk scores.12 Such an approach is promising for managing TCOC and advanced APMs as well but will require linking of disparate data sets, minimizing biases in the captured data, and simultaneously integrating COVID-19 transmission risk data.Solutions and Implications for Radiation OncologyProviders and payers will also need to engage in closer collaborations and data sharing, with an emphasis on near real-time interoperability between clinical and administrative claims data.", [["TCOC", "DISEASE", 318, 322], ["TCOC", "CANCER", 318, 322], ["APMs", "CANCER", 336, 340], ["aggregate polygenic (genetic risk)", "PROBLEM", 86, 120], ["managing TCOC and advanced APMs", "TREATMENT", 309, 340], ["Radiation OncologyProviders", "TREATMENT", 532, 559]]], ["This effort would benefit from a national health information exchange infrastructure, which is not currently available, and successful navigation of the complexity of HIPAA security and privacy rules that could potentially impede data gathering and sharing efforts.Solutions and Implications for Radiation OncologySimilarly, APMs will require more robust and efficient approaches to reattribution of patients, episodes, and costs.", [["patients", "ORGANISM", 400, 408], ["patients", "SPECIES", 400, 408], ["HIPAA security", "TREATMENT", 167, 181], ["Radiation OncologySimilarly", "TREATMENT", 296, 323], ["episodes", "PROBLEM", 410, 418]]], ["Although CMS has agreed to remove COVID-19\u2013related episodes from reconciled expenditures,11 sophisticated and reliable data analytics platforms will be needed to make those adjustments and to appropriately recalculate benchmarks and quality performance scores.", [["COVID", "TEST", 34, 39]]], ["Currently, reconciliation in APMs may occur as late as 18 to 24 months after the performance period, but with advanced analytics, stakeholder collaborations, and interoperability, such reconciliation can and should be completed closer to the end of the performance period.Solutions and Implications for Radiation OncologyIn conclusion, Big Data analytics holds promise for long-term episode attribution and more rapid reconciliation of claims data for APMs in the post\u2013COVID-19 era.", [["APMs", "DISEASE", 452, 456], ["COVID", "PROTEIN", 469, 474], ["Radiation OncologyIn conclusion", "TREATMENT", 303, 334], ["APMs", "PROBLEM", 452, 456], ["COVID", "TEST", 469, 474]]], ["Future APMs should focus on costs that are controllable by practices, or practices in 2-sided risk APMs will remain in financial risk, threatening not only the movement to VBC but also access to high-quality care in the United States.", [["Future APMs", "TREATMENT", 0, 11], ["VBC", "TREATMENT", 172, 175]]]], "PMC7332312": [["Following graduation from high school, he pursued medical studies at Peking Medical University.", [["medical studies", "TEST", 50, 65]]]], "5df7afb38452fc967d4d260fb5aa47326500756a": [["IntroductionIn 1969, a Louisiana dairy cow (R-29) was found to be infected with a virus that was identified as a retrovirus.", [["cow", "ORGANISM", 39, 42], ["retrovirus", "ORGANISM", 113, 123], ["cow", "SPECIES", 39, 42], ["Louisiana dairy cow (R-29", "SPECIES", 23, 48], ["a virus", "PROBLEM", 80, 87], ["a retrovirus", "PROBLEM", 111, 123], ["infected", "OBSERVATION", 66, 74], ["virus", "OBSERVATION", 82, 87], ["retrovirus", "OBSERVATION", 113, 123]]], ["It was subsequently named bovine immunodeficiency virus, also known as bovine lentivirus-1 (BIV) [1 -4] .", [["bovine immunodeficiency virus", "DISEASE", 26, 55], ["bovine immunodeficiency virus", "ORGANISM", 26, 55], ["bovine", "ORGANISM", 71, 77], ["lentivirus-1", "ORGANISM", 78, 90], ["BIV", "ORGANISM", 92, 95], ["bovine", "SPECIES", 26, 32], ["immunodeficiency virus", "SPECIES", 33, 55], ["bovine", "SPECIES", 71, 77], ["bovine immunodeficiency virus", "SPECIES", 26, 55], ["bovine lentivirus-1", "SPECIES", 71, 90], ["BIV", "SPECIES", 92, 95], ["bovine immunodeficiency virus", "PROBLEM", 26, 55], ["bovine lentivirus", "TEST", 71, 88], ["bovine immunodeficiency", "OBSERVATION", 26, 49]]], ["The cow had persistent lymphocytosis, became severely weak and emaciated following parturition and was euthanized.", [["lymphocytosis", "DISEASE", 23, 36], ["cow", "ORGANISM", 4, 7], ["cow", "SPECIES", 4, 7], ["cow", "SPECIES", 4, 7], ["persistent lymphocytosis", "PROBLEM", 12, 36], ["severely weak", "PROBLEM", 45, 58], ["persistent", "OBSERVATION_MODIFIER", 12, 22], ["lymphocytosis", "OBSERVATION", 23, 36], ["severely", "OBSERVATION_MODIFIER", 45, 53], ["weak", "OBSERVATION", 54, 58], ["emaciated", "OBSERVATION_MODIFIER", 63, 72]]], ["The lymph nodes (LN) were enlarged; although, evidence of lymphosarcoma was not detected.", [["lymph nodes", "ANATOMY", 4, 15], ["LN", "ANATOMY", 17, 19], ["lymphosarcoma", "ANATOMY", 58, 71], ["lymphosarcoma", "DISEASE", 58, 71], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 4, 15], ["LN", "MULTI-TISSUE_STRUCTURE", 17, 19], ["lymphosarcoma", "CANCER", 58, 71], ["lymphosarcoma", "PROBLEM", 58, 71], ["lymph nodes", "OBSERVATION", 4, 15], ["LN", "OBSERVATION_MODIFIER", 17, 19], ["enlarged", "OBSERVATION_MODIFIER", 26, 34], ["evidence of", "UNCERTAINTY", 46, 57], ["lymphosarcoma", "OBSERVATION", 58, 71]]], ["The LN had generalized hyperplasia and the brain had mild lymphocytic perivascular cuffing [1] .", [["LN", "ANATOMY", 4, 6], ["brain", "ANATOMY", 43, 48], ["lymphocytic perivascular", "ANATOMY", 58, 82], ["hyperplasia", "DISEASE", 23, 34], ["LN", "CANCER", 4, 6], ["brain", "ORGAN", 43, 48], ["generalized hyperplasia", "PROBLEM", 11, 34], ["mild lymphocytic perivascular cuffing", "PROBLEM", 53, 90], ["LN", "ANATOMY", 4, 6], ["generalized", "OBSERVATION_MODIFIER", 11, 22], ["hyperplasia", "OBSERVATION", 23, 34], ["brain", "ANATOMY", 43, 48], ["mild", "OBSERVATION_MODIFIER", 53, 57], ["lymphocytic", "OBSERVATION", 58, 69], ["perivascular", "ANATOMY_MODIFIER", 70, 82], ["cuffing", "OBSERVATION", 83, 90]]], ["Subsequent experimental infection of cattle with this isolated agent (BIV isolate R-29) produced lesions in the lymphoid system, ranging from lymphocytosis to lymphoid hyperplasia of the LN and hemal lymph nodes (HLN).", [["lesions", "ANATOMY", 97, 104], ["lymphoid system", "ANATOMY", 112, 127], ["lymphoid hyperplasia", "ANATOMY", 159, 179], ["LN", "ANATOMY", 187, 189], ["hemal lymph nodes", "ANATOMY", 194, 211], ["HLN", "ANATOMY", 213, 216], ["infection", "DISEASE", 24, 33], ["R-29", "CHEMICAL", 82, 86], ["lymphocytosis", "DISEASE", 142, 155], ["lymphoid hyperplasia", "DISEASE", 159, 179], ["cattle", "ORGANISM", 37, 43], ["lesions", "PATHOLOGICAL_FORMATION", 97, 104], ["lymphoid system", "MULTI-TISSUE_STRUCTURE", 112, 127], ["lymphoid hyperplasia", "PATHOLOGICAL_FORMATION", 159, 179], ["LN", "MULTI-TISSUE_STRUCTURE", 187, 189], ["hemal lymph nodes", "MULTI-TISSUE_STRUCTURE", 194, 211], ["HLN", "CANCER", 213, 216], ["cattle", "SPECIES", 37, 43], ["cattle", "SPECIES", 37, 43], ["Subsequent experimental infection of cattle", "PROBLEM", 0, 43], ["this isolated agent", "TREATMENT", 49, 68], ["BIV isolate R", "TEST", 70, 83], ["lesions in the lymphoid system", "PROBLEM", 97, 127], ["lymphocytosis", "PROBLEM", 142, 155], ["lymphoid hyperplasia of the LN", "PROBLEM", 159, 189], ["hemal lymph nodes", "PROBLEM", 194, 211], ["experimental", "OBSERVATION_MODIFIER", 11, 23], ["infection", "OBSERVATION", 24, 33], ["lesions", "OBSERVATION", 97, 104], ["lymphoid system", "ANATOMY", 112, 127], ["ranging", "OBSERVATION_MODIFIER", 129, 136], ["lymphocytosis", "OBSERVATION", 142, 155], ["lymphoid hyperplasia", "OBSERVATION", 159, 179], ["LN", "ANATOMY", 187, 189], ["hemal", "ANATOMY_MODIFIER", 194, 199], ["lymph nodes", "OBSERVATION", 200, 211]]], ["Studies of BIV were discontinued until the value of investigating the comparative features of this agent with the human immunodeficiency virus (HIV) was recognized [5 -8] .IntroductionSerological studies in Louisiana have demonstrated substantial prevalence (11%) of BIV infection in dairy cattle [9] .", [["human immunodeficiency virus (HIV)", "DISEASE", 114, 148], ["BIV infection", "DISEASE", 267, 280], ["BIV", "ORGANISM", 11, 14], ["human immunodeficiency virus", "ORGANISM", 114, 142], ["HIV", "ORGANISM", 144, 147], ["BIV", "ORGANISM", 267, 270], ["human immunodeficiency virus", "SPECIES", 114, 142], ["HIV", "SPECIES", 144, 147], ["cattle", "SPECIES", 290, 296], ["BIV", "SPECIES", 11, 14], ["human immunodeficiency virus", "SPECIES", 114, 142], ["HIV", "SPECIES", 144, 147], ["BIV", "SPECIES", 267, 270], ["cattle", "SPECIES", 290, 296], ["BIV", "TREATMENT", 11, 14], ["this agent", "TREATMENT", 94, 104], ["the human immunodeficiency virus", "PROBLEM", 110, 142], ["Serological studies", "TEST", 184, 203], ["BIV infection", "PROBLEM", 267, 280], ["substantial", "OBSERVATION_MODIFIER", 235, 246], ["infection", "OBSERVATION", 271, 280]]], ["Endemic BIV infection of 48-77% has been documented [10] .", [["BIV infection", "DISEASE", 8, 21], ["BIV", "ORGANISM", 8, 11], ["Endemic BIV infection", "PROBLEM", 0, 21], ["infection", "OBSERVATION", 12, 21]]], ["During an adverse winter and spring of 1991, more than 30% of the cows in a production herd died or were culled for multiple primary and secondary disease processes [10] .", [["cows", "ORGANISM", 66, 70], ["cows", "SPECIES", 66, 70], ["multiple primary and secondary disease processes", "PROBLEM", 116, 164]]], ["The cows had multiple disease conditions including abscesses (non-responsive to treatment), laminitis and infectious pododermatitis, and mastitis.", [["abscesses", "ANATOMY", 51, 60], ["abscesses", "DISEASE", 51, 60], ["laminitis", "DISEASE", 92, 101], ["infectious pododermatitis", "DISEASE", 106, 131], ["mastitis", "DISEASE", 137, 145], ["cows", "ORGANISM", 4, 8], ["abscesses", "PATHOLOGICAL_FORMATION", 51, 60], ["cows", "SPECIES", 4, 8], ["multiple disease conditions", "PROBLEM", 13, 40], ["abscesses", "PROBLEM", 51, 60], ["treatment", "TREATMENT", 80, 89], ["laminitis", "PROBLEM", 92, 101], ["infectious pododermatitis", "PROBLEM", 106, 131], ["mastitis", "PROBLEM", 137, 145], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["disease", "OBSERVATION", 22, 29], ["abscesses", "OBSERVATION", 51, 60], ["laminitis", "OBSERVATION", 92, 101], ["infectious pododermatitis", "OBSERVATION", 106, 131], ["mastitis", "OBSERVATION", 137, 145]]], ["A cosmopolitan distribution of BIV has been demonstrated by detection of immunologic and molecular methods [3, 4, 11] .IntroductionUntil recently, studies of cattle maintained under non-stressful experimental conditions and inoculated with BIV isolates have demonstrated subclinical effects in lymphoid tissues and relatively minor alterations of in vivo immunological function [3, 12] .", [["lymphoid tissues", "ANATOMY", 294, 310], ["BIV", "ORGANISM", 31, 34], ["cattle", "ORGANISM", 158, 164], ["BIV", "ORGANISM", 240, 243], ["lymphoid tissues", "TISSUE", 294, 310], ["cattle", "SPECIES", 158, 164], ["BIV", "SPECIES", 31, 34], ["cattle", "SPECIES", 158, 164], ["BIV", "SPECIES", 240, 243], ["BIV", "PROBLEM", 31, 34], ["BIV isolates", "TREATMENT", 240, 252], ["subclinical effects in lymphoid tissues", "PROBLEM", 271, 310], ["BIV", "OBSERVATION", 31, 34], ["lymphoid tissues", "OBSERVATION", 294, 310]]], ["Experimental BIV infection of cattle has been associated with immune dysfunction which included a decreased CD4/CD8 ratio with delayed and lower antibody responses to bovine viral diarrhea virus (BVDV) and bovine herpesvirus 1 [13] .", [["BIV infection", "DISEASE", 13, 26], ["immune dysfunction", "DISEASE", 62, 80], ["bovine viral diarrhea", "DISEASE", 167, 188], ["BIV", "ORGANISM", 13, 16], ["cattle", "ORGANISM", 30, 36], ["CD4", "GENE_OR_GENE_PRODUCT", 108, 111], ["CD8", "GENE_OR_GENE_PRODUCT", 112, 115], ["bovine viral diarrhea virus", "ORGANISM", 167, 194], ["BVDV", "ORGANISM", 196, 200], ["bovine herpesvirus 1", "ORGANISM", 206, 226], ["CD4", "PROTEIN", 108, 111], ["CD8", "PROTEIN", 112, 115], ["cattle", "SPECIES", 30, 36], ["bovine", "SPECIES", 167, 173], ["viral diarrhea virus", "SPECIES", 174, 194], ["BVDV", "SPECIES", 196, 200], ["bovine", "SPECIES", 206, 212], ["BIV", "SPECIES", 13, 16], ["cattle", "SPECIES", 30, 36], ["bovine viral diarrhea virus", "SPECIES", 167, 194], ["BVDV", "SPECIES", 196, 200], ["bovine herpesvirus 1", "SPECIES", 206, 226], ["Experimental BIV infection of cattle", "PROBLEM", 0, 36], ["immune dysfunction", "PROBLEM", 62, 80], ["a decreased CD4/CD8 ratio", "PROBLEM", 96, 121], ["delayed and lower antibody responses", "PROBLEM", 127, 163], ["bovine viral diarrhea virus", "PROBLEM", 167, 194], ["BVDV", "PROBLEM", 196, 200], ["bovine herpesvirus", "TEST", 206, 224], ["BIV", "OBSERVATION_MODIFIER", 13, 16], ["infection", "OBSERVATION", 17, 26], ["associated with", "UNCERTAINTY", 46, 61], ["immune dysfunction", "OBSERVATION", 62, 80], ["decreased", "OBSERVATION_MODIFIER", 98, 107]]], ["Viral replication was identified by detection of BIV provirus or by virus isolation in a variety of tissues, including brain [14 -17] .", [["tissues", "ANATOMY", 100, 107], ["brain", "ANATOMY", 119, 124], ["Viral", "ORGANISM", 0, 5], ["BIV", "ORGANISM", 49, 52], ["tissues", "TISSUE", 100, 107], ["brain", "ORGAN", 119, 124], ["BIV", "SPECIES", 49, 52], ["Viral replication", "PROBLEM", 0, 17], ["BIV provirus", "PROBLEM", 49, 61], ["virus isolation", "PROBLEM", 68, 83], ["BIV provirus", "OBSERVATION", 49, 61], ["brain", "ANATOMY", 119, 124]]], ["Lymphadenopathy and non-suppurative meningoencephalitis have been identified in calves experimentally infected with BIV strain FL112 isolated from a dairy cow in Florida, USA [18 -21] .", [["Lymphadenopathy", "DISEASE", 0, 15], ["meningoencephalitis", "DISEASE", 36, 55], ["calves", "ORGANISM", 80, 86], ["BIV strain FL112", "ORGANISM", 116, 132], ["cow", "ORGANISM_SUBDIVISION", 155, 158], ["calves", "SPECIES", 80, 86], ["cow", "SPECIES", 155, 158], ["BIV", "SPECIES", 116, 119], ["FL112", "SPECIES", 127, 132], ["cow", "SPECIES", 155, 158], ["Lymphadenopathy", "PROBLEM", 0, 15], ["non-suppurative meningoencephalitis", "PROBLEM", 20, 55], ["BIV strain FL112", "PROBLEM", 116, 132], ["non-suppurative", "OBSERVATION_MODIFIER", 20, 35], ["meningoencephalitis", "OBSERVATION", 36, 55], ["calves", "ANATOMY", 80, 86], ["infected", "OBSERVATION_MODIFIER", 102, 110], ["BIV strain", "OBSERVATION", 116, 126]]], ["Two of six calves inoculated with BIV had clinical ataxia [21] , suggestive of the bovine paraplegic syndrome (BPS) observed in Venezuelan cattle [22] .IntroductionDuring a 17 month period, 16 cows were removed from a dairy herd with endemic BIV infection and euthanized due to one or more disease conditions.", [["ataxia", "DISEASE", 51, 57], ["bovine paraplegic syndrome", "DISEASE", 83, 109], ["BPS", "DISEASE", 111, 114], ["BIV infection", "DISEASE", 242, 255], ["calves", "ORGANISM", 11, 17], ["bovine", "ORGANISM", 83, 89], ["cows", "ORGANISM", 193, 197], ["BIV", "ORGANISM", 242, 245], ["calves", "SPECIES", 11, 17], ["bovine", "SPECIES", 83, 89], ["cattle", "SPECIES", 139, 145], ["cows", "SPECIES", 193, 197], ["Venezuelan cattle", "SPECIES", 128, 145], ["BIV", "SPECIES", 242, 245], ["clinical ataxia", "PROBLEM", 42, 57], ["the bovine paraplegic syndrome", "PROBLEM", 79, 109], ["BPS", "TEST", 111, 114], ["endemic BIV infection", "PROBLEM", 234, 255], ["more disease conditions", "PROBLEM", 285, 308], ["suggestive of", "UNCERTAINTY", 65, 78], ["bovine paraplegic syndrome", "OBSERVATION", 83, 109], ["infection", "OBSERVATION", 246, 255]]], ["Efforts were made to: (1) identify all the infectious disease processes and the etiologic agents in each cow, (2) document the presence of BIV provirus in the brain and lymphoid organs, and (3) characterize the lymphoid tissue and brain lesions.", [["brain", "ANATOMY", 159, 164], ["lymphoid organs", "ANATOMY", 169, 184], ["lymphoid tissue", "ANATOMY", 211, 226], ["brain lesions", "ANATOMY", 231, 244], ["cow", "ORGANISM_SUBDIVISION", 105, 108], ["BIV", "ORGANISM", 139, 142], ["brain", "ORGAN", 159, 164], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 169, 184], ["lymphoid tissue", "TISSUE", 211, 226], ["brain lesions", "CANCER", 231, 244], ["cow", "SPECIES", 105, 108], ["BIV", "SPECIES", 139, 142], ["all the infectious disease processes", "PROBLEM", 35, 71], ["BIV provirus in the brain", "PROBLEM", 139, 164], ["the lymphoid tissue", "PROBLEM", 207, 226], ["brain lesions", "PROBLEM", 231, 244], ["infectious", "OBSERVATION", 43, 53], ["BIV provirus", "OBSERVATION", 139, 151], ["brain", "ANATOMY", 159, 164], ["lymphoid organs", "ANATOMY", 169, 184], ["lymphoid tissue", "OBSERVATION", 211, 226], ["brain", "ANATOMY", 231, 236], ["lesions", "OBSERVATION", 237, 244]]], ["This report documents clinical, serological, and pathological observations in Holstein dairy cattle associated with natural infections of bovine lentivirus-1 (BIV).Animals and analysesFifteen adult Holstein cows and one juvenile adult, ages 14 months to 6 years (mean \u00bc 2.9 years) were obtained from a dairy herd \u00f0n \u00bc 90\u00de; with endemic retroviral infection, humanely euthanized and necropsied during a 17 month period ( Table 1 ).", [["infections", "DISEASE", 124, 134], ["retroviral infection", "DISEASE", 336, 356], ["cattle", "ORGANISM", 93, 99], ["bovine", "ORGANISM", 138, 144], ["lentivirus-1", "ORGANISM", 145, 157], ["BIV", "ORGANISM", 159, 162], ["cows", "ORGANISM", 207, 211], ["retroviral", "ORGANISM", 336, 346], ["cattle", "SPECIES", 93, 99], ["bovine", "SPECIES", 138, 144], ["cows", "SPECIES", 207, 211], ["Holstein dairy cattle", "SPECIES", 78, 99], ["bovine lentivirus-1", "SPECIES", 138, 157], ["BIV", "SPECIES", 159, 162], ["dairy herd \u00f0n \u00bc 90\u00de", "SPECIES", 302, 321], ["retroviral", "SPECIES", 336, 346], ["natural infections of bovine lentivirus", "TREATMENT", 116, 155], ["endemic retroviral infection", "PROBLEM", 328, 356], ["endemic", "OBSERVATION_MODIFIER", 328, 335], ["retroviral infection", "OBSERVATION", 336, 356]]], ["Cows were fed a total mixed ration and had rolling herd average milk of 8816 kg (19,395 lb) per year.", [["Cows", "ORGANISM", 0, 4], ["milk", "ORGANISM_SUBSTANCE", 64, 68], ["Cows", "SPECIES", 0, 4], ["a total mixed ration", "TREATMENT", 14, 34]]], ["Veterinary examinations and treatments were provided, as needed, through the Large Animal Clinical Service of the LSU Veterinary Teaching Hospital and Clinics.", [["Veterinary examinations", "TEST", 0, 23], ["treatments", "TREATMENT", 28, 38]]], ["There were no unusual environmental stresses such as exposure to inclement weather.", [["unusual environmental stresses", "PROBLEM", 14, 44], ["no", "UNCERTAINTY", 11, 13], ["unusual", "OBSERVATION_MODIFIER", 14, 21], ["environmental stresses", "OBSERVATION", 22, 44]]], ["Clinical disease problems, weights, and body condition scores [23] were recorded, at the time of parturition, before the onset of clinical disease, and at euthanasia (Tables 1 and 2) .", [["body", "ANATOMY", 40, 44], ["body", "ORGANISM_SUBDIVISION", 40, 44], ["Clinical disease problems", "PROBLEM", 0, 25], ["weights", "TEST", 27, 34], ["body condition scores", "TEST", 40, 61], ["clinical disease", "PROBLEM", 130, 146]]], ["Immediately prior to euthanasia, whole blood was collected for hematological and serological analyses.", [["whole blood", "ANATOMY", 33, 44], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["euthanasia", "PROBLEM", 21, 31], ["whole blood", "TEST", 33, 44], ["hematological and serological analyses", "TEST", 63, 101]]], ["A prompt necropsy was conducted beginning with the collection of the brain and completed for all tissues within 2 h following death.Animals and analysesTissues were submitted to the Louisiana Veterinary Medical Diagnostic Laboratory for immunofluorescence examination and/or culture for the following pathogens: BVDV, infectious bovine rhinotracheitis virus (IBRV), parainfluenza virus-3 (PI3), bovine respiratory syncytial virus (BRSV), bovine parvovirus (BPV), bovine rotavirus (BRV), bovine coronavirus (BCV), and Chlamydia psittaci.", [["brain", "ANATOMY", 69, 74], ["tissues", "ANATOMY", 97, 104], ["Tissues", "ANATOMY", 152, 159], ["death", "DISEASE", 126, 131], ["infectious bovine rhinotracheitis virus", "DISEASE", 318, 357], ["respiratory syncytial virus", "DISEASE", 402, 429], ["bovine parvovirus (BPV), bovine rotavirus (BRV), bovine coronavirus (BCV)", "DISEASE", 438, 511], ["Chlamydia psittaci", "DISEASE", 517, 535], ["brain", "ORGAN", 69, 74], ["tissues", "TISSUE", 97, 104], ["BVDV", "ORGANISM", 312, 316], ["infectious", "ORGANISM", 318, 328], ["bovine rhinotracheitis virus", "ORGANISM", 329, 357], ["IBRV", "ORGANISM", 359, 363], ["parainfluenza virus-3", "ORGANISM", 366, 387], ["PI3", "GENE_OR_GENE_PRODUCT", 389, 392], ["bovine", "ORGANISM", 395, 401], ["respiratory syncytial virus", "ORGANISM", 402, 429], ["BRSV", "ORGANISM", 431, 435], ["bovine parvovirus", "ORGANISM", 438, 455], ["BPV", "ORGANISM", 457, 460], ["bovine rotavirus", "ORGANISM", 463, 479], ["BRV", "ORGANISM", 481, 484], ["bovine coronavirus", "ORGANISM", 487, 505], ["BCV", "ORGANISM", 507, 510], ["Chlamydia psittaci", "ORGANISM", 517, 535], ["BVDV", "SPECIES", 312, 316], ["bovine", "SPECIES", 329, 335], ["rhinotracheitis virus", "SPECIES", 336, 357], ["parainfluenza virus-3", "SPECIES", 366, 387], ["bovine", "SPECIES", 395, 401], ["respiratory syncytial virus", "SPECIES", 402, 429], ["BRSV", "SPECIES", 431, 435], ["bovine", "SPECIES", 438, 444], ["parvovirus", "SPECIES", 445, 455], ["bovine", "SPECIES", 463, 469], ["rotavirus", "SPECIES", 470, 479], ["bovine", "SPECIES", 487, 493], ["coronavirus", "SPECIES", 494, 505], ["Chlamydia psittaci", "SPECIES", 517, 535], ["BVDV", "SPECIES", 312, 316], ["bovine rhinotracheitis virus", "SPECIES", 329, 357], ["IBRV", "SPECIES", 359, 363], ["parainfluenza virus-3", "SPECIES", 366, 387], ["bovine respiratory syncytial virus", "SPECIES", 395, 429], ["BRSV", "SPECIES", 431, 435], ["bovine parvovirus", "SPECIES", 438, 455], ["BPV", "SPECIES", 457, 460], ["bovine", "SPECIES", 463, 469], ["BRV", "SPECIES", 481, 484], ["bovine coronavirus", "SPECIES", 487, 505], ["BCV", "SPECIES", 507, 510], ["Chlamydia psittaci", "SPECIES", 517, 535], ["A prompt necropsy", "TEST", 0, 17], ["the collection of the brain", "TEST", 47, 74], ["death", "PROBLEM", 126, 131], ["immunofluorescence examination", "TEST", 237, 267], ["culture", "TEST", 275, 282], ["BVDV", "PROBLEM", 312, 316], ["infectious bovine rhinotracheitis virus", "PROBLEM", 318, 357], ["IBRV", "TEST", 359, 363], ["parainfluenza virus", "PROBLEM", 366, 385], ["PI3", "TEST", 389, 392], ["bovine respiratory syncytial virus", "PROBLEM", 395, 429], ["BRSV", "TEST", 431, 435], ["bovine parvovirus", "PROBLEM", 438, 455], ["BPV", "TEST", 457, 460], ["bovine rotavirus (BRV", "PROBLEM", 463, 484], ["bovine coronavirus", "PROBLEM", 487, 505], ["Chlamydia psittaci", "PROBLEM", 517, 535], ["brain", "ANATOMY", 69, 74], ["respiratory syncytial", "ANATOMY", 402, 423], ["Chlamydia psittaci", "OBSERVATION", 517, 535]]], ["Serum samples were tested for antibody to bovine leukosis virus (BLV) (ELISA kit, IDEXX Herd Chek BLV Antibody Test Kit).", [["Serum samples", "ANATOMY", 0, 13], ["bovine leukosis", "DISEASE", 42, 57], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["bovine leukosis virus", "ORGANISM", 42, 63], ["BLV", "ORGANISM", 65, 68], ["bovine", "SPECIES", 42, 48], ["leukosis virus", "SPECIES", 49, 63], ["bovine leukosis virus", "SPECIES", 42, 63], ["BLV", "SPECIES", 65, 68], ["BLV", "SPECIES", 98, 101], ["Serum samples", "TEST", 0, 13], ["antibody", "TEST", 30, 38], ["bovine leukosis virus", "PROBLEM", 42, 63], ["BLV", "TEST", 65, 68], ["ELISA kit", "TEST", 71, 80], ["IDEXX", "TEST", 82, 87], ["BLV Antibody Test Kit", "TEST", 98, 119]]], ["Detection of BIV antibody by ELISA was performed as previously described [10] .", [["BIV", "ORGANISM", 13, 16], ["BIV antibody", "PROTEIN", 13, 25], ["BIV", "SPECIES", 13, 16], ["BIV antibody", "TEST", 13, 25], ["ELISA", "TEST", 29, 34], ["BIV antibody", "OBSERVATION", 13, 25]]], ["Bacteriologic cultures were performed on all gross tissue lesions suspected to have a bacterial etiology.", [["tissue lesions", "ANATOMY", 51, 65], ["tissue lesions", "CANCER", 51, 65], ["Bacteriologic cultures", "TEST", 0, 22], ["all gross tissue lesions", "PROBLEM", 41, 65], ["a bacterial etiology", "PROBLEM", 84, 104], ["gross tissue", "OBSERVATION_MODIFIER", 45, 57], ["lesions", "OBSERVATION", 58, 65], ["bacterial", "OBSERVATION_MODIFIER", 86, 95]]], ["Intestine and liver were submitted for Salmonella culture.", [["Intestine", "ANATOMY", 0, 9], ["liver", "ANATOMY", 14, 19], ["Intestine", "ORGAN", 0, 9], ["liver", "ORGAN", 14, 19], ["Salmonella", "SPECIES", 39, 49], ["Salmonella culture", "TEST", 39, 57], ["liver", "ANATOMY", 14, 19]]], ["Colon contents and bile were collected for parasitological examination.", [["Colon", "ANATOMY", 0, 5], ["bile", "ANATOMY", 19, 23], ["Colon", "MULTI-TISSUE_STRUCTURE", 0, 5], ["bile", "MULTI-TISSUE_STRUCTURE", 19, 23], ["parasitological examination", "TEST", 43, 70], ["contents", "OBSERVATION", 6, 14], ["bile", "ANATOMY", 19, 23]]], ["Routine sections of all major organs were collected, fixed in 10% zinc formalin, and processed by routine methods for staining and histology.Detection of BIV in tissuesThe polymerase chain reaction (PCR) to amplify BIV proviral sequences was completed on DNA recovered from various brain regions and from selected lymphoid organs, using standard methods [24 -27] .", [["sections", "ANATOMY", 8, 16], ["organs", "ANATOMY", 30, 36], ["tissues", "ANATOMY", 161, 168], ["brain", "ANATOMY", 282, 287], ["lymphoid organs", "ANATOMY", 314, 329], ["zinc formalin", "CHEMICAL", 66, 79], ["zinc formalin", "CHEMICAL", 66, 79], ["organs", "ORGAN", 30, 36], ["zinc", "SIMPLE_CHEMICAL", 66, 70], ["formalin", "SIMPLE_CHEMICAL", 71, 79], ["BIV", "ORGANISM", 154, 157], ["tissues", "TISSUE", 161, 168], ["BIV", "ORGANISM", 215, 218], ["DNA", "CELLULAR_COMPONENT", 255, 258], ["brain", "ORGAN", 282, 287], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 314, 329], ["BIV proviral sequences", "DNA", 215, 237], ["BIV", "SPECIES", 154, 157], ["BIV", "SPECIES", 215, 218], ["Routine sections", "TEST", 0, 16], ["10% zinc formalin", "TREATMENT", 62, 79], ["histology", "TEST", 131, 140], ["BIV in tissues", "PROBLEM", 154, 168], ["The polymerase chain reaction", "PROBLEM", 168, 197], ["PCR", "TEST", 199, 202], ["BIV proviral sequences", "TEST", 215, 237], ["DNA", "TEST", 255, 258], ["BIV", "OBSERVATION", 154, 157], ["tissues", "ANATOMY", 161, 168], ["brain", "ANATOMY", 282, 287], ["regions", "ANATOMY_MODIFIER", 288, 295], ["lymphoid organs", "OBSERVATION", 314, 329]]], ["The left hemisphere of the brain was sectioned for the collection of regions identified as cerebral cortex, hippocampus, medial geniculate body, brainstem, cerebellar peduncles, cerebellar folia, and medulla oblongata at the level of the cerebellar vermis.", [["left hemisphere", "ANATOMY", 4, 19], ["brain", "ANATOMY", 27, 32], ["cerebral cortex", "ANATOMY", 91, 106], ["hippocampus", "ANATOMY", 108, 119], ["medial geniculate body", "ANATOMY", 121, 143], ["brainstem", "ANATOMY", 145, 154], ["cerebellar peduncles", "ANATOMY", 156, 176], ["cerebellar folia", "ANATOMY", 178, 194], ["medulla oblongata", "ANATOMY", 200, 217], ["cerebellar vermis", "ANATOMY", 238, 255], ["left hemisphere", "MULTI-TISSUE_STRUCTURE", 4, 19], ["brain", "ORGAN", 27, 32], ["cerebral cortex", "CANCER", 91, 106], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 108, 119], ["medial geniculate body", "TISSUE", 121, 143], ["brainstem", "ANATOMICAL_SYSTEM", 145, 154], ["cerebellar peduncles", "MULTI-TISSUE_STRUCTURE", 156, 176], ["cerebellar folia", "CANCER", 178, 194], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 200, 217], ["cerebellar vermis", "MULTI-TISSUE_STRUCTURE", 238, 255], ["cerebral cortex, hippocampus, medial geniculate body, brainstem, cerebellar peduncles, cerebellar folia, and medulla oblongata", "PROBLEM", 91, 217], ["left", "ANATOMY_MODIFIER", 4, 8], ["hemisphere", "ANATOMY_MODIFIER", 9, 19], ["brain", "ANATOMY", 27, 32], ["collection", "OBSERVATION", 55, 65], ["regions", "ANATOMY_MODIFIER", 69, 76], ["cerebral cortex", "ANATOMY", 91, 106], ["hippocampus", "ANATOMY", 108, 119], ["medial", "ANATOMY_MODIFIER", 121, 127], ["geniculate", "ANATOMY_MODIFIER", 128, 138], ["body", "ANATOMY_MODIFIER", 139, 143], ["brainstem", "ANATOMY", 145, 154], ["cerebellar peduncles", "ANATOMY", 156, 176], ["cerebellar folia", "ANATOMY", 178, 194], ["medulla", "ANATOMY", 200, 207], ["oblongata", "ANATOMY_MODIFIER", 208, 217], ["cerebellar vermis", "ANATOMY", 238, 255]]], ["Tissues were frozen at 2 20 8C and stored at 2 70 8C for 1 -52 weeks prior to shipment to Mississippi State for BIV-PCR analysis.", [["Tissues", "ANATOMY", 0, 7], ["Tissues", "CANCER", 0, 7], ["BIV-PCR analysis", "TEST", 112, 128]]], ["Brain tissues from 14 of 16 cows, and lymphoid organs from 15 of 16 cows, were tested for the presence of BIV proviral DNA ( Table 3) .Detection of BIV in tissuesPurification of DNA from tissue was accomplished with the Puregene kit (Gentra Systems).", [["Brain tissues", "ANATOMY", 0, 13], ["cows", "ANATOMY", 28, 32], ["lymphoid organs", "ANATOMY", 38, 53], ["tissues", "ANATOMY", 155, 162], ["tissue", "ANATOMY", 187, 193], ["Brain tissues", "TISSUE", 0, 13], ["cows", "ORGANISM", 28, 32], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 38, 53], ["cows", "ORGANISM", 68, 72], ["BIV", "ORGANISM", 106, 109], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["BIV", "ORGANISM", 148, 151], ["tissues", "TISSUE", 155, 162], ["DNA", "CELLULAR_COMPONENT", 178, 181], ["tissue", "TISSUE", 187, 193], ["BIV proviral DNA", "DNA", 106, 122], ["cows", "SPECIES", 28, 32], ["cows", "SPECIES", 68, 72], ["BIV", "SPECIES", 106, 109], ["BIV", "SPECIES", 148, 151], ["Brain tissues", "TEST", 0, 13], ["lymphoid organs", "TEST", 38, 53], ["BIV proviral DNA", "TREATMENT", 106, 122], ["BIV in tissues", "PROBLEM", 148, 162], ["DNA from tissue", "PROBLEM", 178, 193], ["the Puregene kit (Gentra Systems", "TREATMENT", 216, 248], ["lymphoid organs", "ANATOMY", 38, 53], ["proviral DNA", "OBSERVATION", 110, 122], ["BIV", "OBSERVATION", 148, 151], ["tissues", "ANATOMY", 155, 162], ["DNA", "OBSERVATION", 178, 181]]], ["The DNA from BIV-R29-infected, and uninfected, fetal bovine lung (FBL) cells was purified by the same method and served as positive and negative controls, respectively.", [["fetal bovine lung (FBL) cells", "ANATOMY", 47, 76], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["BIV-R29", "ORGANISM", 13, 20], ["bovine", "ORGANISM", 53, 59], ["lung (FBL) cells", "CELL", 60, 76], ["fetal bovine lung (FBL) cells", "CELL_TYPE", 47, 76], ["bovine", "SPECIES", 53, 59], ["BIV-R29", "SPECIES", 13, 20], ["bovine", "SPECIES", 53, 59], ["The DNA", "TEST", 0, 7], ["BIV", "TEST", 13, 16], ["infected", "PROBLEM", 21, 29], ["fetal bovine lung (FBL) cells", "PROBLEM", 47, 76], ["infected", "OBSERVATION", 21, 29], ["fetal", "ANATOMY_MODIFIER", 47, 52], ["bovine", "ANATOMY_MODIFIER", 53, 59], ["lung", "ANATOMY", 60, 64]]], ["The purified DNA was probed for BIV proviral DNA sequences by targeting a 495 bp region of the reverse transcriptase domain of the BIV pol gene [27] .", [["DNA", "CELLULAR_COMPONENT", 13, 16], ["DNA", "CELLULAR_COMPONENT", 45, 48], ["BIV pol", "GENE_OR_GENE_PRODUCT", 131, 138], ["purified DNA", "DNA", 4, 16], ["BIV proviral DNA sequences", "DNA", 32, 58], ["495 bp region", "DNA", 74, 87], ["reverse transcriptase domain", "PROTEIN", 95, 123], ["BIV pol gene", "DNA", 131, 143], ["BIV", "SPECIES", 32, 35], ["The purified DNA", "PROBLEM", 0, 16], ["BIV proviral DNA sequences", "TREATMENT", 32, 58], ["BIV pol", "OBSERVATION", 131, 138]]], ["The positive sense primer sequence was 5 0 ATGCTAATGGATTTTAGGGA3 0 and the negative primer sequence was 5 0 AACGCCATTTCTTGGGTGTG3 0 .", [["positive sense primer sequence", "DNA", 4, 34], ["negative primer sequence", "DNA", 75, 99], ["The positive sense primer sequence", "TEST", 0, 34], ["ATGCTAATGGATTTTAGGGA3", "TEST", 43, 64]]], ["The PCR reaction mixture consisted of 0.1 mM of each primer, 2.5 mM MgCl 2 , PCR reaction buffer, and 5 -10 mg template DNA.", [["MgCl", "CHEMICAL", 68, 72], ["MgCl 2", "CHEMICAL", 68, 74], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["The PCR reaction mixture", "TEST", 0, 24], ["2.5 mM MgCl", "TREATMENT", 61, 72], ["PCR reaction buffer", "TREATMENT", 77, 96]]], ["The reaction mixture was heated from 93 to 100 8C for 10 min.", [["The reaction mixture", "PROBLEM", 0, 20]]], ["The mixture was cooled on ice for 5 min, then 200 mM each of dATP, dTTP, dCTP, dGTP, and 1 ml of 0.5 U Taq DNA polymerase (Promega) was added.", [["dATP", "CHEMICAL", 61, 65], ["dTTP", "CHEMICAL", 67, 71], ["dCTP", "CHEMICAL", 73, 77], ["dGTP", "CHEMICAL", 79, 83], ["dATP", "CHEMICAL", 61, 65], ["dTTP", "CHEMICAL", 67, 71], ["dCTP", "CHEMICAL", 73, 77], ["dGTP", "CHEMICAL", 79, 83], ["dATP", "SIMPLE_CHEMICAL", 61, 65], ["dTTP", "SIMPLE_CHEMICAL", 67, 71], ["dCTP", "SIMPLE_CHEMICAL", 73, 77], ["dGTP", "SIMPLE_CHEMICAL", 79, 83], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["dATP", "TREATMENT", 61, 65], ["dTTP", "TREATMENT", 67, 71], ["dCTP", "TREATMENT", 73, 77], ["dGTP", "TREATMENT", 79, 83], ["0.5 U Taq DNA polymerase (Promega)", "TREATMENT", 97, 131]]], ["The final reaction volume was 100 ml.", [["The final reaction volume", "TEST", 0, 25], ["volume", "OBSERVATION_MODIFIER", 19, 25]]], ["The reaction mixture was overlaid with mineral oil, then subjected to 33 cycles of the following cycling scheme, using the Delta Cycler II thermocycler (Ericomp): 94 8C for 45 s, 45 8C for 30 s, and 72 8C for 2 min.", [["The reaction mixture", "TREATMENT", 0, 20], ["mineral oil", "TREATMENT", 39, 50], ["cycling scheme", "TREATMENT", 97, 111], ["the Delta Cycler II thermocycler", "TREATMENT", 119, 151]]], ["The PCR reaction products were electrophoresed in 7.5% polyacrylamide gels; the gels were stained with ethidium bromide, and the DNA products were visualized using a UV transilluminator.", [["ethidium bromide", "CHEMICAL", 103, 119], ["polyacrylamide", "CHEMICAL", 55, 69], ["ethidium bromide", "CHEMICAL", 103, 119], ["ethidium bromide", "SIMPLE_CHEMICAL", 103, 119], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["DNA products", "PROTEIN", 129, 141], ["The PCR reaction products", "TREATMENT", 0, 25], ["7.5% polyacrylamide gels", "TREATMENT", 50, 74], ["the gels", "TREATMENT", 76, 84], ["ethidium bromide", "TREATMENT", 103, 119], ["the DNA products", "TREATMENT", 125, 141], ["a UV transilluminator", "TREATMENT", 164, 185]]], ["Tissues that yielded indeterminate PCR reactions had product of inappropriate size, compared to the positive controls.Clinical observationsEleven of the 16 cows had between 7.1 and 39.3% weight loss after the onset of clinical problems and the majority had more than one active disease process at the time of euthanasia (Tables 1 and 2 ).", [["Tissues", "ANATOMY", 0, 7], ["weight loss", "DISEASE", 187, 198], ["Tissues", "CANCER", 0, 7], ["cows", "ORGANISM", 156, 160], ["cows", "SPECIES", 156, 160], ["indeterminate PCR reactions", "PROBLEM", 21, 48], ["inappropriate size", "PROBLEM", 64, 82], ["Clinical observations", "TEST", 118, 139], ["weight loss", "PROBLEM", 187, 198], ["clinical problems", "PROBLEM", 218, 235], ["one active disease process", "PROBLEM", 267, 293], ["indeterminate", "OBSERVATION_MODIFIER", 21, 34], ["PCR reactions", "OBSERVATION", 35, 48], ["inappropriate", "OBSERVATION_MODIFIER", 64, 77], ["size", "OBSERVATION_MODIFIER", 78, 82], ["active", "OBSERVATION_MODIFIER", 271, 277], ["disease", "OBSERVATION", 278, 285]]], ["Body condition scores fell from a preclinical disease level of 2.5 -3.5 (mean 2.9) to 1.5 -3.5 (mean 2.4).", [["Body", "ANATOMY", 0, 4], ["Body condition scores", "TEST", 0, 21], ["a preclinical disease level", "PROBLEM", 32, 59]]], ["Twelve of 15 postpartum cows were in the first The secondary disease processes, and their incidence included: metritis (12.5%), subcutaneous abscesses (18.75%), purulent arthritis (18.75%), laminitis and infectious pododermatitis (37.5%), distomiasis (50%), and mastitis (56.25%) ( Table 2 ).", [["subcutaneous abscesses", "ANATOMY", 128, 150], ["metritis", "DISEASE", 110, 118], ["subcutaneous abscesses", "DISEASE", 128, 150], ["purulent arthritis", "DISEASE", 161, 179], ["laminitis", "DISEASE", 190, 199], ["infectious pododermatitis", "DISEASE", 204, 229], ["distomiasis", "DISEASE", 239, 250], ["mastitis", "DISEASE", 262, 270], ["cows", "ORGANISM", 24, 28], ["subcutaneous abscesses", "PATHOLOGICAL_FORMATION", 128, 150], ["cows", "SPECIES", 24, 28], ["The secondary disease processes", "PROBLEM", 47, 78], ["metritis", "PROBLEM", 110, 118], ["subcutaneous abscesses", "PROBLEM", 128, 150], ["purulent arthritis", "PROBLEM", 161, 179], ["laminitis", "PROBLEM", 190, 199], ["infectious pododermatitis", "PROBLEM", 204, 229], ["distomiasis", "PROBLEM", 239, 250], ["mastitis", "PROBLEM", 262, 270], ["secondary", "OBSERVATION_MODIFIER", 51, 60], ["disease", "OBSERVATION", 61, 68], ["metritis", "OBSERVATION", 110, 118], ["subcutaneous", "ANATOMY", 128, 140], ["abscesses", "OBSERVATION", 141, 150], ["purulent", "OBSERVATION_MODIFIER", 161, 169], ["arthritis", "OBSERVATION", 170, 179], ["laminitis", "OBSERVATION", 190, 199], ["infectious", "OBSERVATION_MODIFIER", 204, 214], ["mastitis", "OBSERVATION", 262, 270]]], ["In addition to weight loss, clinical signs included reduced vitality, torpidity, dullness, and stupor.Microbiologic and serologic findingsEleven of 15 cows had positive BIV ELISA reactions, four were negative and the juvenile adult, animal 13, was not tested.", [["weight loss", "DISEASE", 15, 26], ["torpidity", "DISEASE", 70, 79], ["dullness", "DISEASE", 81, 89], ["stupor", "DISEASE", 95, 101], ["cows", "ORGANISM", 151, 155], ["BIV", "ORGANISM", 169, 172], ["cows", "SPECIES", 151, 155], ["BIV", "SPECIES", 169, 172], ["weight loss", "PROBLEM", 15, 26], ["clinical signs", "TEST", 28, 42], ["reduced vitality", "PROBLEM", 52, 68], ["torpidity", "PROBLEM", 70, 79], ["dullness", "PROBLEM", 81, 89], ["stupor", "PROBLEM", 95, 101], ["Microbiologic", "TEST", 102, 115], ["serologic findings", "TEST", 120, 138], ["positive BIV ELISA reactions", "PROBLEM", 160, 188], ["weight loss", "OBSERVATION", 15, 26], ["reduced", "OBSERVATION_MODIFIER", 52, 59], ["vitality", "OBSERVATION_MODIFIER", 60, 68], ["dullness", "OBSERVATION", 81, 89]]], ["Antibody to BLV was demonstrated in 11 of 16 cows; however, three of the BLV negative cows had previously tested positive for BLV, yielding 14 of 16 (87.5%) serologically positive animals ( Table 2 ).", [["BLV", "ORGANISM", 12, 15], ["cows", "ORGANISM", 45, 49], ["BLV", "ORGANISM", 73, 76], ["cows", "ORGANISM", 86, 90], ["BLV", "ORGANISM", 126, 129], ["cows", "SPECIES", 45, 49], ["cows", "SPECIES", 86, 90], ["BLV", "SPECIES", 12, 15], ["BLV", "SPECIES", 73, 76], ["BLV", "SPECIES", 126, 129], ["Antibody to BLV", "TEST", 0, 15], ["the BLV", "TEST", 69, 76], ["BLV", "TEST", 126, 129]]], ["Four cows (animals 6, 7, 8, and 9) tested positive by tissue culture for non-cytopathic BVDV (NC-BVDV), although the tissues had initially tested negative using the fluorescent antibody method.", [["tissue culture", "ANATOMY", 54, 68], ["tissues", "ANATOMY", 117, 124], ["cows", "ORGANISM", 5, 9], ["tissue", "TISSUE", 54, 60], ["BVDV", "ORGANISM", 88, 92], ["NC-BVDV", "ORGANISM", 94, 101], ["tissues", "TISSUE", 117, 124], ["cows", "SPECIES", 5, 9], ["BVDV", "SPECIES", 88, 92], ["BVDV", "SPECIES", 97, 101], ["Four cows (animals", "TEST", 0, 18], ["tissue culture", "TEST", 54, 68], ["non-cytopathic BVDV", "PROBLEM", 73, 92], ["BVDV", "PROBLEM", 97, 101], ["the fluorescent antibody method", "TEST", 161, 192], ["tissues", "ANATOMY", 117, 124]]], ["Cow 12 yielded cytopathic BVDV (C-BVDV) from the buffy coat cells of a fresh blood sample collected prior to euthanasia.", [["buffy coat cells", "ANATOMY", 49, 65], ["blood sample", "ANATOMY", 77, 89], ["BVDV", "ORGANISM", 26, 30], ["C-BVDV", "ORGANISM", 32, 38], ["buffy coat cells", "CELL", 49, 65], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["buffy coat cells", "CELL_TYPE", 49, 65], ["BVDV", "SPECIES", 26, 30], ["BVDV", "SPECIES", 34, 38], ["Cow", "TEST", 0, 3], ["cytopathic BVDV", "PROBLEM", 15, 30], ["BVDV", "PROBLEM", 34, 38], ["the buffy coat cells", "TEST", 45, 65], ["a fresh blood sample", "TEST", 69, 89], ["euthanasia", "PROBLEM", 109, 119], ["cytopathic", "OBSERVATION_MODIFIER", 15, 25], ["BVDV", "OBSERVATION", 26, 30], ["buffy coat cells", "OBSERVATION", 49, 65]]], ["No cow had clinical or morphologic changes diagnostic for acute or chronic BVDV infection.", [["BVDV infection", "DISEASE", 75, 89], ["cow", "ORGANISM", 3, 6], ["BVDV", "ORGANISM", 75, 79], ["cow", "SPECIES", 3, 6], ["BVDV", "SPECIES", 75, 79], ["acute or chronic BVDV infection", "PROBLEM", 58, 89], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["chronic", "OBSERVATION_MODIFIER", 67, 74], ["BVDV", "OBSERVATION_MODIFIER", 75, 79], ["infection", "OBSERVATION", 80, 89]]], ["Tests for IBRV, PI3, BRSV, BPV, BRV, and BCV were negative.Microbiologic and serologic findingsTissue from the brain and small intestine of each cow tested negative for C. psittaci using the fluorescent antibody method and cell culture inoculation.", [["Tissue", "ANATOMY", 95, 101], ["brain", "ANATOMY", 111, 116], ["small intestine", "ANATOMY", 121, 136], ["cell", "ANATOMY", 223, 227], ["IBRV", "GENE_OR_GENE_PRODUCT", 10, 14], ["PI3", "GENE_OR_GENE_PRODUCT", 16, 19], ["BRSV", "ORGANISM", 21, 25], ["BPV", "ORGANISM", 27, 30], ["BRV", "GENE_OR_GENE_PRODUCT", 32, 35], ["BCV", "ORGANISM", 41, 44], ["Tissue", "TISSUE", 95, 101], ["brain", "ORGAN", 111, 116], ["small intestine", "ORGAN", 121, 136], ["cow", "ORGANISM", 145, 148], ["C. psittaci", "ORGANISM", 169, 180], ["cell", "CELL", 223, 227], ["IBRV", "PROTEIN", 10, 14], ["PI3", "PROTEIN", 16, 19], ["BRSV", "SPECIES", 21, 25], ["cow", "SPECIES", 145, 148], ["C. psittaci", "SPECIES", 169, 180], ["IBRV", "SPECIES", 10, 14], ["BRSV", "SPECIES", 21, 25], ["BPV", "SPECIES", 27, 30], ["BRV", "SPECIES", 32, 35], ["BCV", "SPECIES", 41, 44], ["cow", "SPECIES", 145, 148], ["C. psittaci", "SPECIES", 169, 180], ["Tests", "TEST", 0, 5], ["IBRV", "TEST", 10, 14], ["PI3", "TEST", 16, 19], ["BRSV", "TEST", 21, 25], ["BPV", "TEST", 27, 30], ["BRV", "TEST", 32, 35], ["BCV", "TEST", 41, 44], ["Microbiologic", "TEST", 59, 72], ["serologic findings", "TEST", 77, 95], ["Tissue from the brain", "TEST", 95, 116], ["C. psittaci", "PROBLEM", 169, 180], ["the fluorescent antibody method", "TEST", 187, 218], ["cell culture inoculation", "TEST", 223, 247], ["BCV", "ANATOMY", 41, 44], ["negative", "OBSERVATION", 50, 58], ["brain", "ANATOMY", 111, 116], ["small intestine", "ANATOMY", 121, 136], ["psittaci", "OBSERVATION", 172, 180]]], ["Cow 15 aborted 2 months prior to euthanasia and had uterine lymphosarcoma as well as a positive serological response for C. psittaci.Microbiologic and serologic findingsBacteriologic culture of abscesses, mastitic glands, and regional LN yielded the following pathogens (Table 2) : Streptococcus bovis, Streptococcus agalactiae, Streptococcus uberis, E. coli, Nocardia sp., and Corynebacterium sp.", [["uterine lymphosarcoma", "ANATOMY", 52, 73], ["abscesses", "ANATOMY", 194, 203], ["mastitic glands", "ANATOMY", 205, 220], ["LN", "ANATOMY", 235, 237], ["uterine lymphosarcoma", "DISEASE", 52, 73], ["C. psittaci", "DISEASE", 121, 132], ["abscesses", "DISEASE", 194, 203], ["Streptococcus bovis", "DISEASE", 282, 301], ["Streptococcus agalactiae", "DISEASE", 303, 327], ["uterine lymphosarcoma", "CANCER", 52, 73], ["C. psittaci", "ORGANISM", 121, 132], ["abscesses", "PATHOLOGICAL_FORMATION", 194, 203], ["glands", "ORGAN", 214, 220], ["LN", "MULTI-TISSUE_STRUCTURE", 235, 237], ["Streptococcus bovis", "ORGANISM", 282, 301], ["Streptococcus agalactiae", "ORGANISM", 303, 327], ["Streptococcus uberis", "ORGANISM", 329, 349], ["E. coli", "ORGANISM", 351, 358], ["Nocardia sp.", "ORGANISM", 360, 372], ["Corynebacterium sp", "ORGANISM", 378, 396], ["C. psittaci", "SPECIES", 121, 132], ["Streptococcus bovis", "SPECIES", 282, 301], ["Streptococcus agalactiae", "SPECIES", 303, 327], ["Streptococcus uberis", "SPECIES", 329, 349], ["E. coli", "SPECIES", 351, 358], ["Nocardia sp.", "SPECIES", 360, 372], ["C. psittaci", "SPECIES", 121, 132], ["Streptococcus bovis", "SPECIES", 282, 301], ["Streptococcus agalactiae", "SPECIES", 303, 327], ["Streptococcus uberis", "SPECIES", 329, 349], ["E. coli", "SPECIES", 351, 358], ["Nocardia sp.", "SPECIES", 360, 372], ["euthanasia", "PROBLEM", 33, 43], ["uterine lymphosarcoma", "PROBLEM", 52, 73], ["a positive serological response", "PROBLEM", 85, 116], ["C. psittaci", "PROBLEM", 121, 132], ["Microbiologic", "TEST", 133, 146], ["serologic findings", "TEST", 151, 169], ["Bacteriologic culture", "TEST", 169, 190], ["abscesses", "PROBLEM", 194, 203], ["mastitic glands", "PROBLEM", 205, 220], ["regional LN", "TEST", 226, 237], ["Streptococcus bovis", "PROBLEM", 282, 301], ["Streptococcus agalactiae", "PROBLEM", 303, 327], ["Streptococcus uberis", "PROBLEM", 329, 349], ["E. coli", "PROBLEM", 351, 358], ["Nocardia sp.", "PROBLEM", 360, 372], ["Corynebacterium sp", "PROBLEM", 378, 396], ["euthanasia", "OBSERVATION", 33, 43], ["uterine", "ANATOMY", 52, 59], ["lymphosarcoma", "OBSERVATION", 60, 73], ["abscesses", "OBSERVATION", 194, 203], ["mastitic glands", "ANATOMY", 205, 220], ["LN", "ANATOMY", 235, 237], ["Streptococcus bovis", "OBSERVATION", 282, 301]]], ["Normal liver tissue from cow 11 yielded a Salmonella sp. although no signs or lesions of salmonellosis were detected histologically.Microbiologic and serologic findingsGeneralized Demodex folliculorum infestation was present in cow 14.", [["liver tissue", "ANATOMY", 7, 19], ["lesions", "ANATOMY", 78, 85], ["salmonellosis", "DISEASE", 89, 102], ["Demodex folliculorum infestation", "DISEASE", 180, 212], ["liver tissue", "TISSUE", 7, 19], ["cow", "ORGANISM", 25, 28], ["lesions", "PATHOLOGICAL_FORMATION", 78, 85], ["Demodex folliculorum", "ORGANISM", 180, 200], ["cow", "ORGANISM", 228, 231], ["cow", "SPECIES", 25, 28], ["Demodex folliculorum", "SPECIES", 180, 200], ["cow", "SPECIES", 228, 231], ["cow", "SPECIES", 25, 28], ["Demodex folliculorum", "SPECIES", 180, 200], ["cow", "SPECIES", 228, 231], ["a Salmonella sp", "PROBLEM", 40, 55], ["signs", "PROBLEM", 69, 74], ["lesions", "PROBLEM", 78, 85], ["salmonellosis", "PROBLEM", 89, 102], ["Microbiologic", "TEST", 132, 145], ["serologic findings", "TEST", 150, 168], ["Generalized Demodex folliculorum infestation", "PROBLEM", 168, 212], ["liver", "ANATOMY", 7, 12], ["Salmonella sp", "OBSERVATION", 42, 55], ["no signs", "UNCERTAINTY", 66, 74], ["lesions", "OBSERVATION", 78, 85], ["salmonellosis", "OBSERVATION", 89, 102], ["Demodex", "OBSERVATION_MODIFIER", 180, 187], ["folliculorum infestation", "OBSERVATION", 188, 212]]], ["Hepatic distomiasis due to Fasciola hepatica was identified in 8 of 16 cows by the presence of ova in the bile or feces or enlarged fibrotic bile ducts (Table 2) .", [["Hepatic", "ANATOMY", 0, 7], ["ova", "ANATOMY", 95, 98], ["bile", "ANATOMY", 106, 110], ["feces", "ANATOMY", 114, 119], ["fibrotic bile ducts", "ANATOMY", 132, 151], ["Hepatic distomiasis", "DISEASE", 0, 19], ["Fasciola hepatica", "DISEASE", 27, 44], ["Fasciola hepatica", "ORGANISM", 27, 44], ["cows", "ORGANISM", 71, 75], ["ova", "ORGANISM_SUBSTANCE", 95, 98], ["bile", "MULTI-TISSUE_STRUCTURE", 106, 110], ["feces", "ORGANISM_SUBSTANCE", 114, 119], ["bile ducts", "MULTI-TISSUE_STRUCTURE", 141, 151], ["Fasciola hepatica", "SPECIES", 27, 44], ["cows", "SPECIES", 71, 75], ["Fasciola hepatica", "SPECIES", 27, 44], ["Hepatic distomiasis", "PROBLEM", 0, 19], ["Fasciola hepatica", "PROBLEM", 27, 44], ["ova in the bile or feces", "PROBLEM", 95, 119], ["enlarged fibrotic bile ducts", "PROBLEM", 123, 151], ["distomiasis", "OBSERVATION", 8, 19], ["Fasciola hepatica", "OBSERVATION", 27, 44], ["ova", "OBSERVATION", 95, 98], ["bile", "ANATOMY", 106, 110], ["feces", "OBSERVATION", 114, 119], ["enlarged", "OBSERVATION_MODIFIER", 123, 131], ["fibrotic", "OBSERVATION", 132, 140], ["bile ducts", "ANATOMY", 141, 151]]], ["Occasional cows had low numbers of Trichostrongylid ova in the feces; however, no parasite-induced abomasal or intestinal lesions were observed.Lesions observedThirteen cows had moderate to marked enlargement of the HLN.", [["ova", "ANATOMY", 52, 55], ["feces", "ANATOMY", 63, 68], ["abomasal", "ANATOMY", 99, 107], ["intestinal lesions", "ANATOMY", 111, 129], ["HLN", "ANATOMY", 216, 219], ["enlargement of the HLN", "DISEASE", 197, 219], ["cows", "ORGANISM", 11, 15], ["Trichostrongylid ova", "ORGAN", 35, 55], ["feces", "ORGANISM_SUBSTANCE", 63, 68], ["abomasal", "ORGANISM_SUBDIVISION", 99, 107], ["intestinal lesions", "PATHOLOGICAL_FORMATION", 111, 129], ["cows", "ORGANISM", 169, 173], ["HLN", "CANCER", 216, 219], ["cows", "SPECIES", 11, 15], ["cows", "SPECIES", 169, 173], ["Occasional cows", "PROBLEM", 0, 15], ["low numbers", "PROBLEM", 20, 31], ["Trichostrongylid ova in the feces", "PROBLEM", 35, 68], ["parasite", "PROBLEM", 82, 90], ["intestinal lesions", "PROBLEM", 111, 129], ["Lesions", "PROBLEM", 144, 151], ["moderate to marked enlargement of the HLN", "PROBLEM", 178, 219], ["cows", "OBSERVATION", 11, 15], ["low numbers", "OBSERVATION_MODIFIER", 20, 31], ["Trichostrongylid ova", "OBSERVATION", 35, 55], ["feces", "ANATOMY", 63, 68], ["no", "UNCERTAINTY", 79, 81], ["parasite", "OBSERVATION_MODIFIER", 82, 90], ["abomasal", "ANATOMY", 99, 107], ["intestinal", "ANATOMY", 111, 121], ["lesions", "OBSERVATION", 122, 129], ["moderate", "OBSERVATION_MODIFIER", 178, 186], ["marked", "OBSERVATION_MODIFIER", 190, 196], ["enlargement", "OBSERVATION", 197, 208]]], ["These were evident as slightly movable subcutaneous nodules, most commonly in the neck and flank.", [["subcutaneous nodules", "ANATOMY", 39, 59], ["neck", "ANATOMY", 82, 86], ["flank", "ANATOMY", 91, 96], ["subcutaneous nodules", "PATHOLOGICAL_FORMATION", 39, 59], ["neck", "ORGANISM_SUBDIVISION", 82, 86], ["flank", "ORGANISM_SUBDIVISION", 91, 96], ["slightly movable subcutaneous nodules", "PROBLEM", 22, 59], ["slightly", "OBSERVATION_MODIFIER", 22, 30], ["movable", "OBSERVATION_MODIFIER", 31, 38], ["subcutaneous", "ANATOMY", 39, 51], ["nodules", "OBSERVATION", 52, 59], ["neck", "ANATOMY", 82, 86], ["flank", "ANATOMY", 91, 96]]], ["Enlarged HLN were also noted in the sublumbar regions and in association with LN.", [["HLN", "ANATOMY", 9, 12], ["sublumbar regions", "ANATOMY", 36, 53], ["LN", "ANATOMY", 78, 80], ["HLN", "GENE_OR_GENE_PRODUCT", 9, 12], ["LN", "CANCER", 78, 80], ["Enlarged HLN", "PROBLEM", 0, 12], ["HLN", "OBSERVATION", 9, 12], ["sublumbar", "ANATOMY_MODIFIER", 36, 45], ["regions", "ANATOMY_MODIFIER", 46, 53], ["LN", "OBSERVATION", 78, 80]]], ["Morphology of LN varied from hyperplastic to normal to atrophic with changes in architecture which were correlated with immunologic deficiencies [28] .", [["LN", "ANATOMY", 14, 16], ["LN", "MULTI-TISSUE_STRUCTURE", 14, 16], ["hyperplastic", "PROBLEM", 29, 41], ["changes in architecture", "PROBLEM", 69, 92], ["immunologic deficiencies", "PROBLEM", 120, 144], ["LN", "ANATOMY", 14, 16], ["varied", "OBSERVATION_MODIFIER", 17, 23], ["hyperplastic", "OBSERVATION_MODIFIER", 29, 41], ["normal", "OBSERVATION", 45, 51], ["atrophic", "OBSERVATION_MODIFIER", 55, 63]]], ["All 16 cows had morphologic evidence of central nervous system (CNS) disease with variable lesion development.", [["central nervous system", "ANATOMY", 40, 62], ["CNS", "ANATOMY", 64, 67], ["lesion", "ANATOMY", 91, 97], ["central nervous system (CNS) disease", "DISEASE", 40, 76], ["cows", "ORGANISM", 7, 11], ["central nervous system", "ANATOMICAL_SYSTEM", 40, 62], ["CNS", "ANATOMICAL_SYSTEM", 64, 67], ["lesion", "CANCER", 91, 97], ["cows", "SPECIES", 7, 11], ["central nervous system (CNS) disease", "PROBLEM", 40, 76], ["variable lesion development", "PROBLEM", 82, 109], ["evidence of", "UNCERTAINTY", 28, 39], ["central", "ANATOMY_MODIFIER", 40, 47], ["nervous system", "ANATOMY", 48, 62], ["CNS", "ANATOMY", 64, 67], ["variable", "OBSERVATION_MODIFIER", 82, 90], ["lesion", "OBSERVATION", 91, 97]]], ["Encephalitis with mononuclear cell infiltration was present in 15 of 16 cows.", [["mononuclear cell", "ANATOMY", 18, 34], ["Encephalitis", "DISEASE", 0, 12], ["mononuclear cell infiltration", "DISEASE", 18, 47], ["mononuclear cell", "CELL", 18, 34], ["cows", "ORGANISM", 72, 76], ["cows", "SPECIES", 72, 76], ["Encephalitis", "PROBLEM", 0, 12], ["mononuclear cell infiltration", "PROBLEM", 18, 47], ["mononuclear cell infiltration", "OBSERVATION", 18, 47]]], ["The pituitary of some cows had multifocal and perivascular accumulations of lymphocytes similar to the infiltration pattern observed in the brain.PCR analysisBrain tissues from 6 of 14 cows and lymphoid tissues from 5 of 15 cows were positive for BIV provirus using PCR to amplify a region of the BIV pol gene (Table 3 ).", [["pituitary", "ANATOMY", 4, 13], ["perivascular", "ANATOMY", 46, 58], ["lymphocytes", "ANATOMY", 76, 87], ["brain", "ANATOMY", 140, 145], ["Brain tissues", "ANATOMY", 158, 171], ["cows", "ANATOMY", 185, 189], ["lymphoid tissues", "ANATOMY", 194, 210], ["pituitary", "ORGAN", 4, 13], ["cows", "ORGANISM", 22, 26], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 58], ["lymphocytes", "CELL", 76, 87], ["brain", "ORGAN", 140, 145], ["Brain tissues", "TISSUE", 158, 171], ["cows", "ORGANISM", 185, 189], ["lymphoid tissues", "TISSUE", 194, 210], ["cows", "ORGANISM", 224, 228], ["BIV", "ORGANISM", 247, 250], ["BIV pol", "GENE_OR_GENE_PRODUCT", 297, 304], ["lymphocytes", "CELL_TYPE", 76, 87], ["BIV pol gene", "DNA", 297, 309], ["cows", "SPECIES", 22, 26], ["cows", "SPECIES", 185, 189], ["cows", "SPECIES", 224, 228], ["BIV", "SPECIES", 247, 250], ["multifocal and perivascular accumulations of lymphocytes", "PROBLEM", 31, 87], ["the infiltration pattern", "PROBLEM", 99, 123], ["PCR analysis", "TEST", 146, 158], ["Brain tissues", "TEST", 158, 171], ["lymphoid tissues", "TEST", 194, 210], ["BIV provirus", "TREATMENT", 247, 259], ["PCR", "TREATMENT", 266, 269], ["the BIV pol gene", "TREATMENT", 293, 309], ["pituitary", "ANATOMY", 4, 13], ["multifocal", "OBSERVATION_MODIFIER", 31, 41], ["perivascular", "ANATOMY_MODIFIER", 46, 58], ["accumulations", "OBSERVATION", 59, 72], ["lymphocytes", "OBSERVATION", 76, 87], ["infiltration", "OBSERVATION", 103, 115], ["brain", "ANATOMY", 140, 145], ["Brain tissues", "ANATOMY", 158, 171], ["lymphoid tissues", "OBSERVATION", 194, 210], ["BIV pol", "OBSERVATION", 297, 304]]], ["Brain tissue of 3 of 14 cows and lymphoid tissue of 1 of 15 cows yielded indeterminate PCR reactions.", [["Brain tissue", "ANATOMY", 0, 12], ["cows", "ANATOMY", 24, 28], ["lymphoid tissue", "ANATOMY", 33, 48], ["Brain tissue", "TISSUE", 0, 12], ["cows", "ORGANISM", 24, 28], ["lymphoid tissue", "TISSUE", 33, 48], ["cows", "ORGANISM", 60, 64], ["cows", "SPECIES", 24, 28], ["cows", "SPECIES", 60, 64], ["Brain tissue", "TEST", 0, 12], ["lymphoid tissue", "TEST", 33, 48], ["indeterminate PCR reactions", "PROBLEM", 73, 100], ["lymphoid tissue", "OBSERVATION", 33, 48], ["indeterminate", "OBSERVATION_MODIFIER", 73, 86], ["PCR reactions", "OBSERVATION", 87, 100]]], ["Only 5 of 16 cows were negative for BIV provirus in all the tissues examined.", [["tissues", "ANATOMY", 60, 67], ["cows", "ORGANISM", 13, 17], ["BIV", "ORGANISM", 36, 39], ["tissues", "TISSUE", 60, 67], ["cows", "SPECIES", 13, 17], ["BIV", "SPECIES", 36, 39], ["BIV provirus", "PROBLEM", 36, 48], ["provirus", "OBSERVATION", 40, 48], ["tissues", "ANATOMY", 60, 67]]], ["In the brain tissue, BIV provirus was detected in the medial geniculate body \u00f0n \u00bc 3\u00de; brainstem \u00f0n \u00bc 2\u00de; hippocampus \u00f0n \u00bc 3\u00de; and cerebral cortex \u00f0n \u00bc 5\u00de (Table 3 ).", [["brain tissue", "ANATOMY", 7, 19], ["medial geniculate body", "ANATOMY", 54, 76], ["brainstem \u00f0n \u00bc 2\u00de", "ANATOMY", 86, 103], ["hippocampus", "ANATOMY", 105, 116], ["cerebral cortex", "ANATOMY", 130, 145], ["brain tissue", "TISSUE", 7, 19], ["BIV", "ORGANISM", 21, 24], ["brainstem \u00f0n \u00bc 2\u00de", "CANCER", 86, 103], ["cerebral cortex", "CANCER", 130, 145], ["BIV provirus", "PROBLEM", 21, 33], ["brainstem", "TEST", 86, 95], ["hippocampus", "TEST", 105, 116], ["brain tissue", "ANATOMY", 7, 19], ["BIV provirus", "OBSERVATION", 21, 33], ["medial", "ANATOMY_MODIFIER", 54, 60], ["geniculate", "ANATOMY_MODIFIER", 61, 71], ["body", "ANATOMY_MODIFIER", 72, 76], ["hippocampus", "ANATOMY", 105, 116], ["cerebral cortex", "ANATOMY", 130, 145]]], ["In the lymphoid tissues, BIV provirus was detected in the thymus \u00f0n \u00bc 3\u00de; mesenteric LN \u00f0n \u00bc 2\u00de; prescapular LN \u00f0n \u00bc 1\u00de; HLN \u00f0n \u00bc 2\u00de; and spleen \u00f0n \u00bc 3\u00de (Table 3) .", [["lymphoid tissues", "ANATOMY", 7, 23], ["thymus", "ANATOMY", 58, 64], ["mesenteric LN", "ANATOMY", 74, 87], ["LN", "ANATOMY", 109, 111], ["spleen", "ANATOMY", 138, 144], ["lymphoid tissues", "TISSUE", 7, 23], ["BIV", "ORGANISM", 25, 28], ["thymus", "ORGAN", 58, 64], ["mesenteric LN", "CANCER", 74, 87], ["spleen", "ORGAN", 138, 144], ["BIV", "SPECIES", 25, 28], ["BIV provirus", "TREATMENT", 25, 37], ["prescapular", "TEST", 97, 108], ["HLN", "TEST", 121, 124], ["spleen", "TEST", 138, 144], ["lymphoid tissues", "ANATOMY", 7, 23], ["BIV provirus", "OBSERVATION", 25, 37], ["thymus", "ANATOMY", 58, 64], ["mesenteric", "ANATOMY", 74, 84], ["LN", "ANATOMY_MODIFIER", 85, 87], ["LN", "ANATOMY", 109, 111], ["spleen", "ANATOMY", 138, 144]]], ["Brainstem \u00f0n \u00bc 2\u00de; hippocampus, medial geniculate body, spleen, and mesenteric lymph node of three cows yielded indeterminate PCR product.", [["hippocampus", "ANATOMY", 19, 30], ["medial geniculate body", "ANATOMY", 32, 54], ["spleen", "ANATOMY", 56, 62], ["mesenteric lymph node", "ANATOMY", 68, 89], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 19, 30], ["medial geniculate body", "TISSUE", 32, 54], ["spleen", "ORGAN", 56, 62], ["mesenteric lymph node", "MULTI-TISSUE_STRUCTURE", 68, 89], ["cows", "ORGANISM", 99, 103], ["cows", "SPECIES", 99, 103], ["Brainstem \u00f0n \u00bc 2\u00de", "TEST", 0, 17], ["indeterminate PCR product", "PROBLEM", 112, 137], ["hippocampus", "ANATOMY", 19, 30], ["medial", "ANATOMY_MODIFIER", 32, 38], ["geniculate", "ANATOMY_MODIFIER", 39, 49], ["body", "ANATOMY_MODIFIER", 50, 54], ["spleen", "ANATOMY", 56, 62], ["mesenteric", "ANATOMY", 68, 78], ["lymph node", "OBSERVATION", 79, 89], ["indeterminate", "OBSERVATION_MODIFIER", 112, 125], ["PCR product", "OBSERVATION", 126, 137]]], ["Four of the five PCR negative cows were positive by ELISA for serum BIV antibody, and all five had histologic encephalitis.DiscussionDetection of BIV provirus in lymphoid and brain tissue was consistent with the endemic occurrence of BIV in the herd.", [["serum", "ANATOMY", 62, 67], ["lymphoid", "ANATOMY", 162, 170], ["brain tissue", "ANATOMY", 175, 187], ["encephalitis", "DISEASE", 110, 122], ["cows", "ORGANISM", 30, 34], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["BIV", "ORGANISM", 146, 149], ["lymphoid", "CELL", 162, 170], ["brain tissue", "TISSUE", 175, 187], ["BIV", "ORGANISM", 234, 237], ["herd", "ORGANISM_SUBDIVISION", 245, 249], ["serum BIV antibody", "PROTEIN", 62, 80], ["cows", "SPECIES", 30, 34], ["BIV", "SPECIES", 68, 71], ["BIV", "SPECIES", 234, 237], ["the five PCR", "TEST", 8, 20], ["ELISA", "TEST", 52, 57], ["serum BIV antibody", "TEST", 62, 80], ["histologic encephalitis", "PROBLEM", 99, 122], ["BIV provirus in lymphoid and brain tissue", "PROBLEM", 146, 187], ["BIV", "TREATMENT", 234, 237], ["encephalitis", "OBSERVATION", 110, 122], ["BIV provirus", "OBSERVATION", 146, 158], ["lymphoid", "ANATOMY", 162, 170], ["brain tissue", "ANATOMY", 175, 187], ["consistent with", "UNCERTAINTY", 192, 207], ["endemic", "OBSERVATION_MODIFIER", 212, 219], ["BIV", "OBSERVATION", 234, 237]]], ["Storage of tissues for prolonged periods (8-12 months) may have resulted in a higher incidence of negative results.", [["tissues", "ANATOMY", 11, 18], ["tissues", "TISSUE", 11, 18], ["tissues", "ANATOMY", 11, 18]]], ["The frequent development of concurrent infections in BIV-infected animals, especially those associated with abscesses, mastitis, and laminitis, suggested that persistent BIV infection had a role in reducing functional immune competence.", [["abscesses", "ANATOMY", 108, 117], ["infections", "DISEASE", 39, 49], ["BIV-infected", "DISEASE", 53, 65], ["abscesses", "DISEASE", 108, 117], ["mastitis", "DISEASE", 119, 127], ["laminitis", "DISEASE", 133, 142], ["BIV infection", "DISEASE", 170, 183], ["BIV", "ORGANISM", 53, 56], ["abscesses", "PATHOLOGICAL_FORMATION", 108, 117], ["BIV", "ORGANISM", 170, 173], ["BIV", "SPECIES", 53, 56], ["BIV", "SPECIES", 170, 173], ["concurrent infections in BIV-infected animals", "PROBLEM", 28, 73], ["abscesses", "PROBLEM", 108, 117], ["mastitis", "PROBLEM", 119, 127], ["laminitis", "PROBLEM", 133, 142], ["persistent BIV infection", "PROBLEM", 159, 183], ["frequent", "OBSERVATION_MODIFIER", 4, 12], ["concurrent", "OBSERVATION_MODIFIER", 28, 38], ["infections", "OBSERVATION", 39, 49], ["infected", "OBSERVATION_MODIFIER", 57, 65], ["abscesses", "OBSERVATION", 108, 117], ["mastitis", "OBSERVATION", 119, 127], ["laminitis", "OBSERVATION", 133, 142], ["persistent", "OBSERVATION_MODIFIER", 159, 169], ["BIV", "OBSERVATION_MODIFIER", 170, 173], ["infection", "OBSERVATION", 174, 183]]], ["Lentiviral infection of cells of the reticuloendothelial system, such as the follicular dendritic cells (FDC) can interfere with immunological recognition at several levels and may be implicated in the generation of abnormal immunological reactions [29] .", [["cells", "ANATOMY", 24, 29], ["reticuloendothelial system", "ANATOMY", 37, 63], ["follicular dendritic cells", "ANATOMY", 77, 103], ["FDC", "ANATOMY", 105, 108], ["infection", "DISEASE", 11, 20], ["Lentiviral", "ORGANISM", 0, 10], ["cells", "CELL", 24, 29], ["reticuloendothelial system", "ANATOMICAL_SYSTEM", 37, 63], ["follicular dendritic cells", "CELL", 77, 103], ["FDC", "CELL", 105, 108], ["follicular dendritic cells", "CELL_TYPE", 77, 103], ["FDC", "CELL_TYPE", 105, 108], ["Lentiviral", "SPECIES", 0, 10], ["Lentiviral infection of cells of the reticuloendothelial system", "PROBLEM", 0, 63], ["the follicular dendritic cells", "PROBLEM", 73, 103], ["immunological recognition", "PROBLEM", 129, 154], ["abnormal immunological reactions", "PROBLEM", 216, 248], ["infection", "OBSERVATION", 11, 20], ["reticuloendothelial system", "ANATOMY", 37, 63], ["follicular dendritic cells", "OBSERVATION", 77, 103]]], ["In the animals infected with the bovine lentivirus 1, FDC infection and functional alteration of these cells and/or the lymphoid tissue microenvironment [30] may allow the perpetuation of a chronic infection independent of on-going viral effects on the lymphocytes of the immune system.", [["FDC", "ANATOMY", 54, 57], ["cells", "ANATOMY", 103, 108], ["lymphoid tissue", "ANATOMY", 120, 135], ["lymphocytes", "ANATOMY", 253, 264], ["immune system", "ANATOMY", 272, 285], ["infection", "DISEASE", 58, 67], ["infection", "DISEASE", 198, 207], ["bovine", "ORGANISM", 33, 39], ["lentivirus 1", "ORGANISM", 40, 52], ["FDC", "CELL", 54, 57], ["cells", "CELL", 103, 108], ["lymphoid tissue", "TISSUE", 120, 135], ["lymphocytes", "CELL", 253, 264], ["immune system", "ANATOMICAL_SYSTEM", 272, 285], ["lymphocytes", "CELL_TYPE", 253, 264], ["bovine", "SPECIES", 33, 39], ["bovine", "SPECIES", 33, 39], ["the bovine lentivirus 1", "PROBLEM", 29, 52], ["FDC infection", "PROBLEM", 54, 67], ["functional alteration of these cells", "PROBLEM", 72, 108], ["a chronic infection", "PROBLEM", 188, 207], ["viral effects", "PROBLEM", 232, 245], ["infected", "OBSERVATION", 15, 23], ["bovine lentivirus", "OBSERVATION", 33, 50], ["infection", "OBSERVATION", 58, 67], ["functional alteration", "OBSERVATION", 72, 93], ["lymphoid tissue", "OBSERVATION", 120, 135], ["chronic", "OBSERVATION_MODIFIER", 190, 197], ["infection", "OBSERVATION", 198, 207]]], ["Under some circumstances the presence of parasitic and other antigenic sources has produced an accelerated onset and clinical course of HIV disease and may be a factor for precipitation of the BIV-associated clinical disease [31, 32] .", [["HIV disease", "DISEASE", 136, 147], ["HIV", "ORGANISM", 136, 139], ["BIV", "ORGANISM", 193, 196], ["HIV", "SPECIES", 136, 139], ["parasitic and other antigenic sources", "PROBLEM", 41, 78], ["HIV disease", "PROBLEM", 136, 147], ["the BIV-associated clinical disease", "PROBLEM", 189, 224], ["parasitic", "OBSERVATION", 41, 50], ["accelerated", "OBSERVATION_MODIFIER", 95, 106], ["onset", "OBSERVATION_MODIFIER", 107, 112]]], ["Concurrent endemic BLV and co-infection with BIV may have influenced disease manifestation.", [["co-infection", "DISEASE", 27, 39], ["BLV", "ORGANISM", 19, 22], ["BIV", "ORGANISM", 45, 48], ["BLV", "SPECIES", 19, 22], ["BIV", "SPECIES", 45, 48], ["Concurrent endemic BLV", "PROBLEM", 0, 22], ["co-infection", "PROBLEM", 27, 39], ["BIV", "TREATMENT", 45, 48], ["influenced disease manifestation", "PROBLEM", 58, 90], ["endemic", "OBSERVATION_MODIFIER", 11, 18], ["BLV", "OBSERVATION", 19, 22], ["co-infection", "OBSERVATION", 27, 39], ["disease", "OBSERVATION", 69, 76]]], ["In the United States, BLV herd infection rates were 89% for all US dairy operations and 99% for those in the southeast region which included Louisiana [33] .DiscussionThe recovery of four isolates of NC-BVDV and one C-BVDV isolate suggests that BVDV may be a primary or secondary disease agent in BIV-infected cows.", [["infection", "DISEASE", 31, 40], ["BIV-infected", "DISEASE", 297, 309], ["BLV", "ORGANISM", 22, 25], ["NC-BVDV", "ORGANISM", 200, 207], ["C-BVDV", "ORGANISM", 216, 222], ["BVDV", "ORGANISM", 245, 249], ["BIV", "ORGANISM", 297, 300], ["cows", "ORGANISM", 310, 314], ["cows", "SPECIES", 310, 314], ["BLV", "SPECIES", 22, 25], ["BVDV", "SPECIES", 203, 207], ["C-BVDV", "SPECIES", 216, 222], ["BVDV", "SPECIES", 245, 249], ["BIV", "SPECIES", 297, 300], ["BLV herd infection rates", "TEST", 22, 46], ["NC", "TREATMENT", 200, 202], ["BVDV", "PROBLEM", 203, 207], ["BVDV isolate", "PROBLEM", 218, 230], ["BVDV", "PROBLEM", 245, 249], ["secondary disease agent", "PROBLEM", 270, 293], ["infected cows", "PROBLEM", 301, 314], ["BVDV", "OBSERVATION", 245, 249], ["secondary disease", "OBSERVATION", 270, 287], ["infected cows", "OBSERVATION", 301, 314]]], ["The standard of veterinary care for the dairy included calfhood vaccination for BVD using killed BVDV vaccine.", [["BVD", "DISEASE", 80, 83], ["BVD", "ORGANISM", 80, 83], ["BVDV", "ORGANISM", 97, 101], ["BVD", "SPECIES", 80, 83], ["BVDV", "SPECIES", 97, 101], ["veterinary care", "TREATMENT", 16, 31], ["calfhood vaccination", "TREATMENT", 55, 75], ["BVD", "PROBLEM", 80, 83], ["killed BVDV vaccine", "TREATMENT", 90, 109]]], ["A reduced level of antiviral protection may have been related to the BIV infection as a lower antibody titer for BVDV has been demonstrated following experimental BIV infection [13] .", [["BIV infection", "DISEASE", 69, 82], ["BIV infection", "DISEASE", 163, 176], ["BIV", "ORGANISM", 69, 72], ["BVDV", "ORGANISM", 113, 117], ["BIV", "SPECIES", 69, 72], ["BVDV", "SPECIES", 113, 117], ["BIV", "SPECIES", 163, 166], ["antiviral protection", "TREATMENT", 19, 39], ["the BIV infection", "PROBLEM", 65, 82], ["a lower antibody titer", "PROBLEM", 86, 108], ["BVDV", "PROBLEM", 113, 117], ["experimental BIV infection", "PROBLEM", 150, 176], ["reduced", "OBSERVATION_MODIFIER", 2, 9], ["antiviral protection", "OBSERVATION", 19, 39], ["infection", "OBSERVATION", 73, 82], ["infection", "OBSERVATION", 167, 176]]], ["There were no mucosal lesions of BVDV recognized in the cows.DiscussionThe failure to associate Chlamydial infection with the lesions suggests two possibilities.", [["mucosal lesions", "ANATOMY", 14, 29], ["lesions", "ANATOMY", 126, 133], ["Chlamydial infection", "DISEASE", 96, 116], ["mucosal lesions", "PATHOLOGICAL_FORMATION", 14, 29], ["BVDV", "ORGANISM", 33, 37], ["cows", "ORGANISM", 56, 60], ["Chlamydial", "ORGANISM", 96, 106], ["lesions", "PATHOLOGICAL_FORMATION", 126, 133], ["cows", "SPECIES", 56, 60], ["BVDV", "SPECIES", 33, 37], ["mucosal lesions", "PROBLEM", 14, 29], ["BVDV", "PROBLEM", 33, 37], ["The failure", "PROBLEM", 71, 82], ["Chlamydial infection", "PROBLEM", 96, 116], ["the lesions", "PROBLEM", 122, 133], ["no", "UNCERTAINTY", 11, 13], ["mucosal", "ANATOMY", 14, 21], ["lesions", "OBSERVATION", 22, 29], ["BVDV", "OBSERVATION", 33, 37], ["Chlamydial", "OBSERVATION_MODIFIER", 96, 106], ["infection", "OBSERVATION", 107, 116], ["lesions", "OBSERVATION", 126, 133]]], ["The initial reports of Chlamydial-associated sporadic bovine encephalomyelitis (SBE) may have been instances where Chlamydia sp. occurred as a concurrent pathogen and the BIV retroviral infection was not recognized.", [["bovine encephalomyelitis", "DISEASE", 54, 78], ["BIV retroviral infection", "DISEASE", 171, 195], ["Chlamydial", "ORGANISM", 23, 33], ["bovine", "ORGANISM", 54, 60], ["Chlamydia sp", "ORGANISM", 115, 127], ["BIV retroviral", "ORGANISM", 171, 185], ["bovine", "SPECIES", 54, 60], ["BIV", "SPECIES", 171, 174], ["Chlamydial", "PROBLEM", 23, 33], ["sporadic bovine encephalomyelitis", "PROBLEM", 45, 78], ["Chlamydia sp", "PROBLEM", 115, 127], ["a concurrent pathogen", "PROBLEM", 141, 162], ["the BIV retroviral infection", "PROBLEM", 167, 195], ["Chlamydial", "OBSERVATION", 23, 33], ["sporadic", "OBSERVATION_MODIFIER", 45, 53], ["bovine encephalomyelitis", "OBSERVATION", 54, 78], ["pathogen", "OBSERVATION", 154, 162], ["BIV retroviral", "OBSERVATION", 171, 185], ["infection", "OBSERVATION", 186, 195]]], ["Another possibility is that the nervous system lesions of SBE and BIV are closely similar or identical at the light microscopic level [34] .", [["nervous system lesions", "ANATOMY", 32, 54], ["nervous system lesions", "PATHOLOGICAL_FORMATION", 32, 54], ["SBE", "DNA", 58, 61], ["the nervous system lesions of SBE", "PROBLEM", 28, 61], ["BIV", "TREATMENT", 66, 69]]], ["Months after completion of this investigation, a cow aborted with a pigeon strain of C. psittaci which was isolated from the placenta and fetus [35] .", [["placenta", "ANATOMY", 125, 133], ["fetus", "ANATOMY", 138, 143], ["cow", "ORGANISM", 49, 52], ["pigeon", "ORGANISM", 68, 74], ["C. psittaci", "ORGANISM", 85, 96], ["placenta", "ORGAN", 125, 133], ["pigeon", "SPECIES", 68, 74], ["C. psittaci", "SPECIES", 85, 96], ["cow", "SPECIES", 49, 52], ["C. psittaci", "SPECIES", 85, 96], ["this investigation", "TEST", 27, 45], ["C. psittaci", "PROBLEM", 85, 96], ["placenta", "ANATOMY", 125, 133]]], ["Several weeks later this cow (which was serologically positive for BIV) died with metritis and brain lesions of non-suppurative lymphocytic encephalitis.", [["brain lesions", "ANATOMY", 95, 108], ["metritis", "DISEASE", 82, 90], ["brain lesions", "DISEASE", 95, 108], ["non-suppurative lymphocytic encephalitis", "DISEASE", 112, 152], ["cow", "ORGANISM", 25, 28], ["BIV", "ORGANISM", 67, 70], ["brain lesions", "PATHOLOGICAL_FORMATION", 95, 108], ["cow", "SPECIES", 25, 28], ["metritis", "PROBLEM", 82, 90], ["brain lesions", "PROBLEM", 95, 108], ["non-suppurative lymphocytic encephalitis", "PROBLEM", 112, 152], ["metritis", "OBSERVATION", 82, 90], ["brain", "ANATOMY", 95, 100], ["lesions", "OBSERVATION", 101, 108], ["non-suppurative", "OBSERVATION_MODIFIER", 112, 127], ["lymphocytic encephalitis", "OBSERVATION", 128, 152]]], ["At the time of death the cow was negative for Chlamydia antibody [35] , suggestive of anergy, possibly similar to that reported for BIV as a loss of BIV Gag-specific antibody during the course of infection [36] .", [["death", "DISEASE", 15, 20], ["anergy", "DISEASE", 86, 92], ["infection", "DISEASE", 196, 205], ["cow", "ORGANISM", 25, 28], ["BIV", "ORGANISM", 132, 135], ["BIV", "ORGANISM", 149, 152], ["Gag", "GENE_OR_GENE_PRODUCT", 153, 156], ["Chlamydia antibody", "PROTEIN", 46, 64], ["BIV Gag", "PROTEIN", 149, 156], ["specific antibody", "PROTEIN", 157, 174], ["cow", "SPECIES", 25, 28], ["cow", "SPECIES", 25, 28], ["BIV", "SPECIES", 132, 135], ["BIV", "SPECIES", 149, 152], ["Chlamydia antibody", "PROBLEM", 46, 64], ["anergy", "PROBLEM", 86, 92], ["BIV", "PROBLEM", 132, 135], ["a loss of BIV Gag", "PROBLEM", 139, 156], ["infection", "PROBLEM", 196, 205], ["suggestive of", "UNCERTAINTY", 72, 85], ["anergy", "OBSERVATION", 86, 92]]], ["Another potential explanation for the encephalitis, other than primary lentiviral infection, is activation of latent vaccinal IBRV.", [["encephalitis", "DISEASE", 38, 50], ["primary lentiviral infection", "DISEASE", 63, 91], ["lentiviral", "ORGANISM", 71, 81], ["the encephalitis", "PROBLEM", 34, 50], ["primary lentiviral infection", "PROBLEM", 63, 91], ["latent vaccinal IBRV", "TREATMENT", 110, 130], ["potential explanation for", "UNCERTAINTY", 8, 33], ["encephalitis", "OBSERVATION", 38, 50], ["lentiviral infection", "OBSERVATION", 71, 91], ["latent", "OBSERVATION_MODIFIER", 110, 116], ["vaccinal IBRV", "OBSERVATION", 117, 130]]], ["The animals; however, had received calfhood vaccinations and no evidence of IBRV infection or recrudescence was found.DiscussionIn most of the cows with debilitation and weight loss, the LN were normal or reduced in size with reduction or absence of follicular hyperplasia.", [["LN", "ANATOMY", 187, 189], ["follicular hyperplasia", "ANATOMY", 250, 272], ["infection", "DISEASE", 81, 90], ["debilitation", "DISEASE", 153, 165], ["weight loss", "DISEASE", 170, 181], ["follicular hyperplasia", "DISEASE", 250, 272], ["animals", "ORGANISM", 4, 11], ["IBRV", "CANCER", 76, 80], ["cows", "ORGANISM", 143, 147], ["LN", "CANCER", 187, 189], ["follicular hyperplasia", "PATHOLOGICAL_FORMATION", 250, 272], ["cows", "SPECIES", 143, 147], ["IBRV", "SPECIES", 76, 80], ["calfhood vaccinations", "TREATMENT", 35, 56], ["IBRV infection", "PROBLEM", 76, 90], ["recrudescence", "PROBLEM", 94, 107], ["debilitation", "PROBLEM", 153, 165], ["weight loss", "PROBLEM", 170, 181], ["follicular hyperplasia", "PROBLEM", 250, 272], ["no evidence of", "UNCERTAINTY", 61, 75], ["IBRV", "OBSERVATION_MODIFIER", 76, 80], ["infection", "OBSERVATION", 81, 90], ["LN", "ANATOMY", 187, 189], ["normal", "OBSERVATION", 195, 201], ["reduced", "OBSERVATION_MODIFIER", 205, 212], ["size", "OBSERVATION_MODIFIER", 216, 220], ["reduction", "OBSERVATION_MODIFIER", 226, 235], ["follicular hyperplasia", "OBSERVATION", 250, 272]]], ["In cows that had weight loss of approximately 40%, the HLN were not enlarged.", [["weight loss", "DISEASE", 17, 28], ["cows", "ORGANISM", 3, 7], ["HLN", "CANCER", 55, 58], ["cows", "SPECIES", 3, 7], ["weight loss", "PROBLEM", 17, 28], ["enlarged", "PROBLEM", 68, 76], ["weight loss", "OBSERVATION_MODIFIER", 17, 28], ["not", "UNCERTAINTY", 64, 67], ["enlarged", "OBSERVATION", 68, 76]]], ["Muscle wasting, which occurred while the cows had free-choice access to feed, raised the possibility of a central depression in appetite, suggestive of a clinical neurogenic anorexia which was observed in BIV-infected calves [31] .", [["Muscle", "ANATOMY", 0, 6], ["Muscle wasting", "DISEASE", 0, 14], ["depression", "DISEASE", 114, 124], ["neurogenic anorexia", "DISEASE", 163, 182], ["BIV-infected", "DISEASE", 205, 217], ["Muscle", "ORGAN", 0, 6], ["BIV", "ORGANISM", 205, 208], ["calves", "ORGANISM", 218, 224], ["cows", "SPECIES", 41, 45], ["calves", "SPECIES", 218, 224], ["Muscle wasting", "PROBLEM", 0, 14], ["a central depression in appetite", "PROBLEM", 104, 136], ["a clinical neurogenic anorexia", "PROBLEM", 152, 182], ["wasting", "OBSERVATION", 7, 14], ["central", "OBSERVATION_MODIFIER", 106, 113], ["depression", "OBSERVATION", 114, 124], ["suggestive of", "UNCERTAINTY", 138, 151], ["anorexia", "OBSERVATION", 174, 182]]], ["Weight loss is a component of the recognized progressive changes of initial symptomatic disease in humans with AIDS [37, 38] .DiscussionLocalization of BIV provirus in brain and lymphoid tissues was consistent with the observations of others [14] [15] [16] 39] .", [["brain", "ANATOMY", 168, 173], ["lymphoid tissues", "ANATOMY", 178, 194], ["Weight loss", "DISEASE", 0, 11], ["AIDS", "DISEASE", 111, 115], ["humans", "ORGANISM", 99, 105], ["BIV", "ORGANISM", 152, 155], ["brain", "ORGAN", 168, 173], ["lymphoid tissues", "TISSUE", 178, 194], ["[14] [15] [16] 39", "SIMPLE_CHEMICAL", 242, 259], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 99, 105], ["Weight loss", "PROBLEM", 0, 11], ["initial symptomatic disease in humans", "PROBLEM", 68, 105], ["BIV provirus in brain and lymphoid tissues", "PROBLEM", 152, 194], ["loss", "OBSERVATION", 7, 11], ["progressive", "OBSERVATION_MODIFIER", 45, 56], ["symptomatic", "OBSERVATION_MODIFIER", 76, 87], ["disease", "OBSERVATION", 88, 95], ["BIV provirus", "OBSERVATION", 152, 164], ["brain", "ANATOMY", 168, 173], ["lymphoid tissues", "OBSERVATION", 178, 194], ["consistent with", "UNCERTAINTY", 199, 214]]], ["Torpidity, stupor, dullness and reduced vitality were observed and clinically attributed to the systemic effect of the multiple subcutaneous abscesses and laminitis, but were possibly the result of lentiviral-induced CNS lesions [10, 40] .", [["subcutaneous abscesses", "ANATOMY", 128, 150], ["CNS lesions", "ANATOMY", 217, 228], ["Torpidity", "DISEASE", 0, 9], ["stupor", "DISEASE", 11, 17], ["dullness", "DISEASE", 19, 27], ["abscesses", "DISEASE", 141, 150], ["laminitis", "DISEASE", 155, 164], ["lentiviral", "ORGANISM", 198, 208], ["CNS lesions", "PATHOLOGICAL_FORMATION", 217, 228], ["stupor", "PROBLEM", 11, 17], ["dullness", "PROBLEM", 19, 27], ["reduced vitality", "PROBLEM", 32, 48], ["the multiple subcutaneous abscesses", "PROBLEM", 115, 150], ["laminitis", "PROBLEM", 155, 164], ["lentiviral-induced CNS lesions", "PROBLEM", 198, 228], ["stupor", "OBSERVATION", 11, 17], ["dullness", "OBSERVATION", 19, 27], ["multiple", "OBSERVATION_MODIFIER", 119, 127], ["subcutaneous", "ANATOMY", 128, 140], ["abscesses", "OBSERVATION", 141, 150], ["laminitis", "OBSERVATION", 155, 164], ["CNS", "ANATOMY", 217, 220], ["lesions", "OBSERVATION", 221, 228]]], ["Longterm multiyear investigations of dairy cows under modern production stresses are needed to elucidate the mechanisms of cellular infection, viral proliferation, and transmission of BIV.", [["cellular", "ANATOMY", 123, 131], ["infection", "DISEASE", 132, 141], ["cows", "ORGANISM_SUBDIVISION", 43, 47], ["cellular", "CELL", 123, 131], ["BIV", "ORGANISM", 184, 187], ["cows", "SPECIES", 43, 47], ["BIV", "SPECIES", 184, 187], ["dairy cows", "TREATMENT", 37, 47], ["modern production stresses", "TREATMENT", 54, 80], ["cellular infection", "PROBLEM", 123, 141], ["viral proliferation", "PROBLEM", 143, 162], ["BIV", "TREATMENT", 184, 187], ["cellular", "OBSERVATION_MODIFIER", 123, 131], ["infection", "OBSERVATION", 132, 141], ["viral proliferation", "OBSERVATION", 143, 162]]]], "PMC7228326": [["The World Health Organization confirmed 93,090 cases of novel coronavirus SARS\u2010CoV\u20102 infections (COVID\u201019) worldwide on March 04, 2020.", [["coronavirus SARS", "DISEASE", 62, 78], ["CoV\u20102 infections", "DISEASE", 79, 95], ["coronavirus", "ORGANISM", 62, 73], ["novel coronavirus SARS", "PROBLEM", 56, 78], ["CoV\u20102 infections", "PROBLEM", 79, 95]]], ["3,198 deaths were declared (3%).", [["deaths", "DISEASE", 6, 12]]], ["In the United States, 108 cases were confirmed.1 Coronavirus family members are known to be responsible for severe acute respiratory syndrome (SARS\u2010CoV) and Middle East respiratory syndrome (MERS\u2010CoV), associated with severe complications, such as acute respiratory distress syndrome, multiorgan failure, and death, especially in individuals with underlying comorbidities and old age.2, 3", [["respiratory", "ANATOMY", 254, 265], ["multiorgan", "ANATOMY", 285, 295], ["acute respiratory syndrome", "DISEASE", 115, 141], ["SARS\u2010CoV", "DISEASE", 143, 151], ["Middle East respiratory syndrome", "DISEASE", 157, 189], ["acute respiratory distress syndrome", "DISEASE", 248, 283], ["multiorgan failure", "DISEASE", 285, 303], ["death", "DISEASE", 309, 314], ["MERS\u2010CoV", "ORGANISM", 191, 199], ["SARS\u2010CoV", "SPECIES", 143, 151], ["Middle East respiratory syndrome (MERS\u2010CoV", "SPECIES", 157, 199], ["severe acute respiratory syndrome", "PROBLEM", 108, 141], ["SARS\u2010CoV)", "PROBLEM", 143, 152], ["Middle East respiratory syndrome", "PROBLEM", 157, 189], ["severe complications", "PROBLEM", 218, 238], ["acute respiratory distress syndrome", "PROBLEM", 248, 283], ["multiorgan failure", "PROBLEM", 285, 303], ["death", "PROBLEM", 309, 314], ["underlying comorbidities", "PROBLEM", 347, 371], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["respiratory syndrome", "OBSERVATION", 121, 141], ["Middle", "ANATOMY_MODIFIER", 157, 163], ["respiratory syndrome", "OBSERVATION", 169, 189], ["severe", "OBSERVATION_MODIFIER", 218, 224], ["complications", "OBSERVATION", 225, 238], ["acute", "OBSERVATION_MODIFIER", 248, 253], ["respiratory distress", "OBSERVATION", 254, 274], ["multiorgan failure", "OBSERVATION", 285, 303]]]], "8c19ac39dc241cd80f727b31677930eb6f39f2a9": [["INTRODUCTIONThe COVID-19 pandemic has presented unparalleled challenges for healthcare systems around the world [1] [2] [3] [4] [5] [6] [7] [8] .", [["[1] [2] [3] [4] [5] [6] [7]", "CHEMICAL", 112, 139], ["[1] [2] [3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 112, 143]]], ["The SARS-CoV-2 virus first appeared in Wuhan, China in December 2019.", [["SARS-CoV-2 virus", "ORGANISM", 4, 20], ["CoV-2 virus", "SPECIES", 9, 20], ["SARS-CoV-2 virus", "SPECIES", 4, 20], ["The SARS", "TEST", 0, 8]]], ["The first US case was confirmed on January 20 [9] , followed by exponential spread within the US [10] .", [["The first US case", "TEST", 0, 17]]], ["Within Massachusetts, Boston and Chelsea were epicenters for the spread of COVID-19.INTRODUCTIONIn anticipation of the surge of COVID-19 patients and to help limit viral spread, Massachusetts General Hospital (MGH) closed most outpatient and urgent care clinics and set up new Respiratory Illness Clinics (RICs) on March 7, 2020 to manage patients with symptoms of a respiratory infection.", [["respiratory", "ANATOMY", 367, 378], ["Respiratory Illness", "DISEASE", 277, 296], ["respiratory infection", "DISEASE", 367, 388], ["patients", "ORGANISM", 137, 145], ["patients", "ORGANISM", 339, 347], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 339, 347], ["Chelsea", "TREATMENT", 33, 40], ["COVID", "TEST", 75, 80], ["COVID", "TREATMENT", 128, 133], ["symptoms", "PROBLEM", 353, 361], ["a respiratory infection", "PROBLEM", 365, 388], ["respiratory", "ANATOMY", 367, 378], ["infection", "OBSERVATION", 379, 388]]], ["Due to high case volumes and precautions for staff and patients, visit duration and extent of clinical assessments for most patients were curtailed.", [["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 124, 132], ["clinical assessments", "TEST", 94, 114]]], ["In addition to limited clinical assessment, triage decisions were complicated by COVID-19's biphasic clinical course.", [["limited clinical assessment", "TEST", 15, 42], ["COVID", "TEST", 81, 86]]], ["Patients who initially present with mild symptoms often later return for hospital admission, and many subsequently suffer adverse events including ICU transfer, mechanical ventilation (MV) or death.", [["death", "DISEASE", 192, 197], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["MV", "SPECIES", 185, 187], ["mild symptoms", "PROBLEM", 36, 49], ["adverse events", "PROBLEM", 122, 136], ["mechanical ventilation", "TREATMENT", 161, 183], ["death", "PROBLEM", 192, 197], ["mild", "OBSERVATION_MODIFIER", 36, 40]]], ["Various prediction rules have been proposed, but to our knowledge few have been prospectively validated, and most were developed for the inpatient setting rather than outpatient screening.INTRODUCTIONTo help frontline clinicians appropriately triage and plan follow-up care for patients presenting for COVID-19 screening and not requiring immediate hospitalization, we developed an outpatient screening score, COVID-19 Acuity Score (CoVA), that could be incorporated into an electronic medical record (EMR) system.", [["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 278, 286], ["outpatient screening", "TEST", 167, 187], ["COVID", "TEST", 302, 307], ["an outpatient screening score", "TEST", 379, 408], ["COVID", "TEST", 410, 415]]], ["CoVA assigns acuity levels based on demographic, clinical, radiographic, and medical history variables, and provides predicted probabilities for hospital admission, ICU admission or MV, or death within 7 days.Study PopulationWe included data from patients seen in MGH RIC clinics and ED between March 7 and May 14.", [["death", "DISEASE", 189, 194], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["MV", "SPECIES", 182, 184], ["acuity levels", "TEST", 13, 26]]], ["Patients were divided into two mutually exclusive cohorts, a development cohort (March 7 to May 2, 2020, n = 9381); and prospective cohort (May 3 to May 14, 2020, n = 2205).Study PopulationInclusion criteria were: (1) MGH RIC or ED visit between March 7th and May 14th, 2020; (2) age \u2265 18 years; and (3) reason for visit was cough, fever, shortness of breath, COVID-related, or potentially related (see Supplemental Table S6 ).", [["cough", "DISEASE", 325, 330], ["fever", "DISEASE", 332, 337], ["shortness of breath", "DISEASE", 339, 358], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["cough", "PROBLEM", 325, 330], ["fever", "PROBLEM", 332, 337], ["shortness of breath", "PROBLEM", 339, 358], ["COVID", "PROBLEM", 360, 365]]], ["Exclusion criteria were: (1) Patients seen solely for a nasopharyngeal PCR swab without a clinical assessment were excluded; and (2) Patients with visits in both development and prospective cohorts are excluded, to ensure the score is not overfit to those patients.", [["nasopharyngeal", "ANATOMY", 56, 70], ["Patients", "ORGANISM", 29, 37], ["Patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 256, 264], ["Patients", "SPECIES", 29, 37], ["Patients", "SPECIES", 133, 141], ["patients", "SPECIES", 256, 264], ["a nasopharyngeal PCR swab", "TEST", 54, 79], ["a clinical assessment", "TEST", 88, 109]]], ["A data flowchart is provided in Supplemental Figure S1 .", [["A data flowchart", "TEST", 0, 16]]], ["Note that one patient contributes only once in either cohort.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21]]], ["In the development cohort, we randomly sampled one visit from each patient.", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74]]], ["In the prospective cohort, we chose the most recent visit from each patient.Primary OutcomeThe primary outcome was the occurrence of an adverse event within 7 days following an outpatient medical encounter, including either hospitalization at MGH, critical illness (defined as ICU care and/or mechanical ventilation), or death.", [["death", "DISEASE", 321, 326], ["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["ICU care", "TREATMENT", 277, 285], ["mechanical ventilation", "TREATMENT", 293, 315], ["death", "PROBLEM", 321, 326]]], ["The prediction horizon was set to 7 days because this period was considered meaningful by our frontline teams for clinical decision-making (e.g., regarding whether to send a patient home or to the emergency department, or to follow up with phone calls), and because empirically, within the model development cohort most adverse events occurred within 7 days of initial presentation.PredictorsWe selected 98 variables that were routinely available in the outpatient setting during the COVID-19 pandemic to serve as candidate predictors.", [["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["The prediction horizon", "TREATMENT", 0, 22], ["adverse events", "PROBLEM", 320, 334], ["the COVID", "TREATMENT", 480, 489]]], ["These included demographic variables: age, gender, tobacco use history, most recent body mass index (BMI) within the preceding month (represented as binary variables designated as high BMI, >35kg/m 2 , and low BMI, <18.5kg/m 2 ), the most recent vital signs (blood pressure, respiratory rate, heart rate, temperature, blood oxygen saturation level (SpO2)) within the preceding 3 days; COVID testing status (See Supplemental Section \"Predictor encoding\" for encoding details); specific symptoms suggestive of COVID-19 (anosmia, dysgeusia based on ICD-10 codes), and pre-existing medical diagnoses, coded as present or absent based on groups of billing codes (ICD-10 codes; Supplemental Table S3 ) in the EMR.", [["body", "ANATOMY", 84, 88], ["blood", "ANATOMY", 259, 264], ["respiratory", "ANATOMY", 275, 286], ["heart", "ANATOMY", 293, 298], ["blood", "ANATOMY", 318, 323], ["oxygen", "CHEMICAL", 324, 330], ["anosmia", "DISEASE", 518, 525], ["dysgeusia", "DISEASE", 527, 536], ["oxygen", "CHEMICAL", 324, 330], ["tobacco", "ORGANISM", 51, 58], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["blood", "ORGANISM_SUBSTANCE", 259, 264], ["heart", "ORGAN", 293, 298], ["blood", "ORGANISM_SUBSTANCE", 318, 323], ["oxygen", "SIMPLE_CHEMICAL", 324, 330], ["most recent body mass index", "PROBLEM", 72, 99], ["vital signs", "TEST", 246, 257], ["blood pressure", "TEST", 259, 273], ["respiratory rate", "TEST", 275, 291], ["heart rate", "TEST", 293, 303], ["temperature", "TEST", 305, 316], ["blood oxygen saturation level", "TEST", 318, 347], ["SpO2", "TEST", 349, 353], ["COVID testing", "TEST", 385, 398], ["specific symptoms", "PROBLEM", 476, 493], ["COVID", "TEST", 508, 513], ["anosmia", "PROBLEM", 518, 525], ["dysgeusia", "PROBLEM", 527, 536], ["ICD", "TREATMENT", 546, 549], ["ICD", "TREATMENT", 658, 661], ["heart", "ANATOMY", 293, 298]]], ["The Weighted Charlson Comorbidity Index (CCI) was computed based on groups of ICDs using the \"wscore\" from the R package \"comorbidity\" [14] .", [["ICDs", "TREATMENT", 78, 82]]], ["We omitted race and ethnicity as predictors because (1) we have found that these variables were often unavailable or inaccurately recorded, especially ethnicity; and (2) we wanted to limit the influence of local demographic patterns on the score, which might limit the ability to generalize to external populations.PredictorsFor patients who underwent chest X-ray (CXR) imaging during these encounters, we identified groups of common findings based on radiology reports that tend to indicate adverse events in patients with COVID-19.", [["patients", "ORGANISM", 329, 337], ["patients", "ORGANISM", 510, 518], ["patients", "SPECIES", 329, 337], ["patients", "SPECIES", 510, 518], ["chest X-ray", "TEST", 352, 363], ["CXR", "TEST", 365, 368], ["imaging", "TEST", 370, 377], ["adverse events", "PROBLEM", 492, 506], ["COVID", "TEST", 524, 529], ["chest", "ANATOMY", 352, 357]]], ["First, we manually reviewed 50 CXR reports and liberally extracted key words, phrases, and word patterns describing abnormal findings.", [["CXR", "PROTEIN", 31, 34], ["CXR", "TEST", 31, 34], ["abnormal findings", "PROBLEM", 116, 133], ["abnormal", "OBSERVATION_MODIFIER", 116, 124]]], ["Next, a pulmonary and critical care medicine physician (LB) categorized these phrases into groups.", [["pulmonary", "ANATOMY", 8, 17], ["pulmonary", "ORGAN", 8, 17], ["pulmonary", "ANATOMY", 8, 17]]], ["Five groups were identified: multifocal, patterns typical for COVID-19 (pneumonia, bronchopneumonia, Acute Respiratory Distress Syndrome (ARDS)), patchy consolidation, peripheral or interstitial opacity, or hazy or airspace opacities.", [["interstitial", "ANATOMY", 182, 194], ["airspace", "ANATOMY", 215, 223], ["pneumonia", "DISEASE", 72, 81], ["bronchopneumonia", "DISEASE", 83, 99], ["Acute Respiratory Distress Syndrome", "DISEASE", 101, 136], ["ARDS", "DISEASE", 138, 142], ["peripheral or interstitial opacity", "DISEASE", 168, 202], ["opacities", "DISEASE", 224, 233], ["COVID", "TEST", 62, 67], ["pneumonia", "PROBLEM", 72, 81], ["bronchopneumonia", "PROBLEM", 83, 99], ["Acute Respiratory Distress Syndrome (ARDS)", "PROBLEM", 101, 143], ["patchy consolidation", "PROBLEM", 146, 166], ["peripheral or interstitial opacity", "PROBLEM", 168, 202], ["hazy", "PROBLEM", 207, 211], ["airspace opacities", "PROBLEM", 215, 233], ["multifocal", "OBSERVATION_MODIFIER", 29, 39], ["pneumonia", "OBSERVATION", 72, 81], ["bronchopneumonia", "OBSERVATION", 83, 99], ["Acute", "OBSERVATION_MODIFIER", 101, 106], ["Respiratory Distress Syndrome", "OBSERVATION", 107, 136], ["ARDS", "OBSERVATION", 138, 142], ["patchy", "OBSERVATION_MODIFIER", 146, 152], ["consolidation", "OBSERVATION", 153, 166], ["peripheral", "ANATOMY_MODIFIER", 168, 178], ["interstitial", "ANATOMY_MODIFIER", 182, 194], ["opacity", "OBSERVATION", 195, 202], ["hazy", "OBSERVATION_MODIFIER", 207, 211], ["airspace", "ANATOMY_MODIFIER", 215, 223], ["opacities", "OBSERVATION", 224, 233]]], ["CXR predictors were coded as present, not present or unavailable.Data Preprocessing and Selection of Predictor VariablesWe treated predictors outside of physiologically plausible ranges as unavailable (see Supplemental Table S5 ).", [["CXR", "PROTEIN", 0, 3], ["CXR predictors", "TEST", 0, 14]]], ["Unavailable values were imputed using K-nearest neighbors (KNN) [15] , where the value of K was determined by minimizing the imputation error on a subset without unavailable data by randomly masking variables according to the pattern of unavailability in the overall data.", [["K", "TEST", 90, 91]]], ["Note that we did not impute CXR predictors or COVID status for patients who did not have either of them available.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["CXR predictors", "TEST", 28, 42]]], ["Instead, for these we coded unavailability explicitly (described above).Data Preprocessing and Selection of Predictor VariablesPredictors were standardized to zero mean and unit standard deviation using z-score transformation (Supplemental Table S1 ).", [["unit standard deviation using z-score transformation", "TREATMENT", 173, 225]]], ["Predictors were selected for inclusion in the CoVA model in two stages.", [["the CoVA model", "TREATMENT", 42, 56]]], ["First, we used ANOVA statistics to identify predictors associated with hospitalization, ICU care or MV, or death.", [["death", "DISEASE", 107, 112], ["MV", "SPECIES", 100, 102], ["ICU care", "TREATMENT", 88, 96], ["death", "PROBLEM", 107, 112]]], ["At 0.05 significance level, we identified 65 predictors to carry forward into the model fitting procedure (p-values shown in Supplemental Table S7 ).", [["the model fitting procedure", "TREATMENT", 78, 105]]], ["Second, we used least absolute shrinkage and selection (LASSO) regression during the model fitting procedure to select a reduced subset of highly predictive variables.Model DevelopmentWe assigned an ordinal scale to adverse events, including no event, hospitalized, ICU care and/or MV, and death.", [["death", "DISEASE", 290, 295], ["MV", "SPECIES", 282, 284], ["absolute shrinkage", "TREATMENT", 22, 40], ["selection (LASSO) regression", "TREATMENT", 45, 73], ["the model fitting procedure", "TREATMENT", 81, 108], ["death", "PROBLEM", 290, 295], ["absolute shrinkage", "OBSERVATION", 22, 40], ["reduced", "OBSERVATION_MODIFIER", 121, 128], ["highly", "OBSERVATION_MODIFIER", 139, 145]]], ["We used an implementation of ordinal regression: pairwise learning to rank (LTR) with LASSO penalized logistic regression [16, 17] .", [["LTR", "DNA", 76, 79]]], ["Training involves learning to predict which of a pair of patients will have a worse outcome.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["a worse outcome", "PROBLEM", 76, 91]]], ["On biological grounds, and to address co-linearity among predictors, we constrained the model optimization to allow only non-negative coefficients for CXR predictors, medical comorbidities, CCI, and history of current or past tobacco use; and unconstrained for other predictors.", [["CCI", "DISEASE", 190, 193], ["tobacco", "ORGANISM", 226, 233], ["tobacco", "SPECIES", 226, 233], ["the model optimization", "TREATMENT", 84, 106], ["CXR predictors", "TEST", 151, 165], ["medical comorbidities", "PROBLEM", 167, 188], ["CCI", "PROBLEM", 190, 193]]], ["Model training and preliminary evaluation of model performance was performed using the development cohort, using nested 5-fold cross validation (CV) (Supplemental Materials and Supplementary Figure S3 ).", [["Model training", "TREATMENT", 0, 14], ["preliminary evaluation of model performance", "TEST", 19, 62], ["nested 5-fold cross validation", "TREATMENT", 113, 143], ["Supplemental Materials", "TREATMENT", 150, 172]]], ["The final model provides acuity scores between 0 to 100 and predicted probabilities for hospitalization and for critical illness or death within 7 days.", [["illness", "DISEASE", 121, 128], ["death", "DISEASE", 132, 137], ["acuity scores", "TEST", 25, 38], ["death", "PROBLEM", 132, 137]]], ["Performance is reported both for the development cohort (results from cross validation), and for the prospective cohort.Statistical Analysis of CoVA Predictive PerformanceWe summarized the distribution of cohort characteristics and adverse events using event counts and proportions for categorical predictors, and mean and standard deviation for continuous variables.", [["cross validation", "TEST", 70, 86], ["cohort characteristics", "PROBLEM", 205, 227], ["adverse events", "PROBLEM", 232, 246], ["event counts", "TEST", 253, 265], ["categorical predictors", "TEST", 286, 308], ["mean", "TEST", 314, 318]]], ["For model calibration, an expected-to-observed ratio (E/O) [18] of 1.0 indicates that the number of expected events equals the number of observed events; and calibration slope (CS) is defined as the linear correlation between the observed O and expected probabilities E, where the expected (predicted) values (E) are binned into quintiles.Statistical Analysis of CoVA Predictive PerformanceWe calculated the area under the Receiver Operator Characteristic (ROC) curve (AUC, also called the Cstatistic) to quantify how well CoVA scores discriminate between individuals who within 7 days were vs. not hospitalized, and between those who did vs. not experience critical illness (ICU care, MV, or death).", [["death", "DISEASE", 693, 698], ["CoVA", "PROTEIN", 523, 527], ["MV", "SPECIES", 686, 688], ["model calibration", "TEST", 4, 21], ["Statistical Analysis", "TEST", 339, 359], ["CoVA", "TEST", 363, 367], ["critical illness", "PROBLEM", 658, 674], ["critical", "OBSERVATION_MODIFIER", 658, 666], ["illness", "OBSERVATION", 667, 674]]], ["We considered an AUC between 0.50 and 0.55 to be poor; 0.55 and 0.65, moderate; 0.65 and 0.75, acceptable; and >0.75, excellent.", [["an AUC", "TEST", 14, 20], ["moderate", "OBSERVATION_MODIFIER", 70, 78]]], ["We also calculated specificity, positive predictive value (PPV), and negative predictive values (NPV) at the 90% sensitivity level.Statistical Analysis of CoVA Predictive PerformanceWe also looked at the time course of adverse events as a function of CoVA score over 4 weeks (28 days) following initial presentation to the RIC or ED to understand the properties of CoVA score.Statistical Analysis of CoVA Predictive Performance.", [["CoVA", "GENE_OR_GENE_PRODUCT", 365, 369], ["CoVA", "PROTEIN", 365, 369], ["PPV", "TEST", 59, 62], ["NPV", "TEST", 97, 100], ["adverse events", "PROBLEM", 219, 233], ["CoVA score", "PROBLEM", 251, 261]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.17.20134262 doi: medRxiv preprintCohort CharacteristicsFrom March 7 to May 2, 2020, 9381 patients met inclusion criteria and were included in the development cohort.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 398, 406], ["patients", "SPECIES", 398, 406], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 326, 333], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Among these, 3344 (35.6%) had adverse events within 7 days of presentation: 2562 (27.3%) were hospitalized, 679 (7.2%) received ICU care and/or were mechanically ventilated, and 103 (1.1%) died.Cohort CharacteristicsFrom May 3-14, 2205 additional patients met inclusion criteria and were included in the prospective cohort.", [["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["adverse events", "PROBLEM", 30, 44], ["ICU care", "TREATMENT", 128, 136], ["Cohort CharacteristicsFrom", "TEST", 194, 220]]], ["Among these, 726 (32.9%) had adverse events: 575 (26.1%) were hospitalized, 139 (6.3%) received ICU care and/or were mechanically ventilated, and 12 (0.5%) died.Cohort CharacteristicsCohort characteristics are summarized in Table 1 .", [["adverse events", "PROBLEM", 29, 43], ["ICU care", "TREATMENT", 96, 104]]], ["Compared to the model development period, during the prospective validation period there were modest increases in the proportion of patients with CXRs (prospective 52.3% vs. development 41.0%), the proportion of outpatient evaluations performed in RIC clinics (prospective 26.5% vs. development 21.4%), and in testing rates for COVID-19 (prospective 78.8% vs. development 59.5%).", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["CXRs", "TEST", 146, 150], ["prospective", "TEST", 152, 163], ["outpatient evaluations", "TEST", 212, 234], ["development", "TEST", 283, 294], ["testing rates", "TEST", 310, 323], ["COVID", "TEST", 328, 333], ["modest", "OBSERVATION_MODIFIER", 94, 100], ["increases", "OBSERVATION_MODIFIER", 101, 110]]], ["Several other small but likely clinically insignificant differences between cohorts also reached statistical significance, due to the large cohort sizes.", [["the large cohort sizes", "PROBLEM", 130, 152], ["small", "OBSERVATION_MODIFIER", 14, 19], ["likely", "UNCERTAINTY", 24, 30], ["clinically", "OBSERVATION_MODIFIER", 31, 41], ["insignificant", "OBSERVATION_MODIFIER", 42, 55], ["differences", "OBSERVATION", 56, 67], ["large", "OBSERVATION_MODIFIER", 134, 139], ["sizes", "OBSERVATION_MODIFIER", 147, 152]]], ["COVID-19 infections and clinical adverse events by age and decade of life are shown in Supplemental Figure S2 .Predictive PerformanceCoVA showed excellent calibration and discrimination in the development cohort for hospitalization (E Table 2 .Properties of COVA ScoreThe proportion of patients with adverse events at 7 days increases with higher CoVA scores, rising from 18% with CoVA scores in the 0-20 range, to 88% for those with scores in the 80-100 range.", [["infections", "DISEASE", 9, 19], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 286, 294], ["COVID", "TEST", 0, 5], ["infections", "PROBLEM", 9, 19], ["clinical adverse events", "PROBLEM", 24, 47], ["Predictive PerformanceCoVA", "TEST", 111, 137], ["adverse events", "PROBLEM", 300, 314], ["higher CoVA scores", "PROBLEM", 340, 358], ["CoVA scores", "TEST", 381, 392], ["scores", "TEST", 434, 440], ["infections", "OBSERVATION", 9, 19], ["excellent calibration", "OBSERVATION", 145, 166]]], ["The proportion underwent critical illness or death also rises, from 2% for scores between 0-20, to 32% with scores between 80-100 ( Figure 1A) .Properties of COVA ScoreWe investigated the time course of adverse events as a function of CoVA score over 4 weeks (28 days) following initial presentation to the RIC or ED.", [["death", "DISEASE", 45, 50], ["critical illness", "PROBLEM", 25, 41], ["death", "PROBLEM", 45, 50], ["scores", "TEST", 75, 81], ["scores", "TEST", 108, 114], ["adverse events", "PROBLEM", 203, 217], ["CoVA score", "PROBLEM", 235, 245], ["critical", "OBSERVATION_MODIFIER", 25, 33], ["illness", "OBSERVATION", 34, 41]]], ["We limited this investigation to the development cohort, because 28 days have not passed for the prospective validation cohort at the time of writing.", [["this investigation", "TEST", 11, 29]]], ["By 28 days, 3399 (36%) of patients experienced hospitalization, critical illness, or death.", [["illness", "DISEASE", 73, 80], ["death", "DISEASE", 85, 90], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["critical illness", "PROBLEM", 64, 80], ["death", "PROBLEM", 85, 90]]], ["Critical illness or death occurred in 861 .", [["Critical illness", "DISEASE", 0, 16], ["death", "DISEASE", 20, 25], ["Critical illness", "PROBLEM", 0, 16], ["death", "PROBLEM", 20, 25], ["illness", "OBSERVATION", 9, 16]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.17.20134262 doi: medRxiv preprint (9%) of patients within 28 days of presentation.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 351, 359], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint", "TREATMENT", 326, 342], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Curves for the cumulative incidence of adverse events over time for different levels of CoVA scores are shown in Figure 1B .Predictors of Adverse EventsThirty predictors were selected by the data-driven model training procedure (Table 3 ).", [["CoVA", "PROTEIN", 88, 92], ["adverse events", "PROBLEM", 39, 53], ["CoVA scores", "TEST", 88, 99], ["Adverse Events", "PROBLEM", 138, 152], ["driven model training procedure", "TREATMENT", 196, 227]]], ["All but four predictors increase the predicted probability of adverse events when present.", [["adverse events", "PROBLEM", 62, 76]]], ["SpO2, diastolic and systolic blood pressure and low BMI inversely correlated with the probability of adverse events.", [["blood", "ANATOMY", 29, 34], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["SpO2", "TEST", 0, 4], ["diastolic", "TEST", 6, 15], ["systolic blood pressure", "TEST", 20, 43], ["low BMI", "PROBLEM", 48, 55], ["adverse events", "PROBLEM", 101, 115], ["systolic", "OBSERVATION_MODIFIER", 20, 28], ["blood pressure", "OBSERVATION", 29, 43], ["low BMI", "OBSERVATION", 48, 55]]], ["Predictors from CXR reports included in the model were multifocal patterns (diffuse opacities, ground glass) and patterns typical for COVID.Effect of Chest X-Ray Findings and COVID Status on the Probability of Adverse EventsCXRs and testing for COVID-19 were not universal, and testing rates evolved over time.", [["CXR", "PROTEIN", 16, 19], ["CXR", "TEST", 16, 19], ["diffuse opacities", "PROBLEM", 76, 93], ["COVID", "PROBLEM", 134, 139], ["Chest X-Ray Findings", "TEST", 150, 170], ["Adverse EventsCXRs", "TEST", 210, 228], ["testing", "TEST", 233, 240], ["COVID", "TEST", 245, 250], ["testing rates", "TEST", 278, 291], ["multifocal", "OBSERVATION_MODIFIER", 55, 65], ["diffuse", "OBSERVATION_MODIFIER", 76, 83], ["opacities", "OBSERVATION", 84, 93], ["ground glass", "OBSERVATION", 95, 107], ["Chest", "ANATOMY", 150, 155]]], ["One potential use of CoVA is to help determine whether to perform these tests.", [["CoVA", "SIMPLE_CHEMICAL", 21, 25], ["CoVA", "TREATMENT", 21, 25], ["these tests", "TEST", 66, 77]]], ["We therefore investigated the impact of CXR findings on the predicted probability of critical illness or death.", [["illness", "DISEASE", 94, 101], ["death", "DISEASE", 105, 110], ["CXR", "PROTEIN", 40, 43], ["CXR findings", "TEST", 40, 52], ["critical illness", "PROBLEM", 85, 101], ["death", "PROBLEM", 105, 110]]], ["As shown in Supplemental Figure S4 , positive CXR findings are most informative when the pre-CXR probability is 30% (critical illness or death), in which case they increase the predicted probability of an adverse event by 4%.", [["death", "DISEASE", 137, 142], ["positive CXR findings", "PROBLEM", 37, 58], ["the pre-CXR probability", "TEST", 85, 108], ["an adverse event", "PROBLEM", 202, 218]]], ["Negative CXR findings are maximally informative when the pretest probability is near 34% (critical illness or death), in which case they decrease the probability by 4%.Effect of Chest X-Ray Findings and COVID Status on the Probability of Adverse EventsWe also examined the effect of COVID-19 testing results on the predicted probability of adverse events (critical illness or death).", [["death", "DISEASE", 110, 115], ["illness", "DISEASE", 365, 372], ["death", "DISEASE", 376, 381], ["CXR findings", "TEST", 9, 21], ["Chest X-Ray Findings", "TEST", 178, 198], ["COVID", "TEST", 283, 288], ["adverse events", "PROBLEM", 340, 354], ["Chest", "ANATOMY", 178, 183]]], ["The largest effect of a positive test result occurs when pretest probability is 28%, in which case the post-test probability increases by 8%.", [["a positive test", "TEST", 22, 37], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["effect", "OBSERVATION_MODIFIER", 12, 18]]], ["A negative result has the largest impact when pretest probability is 36%, in which case the posttest probability decreases by 8%.DISCUSSIONIdentifying outpatients presenting for COVID-19 screening at high risk or low risk for adverse events is important for medical decisions regarding testing, hospitalization, and follow-up.", [["outpatients", "ORGANISM", 151, 162], ["outpatients", "SPECIES", 151, 162], ["pretest probability", "TEST", 46, 65], ["COVID", "TEST", 178, 183], ["screening", "TEST", 187, 196], ["adverse events", "PROBLEM", 226, 240], ["negative", "OBSERVATION", 2, 10], ["largest", "OBSERVATION_MODIFIER", 26, 33]]], ["We developed and prospectively validated the COVID-19 Acuity Score (CoVA) as an automatable outpatient screening score that can be implemented in the EMR.", [["the COVID", "TEST", 41, 50], ["an automatable outpatient screening score", "TEST", 77, 118]]], ["The model exhibits excellent calibration, discrimination, and negative predictive value both in concurrent validation (n = 9381, March 7-May 2) and in large-scale prospective validation (n = 2205, .", [["excellent calibration", "OBSERVATION", 19, 40]]], ["While several COVID-19 risk prediction models have been proposed for the inpatient setting, CoVA fills an unmet need for a prospectively validated risk designed for outpatient screening.DISCUSSIONSeveral predictors selected into the model have been identified in prior studies, including advanced age [4, 5, 9, 19] ; pre-existing pulmonary [4, 5] , kidney [4] , and cardiovascular disease [4, 9, 20] ; obesity [21] ; and increased respiratory or heart rate or hypoxia [4] .", [["pulmonary", "ANATOMY", 330, 339], ["kidney", "ANATOMY", 349, 355], ["cardiovascular", "ANATOMY", 366, 380], ["respiratory", "ANATOMY", 431, 442], ["heart", "ANATOMY", 446, 451], ["cardiovascular disease", "DISEASE", 366, 388], ["obesity", "DISEASE", 402, 409], ["hypoxia", "DISEASE", 460, 467], ["pulmonary", "ORGAN", 330, 339], ["kidney", "ORGAN", 349, 355], ["heart", "ORGAN", 446, 451], ["outpatient screening", "TEST", 165, 185], ["cardiovascular disease", "PROBLEM", 366, 388], ["obesity", "PROBLEM", 402, 409], ["increased respiratory or heart rate", "PROBLEM", 421, 456], ["hypoxia", "PROBLEM", 460, 467], ["pulmonary", "ANATOMY", 330, 339], ["kidney", "ANATOMY", 349, 355], ["cardiovascular", "ANATOMY", 366, 380], ["disease", "OBSERVATION", 381, 388], ["increased", "OBSERVATION_MODIFIER", 421, 430], ["respiratory", "OBSERVATION_MODIFIER", 431, 442], ["heart", "ANATOMY", 446, 451], ["hypoxia", "OBSERVATION", 460, 467]]], ["We found that other pre-existing medical conditions also increased risk for adverse outcomes, including hematologic malignancy, cancer and pancreatitis.", [["hematologic malignancy", "ANATOMY", 104, 126], ["cancer", "ANATOMY", 128, 134], ["malignancy", "DISEASE", 116, 126], ["cancer", "DISEASE", 128, 134], ["pancreatitis", "DISEASE", 139, 151], ["cancer", "CANCER", 128, 134], ["other pre-existing medical conditions", "PROBLEM", 14, 51], ["adverse outcomes", "PROBLEM", 76, 92], ["hematologic malignancy", "PROBLEM", 104, 126], ["cancer", "PROBLEM", 128, 134], ["pancreatitis", "PROBLEM", 139, 151], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["hematologic", "ANATOMY", 104, 115], ["malignancy", "OBSERVATION", 116, 126], ["cancer", "OBSERVATION", 128, 134], ["pancreatitis", "OBSERVATION", 139, 151]]], ["Hypertension and diabetes mellitus did not emerge as predictors in the CoVA model, despite being identified in prior studies [4, 5, 9] .", [["Hypertension", "DISEASE", 0, 12], ["diabetes mellitus", "DISEASE", 17, 34], ["Hypertension", "PROBLEM", 0, 12], ["diabetes mellitus", "PROBLEM", 17, 34], ["diabetes", "OBSERVATION", 17, 25]]], ["These comorbidities are correlated with outcomes in univariate analysis .", [["These comorbidities", "PROBLEM", 0, 19], ["univariate analysis", "TEST", 52, 71]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Table S7 ) and correlation analysis shows that both are strongly associated with older age, higher CCI, high BMI, and other comorbidities already selected as predictors, helping to explain their not being selected into the model (Supplemental Figure S5 ).", [["CCI", "DISEASE", 99, 102], ["correlation analysis", "TEST", 15, 35], ["high BMI", "PROBLEM", 104, 112], ["other comorbidities", "PROBLEM", 118, 137]]], ["HIV/AIDS was not significantly associated with the outcome, but this may have been due to low numbers (85/9381<1%, less than 1% of developmental cohort).(SupplementalSeveral studies have documented neurological manifestation of COVID-19 [22] [23] [24] .", [["neurological", "ANATOMY", 198, 210], ["HIV/AIDS", "DISEASE", 0, 8], ["COVID-19", "CHEMICAL", 228, 236], ["HIV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV/AIDS", "PROBLEM", 0, 8], ["low numbers", "PROBLEM", 90, 101], ["SupplementalSeveral studies", "TEST", 154, 181], ["COVID", "TEST", 228, 233]]], ["Nevertheless, we were surprised to find a variety of neurological diseases surfaced as robust predictors of adverse outcomes in COVID-19 infection, including ischemic stroke, intracranial hemorrhage, subarachnoid hemorrhage, epilepsy, amyotrophic lateral sclerosis, myasthenia gravis, and spinal muscular atrophy.", [["neurological", "ANATOMY", 53, 65], ["intracranial", "ANATOMY", 175, 187], ["subarachnoid", "ANATOMY", 200, 212], ["spinal muscular", "ANATOMY", 289, 304], ["neurological diseases", "DISEASE", 53, 74], ["infection", "DISEASE", 137, 146], ["ischemic stroke", "DISEASE", 158, 173], ["intracranial hemorrhage", "DISEASE", 175, 198], ["subarachnoid hemorrhage", "DISEASE", 200, 223], ["epilepsy", "DISEASE", 225, 233], ["amyotrophic lateral sclerosis", "DISEASE", 235, 264], ["myasthenia gravis", "DISEASE", 266, 283], ["spinal muscular atrophy", "DISEASE", 289, 312], ["muscular", "ORGAN", 296, 304], ["COVID-19", "SPECIES", 128, 136], ["neurological diseases", "PROBLEM", 53, 74], ["adverse outcomes in COVID-19 infection", "PROBLEM", 108, 146], ["ischemic stroke", "PROBLEM", 158, 173], ["intracranial hemorrhage", "PROBLEM", 175, 198], ["subarachnoid hemorrhage", "PROBLEM", 200, 223], ["epilepsy", "PROBLEM", 225, 233], ["amyotrophic lateral sclerosis", "PROBLEM", 235, 264], ["myasthenia gravis", "PROBLEM", 266, 283], ["spinal muscular atrophy", "PROBLEM", 289, 312], ["infection", "OBSERVATION", 137, 146], ["ischemic", "OBSERVATION_MODIFIER", 158, 166], ["stroke", "OBSERVATION", 167, 173], ["intracranial", "ANATOMY", 175, 187], ["hemorrhage", "OBSERVATION", 188, 198], ["subarachnoid", "ANATOMY", 200, 212], ["hemorrhage", "OBSERVATION", 213, 223], ["epilepsy", "OBSERVATION", 225, 233], ["amyotrophic", "OBSERVATION_MODIFIER", 235, 246], ["lateral", "OBSERVATION_MODIFIER", 247, 254], ["sclerosis", "OBSERVATION", 255, 264], ["myasthenia gravis", "OBSERVATION", 266, 283], ["spinal muscular", "ANATOMY", 289, 304], ["atrophy", "OBSERVATION", 305, 312]]], ["It is unclear if these neurological diseases are merely markers of health or if the worsened outcomes are due to the interaction of COVID-19 with neurological disorders that amplifies the pathology.(SupplementalPrior work on predicting outcomes in COVID-19 patients is summarized in Supplemental Table S2 .", [["neurological", "ANATOMY", 23, 35], ["neurological", "ANATOMY", 146, 158], ["neurological diseases", "DISEASE", 23, 44], ["neurological disorders", "DISEASE", 146, 168], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 257, 265], ["these neurological diseases", "PROBLEM", 17, 44], ["the worsened outcomes", "PROBLEM", 80, 101], ["COVID", "TEST", 132, 137], ["neurological disorders", "PROBLEM", 146, 168], ["the pathology", "TEST", 184, 197], ["unclear if", "UNCERTAINTY", 6, 16]]], ["Like our study, most have attempted to predict critical illness or death.", [["illness", "DISEASE", 56, 63], ["death", "DISEASE", 67, 72], ["our study", "TEST", 5, 14], ["death", "PROBLEM", 67, 72]]], ["However, most are based on small cohorts (median: n = 189, range n = 26 to 577); focus on inpatients; and utilize laboratory values, which were rarely available for our outpatient cohort.", [["laboratory values", "TEST", 114, 131], ["small", "OBSERVATION_MODIFIER", 27, 32]]], ["By contrast, CoVA is designed for the outpatient setting.", [["CoVA", "CHEMICAL", 13, 17], ["CoVA", "SIMPLE_CHEMICAL", 13, 17]]], ["In this setting, the availability of COVID-19 test results are variably available (for 60% in the development and 80% in the prospective cohort) and other laboratory results were rarely available.", [["COVID", "TEST", 37, 42]]], ["To ensure generalizability, we used a large development cohort of 9381 patients, and trained the model using a rigorous approach.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["a rigorous approach", "TREATMENT", 109, 128]]], ["We ensured clinical interpretability by utilizing a linear model with positivity constraints on predictors expected to increase risk.", [["a linear model with positivity constraints", "TREATMENT", 50, 92]]], ["Finally, we validated our model on a large (n = 2205) prospectively collected patient cohort, providing an unbiased assessment of model generalizability.(SupplementalStrengths of this study include its large sample size, careful EMR phenotyping, rigorous statistical approach, and the feature that all variables required by the model are available and automatically extractable within most electronic health record systems.", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["an unbiased assessment", "TEST", 104, 126], ["this study", "TEST", 179, 189], ["careful EMR phenotyping", "TEST", 221, 244], ["rigorous statistical approach", "TEST", 246, 275], ["large", "OBSERVATION_MODIFIER", 202, 207], ["size", "OBSERVATION_MODIFIER", 215, 219]]], ["The study also has limitations.", [["The study", "TEST", 0, 9]]], ["First, our study is from a single center, with patient demographics specific to MGH, Boston.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["our study", "TEST", 7, 16]]], ["Second, although RIC clinics were established for patients with suspicion for COVID-19, patients seen in the ED were seen for a variety of reasons.", [["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 88, 96], ["COVID", "TEST", 78, 83]]], ["Nevertheless COVID-19 was and for now remains a universal concern for patients seen in the ED, and we excluded patients prior to the onset of COVID-19 in Boston (March 7, 2020), therefore our model is relevant for screening during times of high alert for COVID-19.", [["COVID", "DISEASE", 142, 147], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 111, 119], ["COVID", "TEST", 13, 18], ["COVID", "TEST", 142, 147], ["screening", "TEST", 214, 223], ["COVID", "TEST", 255, 260]]], ["Finally, we did not include lab test values, since they were typically not available.", [["lab test values", "TEST", 28, 43]]], ["Among the few studies of inpatients, inclusion of lab tests appears to improve model performance.(SupplementalIn conclusion, the COVID-19 Acuity Score (CoVA) represents a well-calibrated, discriminative, prospectively validated, and interpretable score for assessing the risk for adverse events for outpatients presenting with possible COVID-19 infection.(Supplemental.", [["infection", "DISEASE", 345, 354], ["lab tests", "TEST", 50, 59], ["the COVID", "TEST", 125, 134], ["adverse events", "PROBLEM", 280, 294], ["COVID-19 infection", "PROBLEM", 336, 354], ["infection", "OBSERVATION", 345, 354]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Hematologic malignancy* 0.0765 30 ARDS* 0.0001 Legend: Abbreviations: CXR = chest X-ray; ARDS = Acute Respiratory Distress Syndrome; BMI = Body Mass Index.", [["malignancy", "DISEASE", 12, 22], ["ARDS", "DISEASE", 34, 38], ["ARDS", "DISEASE", 89, 93], ["Acute Respiratory Distress Syndrome", "DISEASE", 96, 131], ["Hematologic malignancy", "PROBLEM", 0, 22], ["CXR", "TEST", 70, 73], ["chest X-ray", "TEST", 76, 87], ["ARDS", "PROBLEM", 89, 93], ["Acute Respiratory Distress Syndrome", "PROBLEM", 96, 131], ["BMI", "PROBLEM", 133, 136], ["Body Mass Index", "PROBLEM", 139, 154], ["malignancy", "OBSERVATION", 12, 22], ["chest", "ANATOMY", 76, 81], ["ARDS", "OBSERVATION", 89, 93], ["Acute", "OBSERVATION_MODIFIER", 96, 101], ["Respiratory Distress", "OBSERVATION", 102, 122], ["Mass", "OBSERVATION", 144, 148]]], ["Diagnoses are based on past medical history, and are coded as present (e.g. Pneumothorax = 1) if recorded in the electronic medical record at any time before the date of presentation for COVID-19 screening.", [["Pneumothorax", "DISEASE", 76, 88], ["Pneumothorax", "PROBLEM", 76, 88], ["COVID", "TEST", 187, 192], ["screening", "TEST", 196, 205], ["Pneumothorax", "OBSERVATION", 76, 88]]], ["Disorders marked by '*' refer to pre-existing conditions documented in the electronic medical record.(which was not certified by peer review).", [["Disorders", "PROBLEM", 0, 9]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2020. . https://doi.org/10.1101/2020.06.17.20134262 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 367, 374], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "PMC7252083": []}